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Abstract 
α-Glucans are important energy storage polysaccharides in bacteria, plants and animals. In 
Mycobacterium tuberculosis, α-glucan also functions as a virulence factor that is exported 
to the mycobacterial capsule and interacts with human immune receptors. In M. tuberculosis 
and other actinomycetes, α-glucan is synthesised from maltose-1-phosphate by the 
maltosyl transferase GlgE and the α-1,6-branching enzyme GlgB. These enzymes have 
been genetically validated as tuberculosis drug targets. The loss of the α-glucan virulence 
factor is exacerbated by the toxic accumulation of maltose-1-phosphate, which results in a 
pleiotropic stress response and cell death. 
α-Glucan produced by this pathway has shorter branches than classical bacterial α-glucan, 
but the mechanistic basis of this was not fully understood. To address this, I produced α-
glucan in vitro, demonstrating GlgE and GlgB alone were sufficient to generate the distinct 
architecture. To investigate the determinants of α-glucan branch lengths, I solved high 
resolution crystal structures of Mycobacterium smegmatis GlgB bound to different 
oligosaccharides. These enabled the identification of several substrate binding sites, 
including the donor and acceptor sites of a newly forming branchpoint, giving novel insights 
into the action of glucan branching enzymes. 
To address M. tuberculosis GlgB as a drug target, I developed a high-throughput screening 
assay and used this to identify a potent, small-molecule inhibitor. I synthesised a selection 
of analogues to investigate structure-activity relationships. I also assessed the action of the 
compounds in vivo, demonstrating growth inhibition at high concentrations, but not via the 
GlgB target. Finally, I explored trehalose analogues as potential precursors for GlgE 
inhibitors, focussing on the synthesis, uptake and processing of 4-deoxy trehalose 
analogues. 
This multidisciplinary work gives a deeper understanding of mycobacterial α-glucan 
synthesis and how this can be targeted to develop new tuberculosis therapeutics. 
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1. Introduction 
This thesis describes the investigation of potential drug targets in Mycobacterium 
tuberculosis α-glucan biosynthesis. Firstly, I briefly review the remarkable structural and 
functional diversity of carbohydrates, along with the multitude of enzymes that control 
carbohydrate metabolic processes. The structure, function and biosynthesis of α-glucan 
polysaccharides across different organisms are then discussed, before focussing on the M. 
tuberculosis pathways. I go on to discuss the bacterium in the context of the devastating 
infectious disease it causes and the current treatments available. Then, I detail the efforts 
so far to target the α-glucan biosynthetic pathway in M. tuberculosis. Finally, I outline the 
questions that this work will address in order to develop the understanding of mycobacterial 
α-glucan synthesis and target the enzymes involved in this process with potential anti-
tuberculosis therapeutics. 
1.1 Carbohydrates 
1.1.1 Carbohydrate diversity 
Carbohydrates are ubiquitous organic molecules that play an integral role in nearly all living 
processes.1 Carbohydrates are fundamental to biological energy storage and transfer, 
being the main product of photosynthesis and the substrate of respiration. They are the 
major component of cell walls, from cellulose in plants to peptidoglycan in bacteria; and as 
chitin, help form the exoskeleton in crustaceans and insects. In addition to structural roles, 
carbohydrates are essential to cellular recognition and adhesion, for example in 
reproduction and immunity. They are also important signalling molecules and ligands, often 
when conjugated to other macromolecules, such as proteins or lipids.2 
The name derives from hydrated carbon, and indeed, carbohydrates were historically 
considered to be compounds with the empirical formula Cn(H2O)n, where n ≥ 3. Generally, 
these are 5- or 6- carbon polyhydroxylated aldoses, with ketoses being less common.3 The 
archetypal carbohydrate is the aldohexose glucose, which is the most abundant organic 
molecule on earth. However, the term carbohydrate also includes many other molecules 
that do not conform to the empirical formula, such as the backbone of DNA, deoxyribose, 
and those with additional heteroatoms, such as iminosugars and glycosyl thiols. 
Carbohydrates exist almost exclusively as cyclic hemiacetals, with the 6-membered 
pyranose ring usually favoured over the 5-membered furanose ring. The anomeric carbon 
is that which is derived from the carbonyl carbon in the open-chain form. A single 
carbohydrate ring is termed a monosaccharide, and rings are linked by glycosidic bonds to 
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form di-, oligo- and poly- saccharides. In a chain of sugar molecules, the end that retains a 
free anomeric carbon is termed the reducing end, with the non-reducing end at the other 
extremity.4 
The wide-ranging biological roles of carbohydrates are matched by an extensive structural 
diversity. Typically, they contain numerous stereogenic centres, and subtle stereochemical 
variations have dramatic effects on carbohydrate properties, and hence their biological 
functions.5 For example, the α and β isomers of glucose play very different biological roles. 
Similarly, glucose and galactose differ only in the stereochemistry of one hydroxyl group, 
but again have markedly different properties. Another source of variation lies in the potential 
for linkages at different positions in the same monosaccharide ring. In turn, this creates 
polysaccharides with radically different secondary structures, such as the linear architecture 
of the β-1,4-glucose polymer cellulose,6 compared to the triple helices that form in the β-
1,3-glucose polymer paramylon,7 Figure 1.1. The combination of mixed linkages in the 
same polysaccharide molecule creates an even greater number of structural possibilities. 
Overall, this results in a vast structural complexity that far surpasses that of proteins, lipids 
or nucleic acids. Furthermore, carbohydrate structure is not encoded in genetic information, 
making it much more challenging to manipulate. This is compounded by the difficulties in 
distinguishing between different isomers and linkages. Carbohydrates are therefore the 
most challenging class of biomolecule to investigate, resulting in glycobiology historically 
lagging behind other fields.8 The advent of automated carbohydrate synthesis9 and 
significant advances in mass spectrometry methods10-11 go some way to addressing these 
challenges, but there is clearly much more to be done in glycobiology to match the progress 
made in other disciplines. 
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Figure 1.1 Carbohydrate structures. A) Fischer projection of D-glucose; B) D-
glucopyranose and D-glucofuranose are the two cyclic hemiacetal forms of D-glucose; C) 
α-D-glucopyranose and β-D-glucopyranose differ in the stereochemistry at the 1-OH; D) D-
galactopyranose differs from D-glucopyranose in the stereochemistry of the 4-OH; E) 
Structures of paramylon and cellulose, forming a triple helix or a sheet respectively, 
adapted from ‘Development of Euglena-based bioplastics’.12  
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1.1.2 Carbohydrate active enzymes 
A plethora of carbohydrate metabolic enzymes is required to orchestrate the immense 
structural variety of carbohydrates. These are usually highly specific for a particular 
stereochemistry or glycosidic linkage, although some enzymes can accommodate a range 
of substrates. Over the last two decades, the carbohydrate active enzymes database13 
(CAZy; http://www.cazy.org/) has been developed, in which enzymes are classified 
according to their amino acid sequence. The major CAZy classes are glycoside 
hydrolases14 (GHs) and glycosyltransferases15 (GTs), with the remaining classes 
comprising polysaccharide lyases, carbohydrate esterases16 and auxiliary activities.17 GHs 
catalyse the cleavage and formation of glycosidic bonds, whilst GTs catalyse the transfer 
of saccharides from activated phosphoester donors to a specific acceptor. There are two 
types of mechanisms for GHs and GTs: retaining and inverting, referring to retention or 
inversion of the anomeric configuration. Each CAZy class is divided into a numerical family 
according to the protein sequence. Since this usually correlates with the three-dimensional 
structure, characteristic folds can be identified in each family, such as a (β/α)8 barrel. 
CAZymes often contain discrete units that bind specific saccharides, termed carbohydrate 
binding modules (CBMs), which are themselves classified into families based on 
sequence.18 
This thesis focuses on enzymes belonging to the GH13 family, which act on substrates 
containing α-glycosidic linkages and includes diverse functionalities, such as isomerases, 
polymerases, branching enzymes and debranching enzymes. Reactions of GH13 enzymes 
retain the α-configuration, following a classical Koshland double displacement 
mechanism.19-20 The aspartate nucleophile attacks the face opposite to the anomeric 
hydroxyl to form a covalent intermediate. The glutamate acid/base residue then aids attack 
by water or a sugar hydroxyl to release the product with a retained configuration. The 
reaction proceeds via oxocarbenium ion-like transition states, Figure 1.2. The subsites that 
bind each monosaccharide moiety are labelled -n to +n, where -n is the non-reducing end 
of the sugar and +n is the reducing end. Cleavage takes places between the -1 and +1 
subsites,21 Figure 1.3. When the reaction results in the formation of a new glycosidic bond, 
the moiety that contains the resultant anomeric carbon is termed the donor, whereas the 
moiety that contains the hydroxyl nucleophile is called the acceptor.4 
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Figure 1.2 Mechanism of an α-retaining GH enzyme. The classical Koshland double 
displacement mechanism gives overall retention of the α-configuration. R1 = a glycosyl 
moiety leaving group; R2 = either a glycosyl moiety in the case of bond formation or H in the 
case of hydrolysis. The mechanism proceeds via an oxocarbenium ion-like transition state 
in which the pyranose most likely adopts a 4H3 conformation, in contrast to the ground-state 
4C1 conformation. 
 
Figure 1.3 Subsite nomenclature in GH enzymes. Protein subsites are labelled from -n 
to +n, with the oligosaccharide orientated such that the non-reducing end is located at the 
-n subsite and the reducing end subsite is located in the +n subsite. Cleavage takes place 
between the -1 and +1 subsites. In the case of bond formation, the -n subsites comprise the 
donor site and the +n subsites comprise the acceptor site. 
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1.2 α-Glucans 
α-Glucans are a subset of carbohydrate polymers composed of α-D-glucose units, which 
can be linked by 1→2, 1→3, 1→4 or 1→6 α-glycosidic bonds.1 In this thesis I exclusively 
refer to α-glucans as those consisting of 1→4 linked chains, which are connected by 1→6 
α-glycosidic bonds, known as branchpoints. α-Glucans have a number of biological roles, 
including being involved in the formation of dental caries by bacteria.22 Most commonly they 
function as energy storage molecules and include the ubiquitous polysaccharides starch 
and glycogen.23 
1.2.1 Structure of α-glucans 
The structural features of α-glucan polymers are illustrated in Figure 1.4. One feature of 
the polysaccharide architecture is the average length of the α-1,4 chains, which is measured 
in units of degree of polymerisation (DP), pertaining to the number of glucose residues in 
the chain. This has a reciprocal relationship with the percentage of branching, which can be 
independently determined by quantifying the number of α-1,6 linkages versus α-1,4. The 
internal chain length can also be measured, giving the average distance between one 
branchpoint and the furthest branch it bears,24 Figure 1.5. 
 
Figure 1.4 Structure of α-glucans. A) α-D-glucopyranose is linked via 1,4 or 1,6 α-
glycosidic bonds. B) Basic structure of α-glucan, consisting of two α-1,4 chains linked by an 
α-1,6 bond. The free anomeric carbon is the reducing end and the free 4-hydroxyls are the 
non-reducing ends.   
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1.2.2 α-Glucan synthesis 
Synthesis of α-glucans is carried out by the iterative action of an α-1,4-glucan polymerase 
and an α-1,6-branching enzyme. The polymerase extends an α-glucan chain and, when a 
threshold length is surpassed, the branching enzyme cleaves an α-1,4 linkage within the 
chain and transfers this to a 6-OH of another glucose unit in the molecule, thus creating an 
α-1,6 branchpoint. This process results in three types of chains within an α-glucan molecule: 
a progenitor C chain, which retains a free reducing end; a B chain that originates from a 
branchpoint and itself bares one or more branches; and an A chain that originates from a 
branchpoint but itself bares no branches, Figure 1.5. Another measure of α-glucan structure 
is the A:BC chain ratio, which defines the distribution of branching in the molecule, and is 
directly related to the number of branches emanating from each B/C chain.24 
 
Figure 1.5 Types of chains in α-glucan. The external A chains bare no branches, the 
internal B chains bares one or more branches and the C chain is the only one that does not 
originate from a branch and hence retains a free reducing end, represented with ø. The 
internal chain length is the distance from one branchpoint to the next. 
1.2.3 Starch 
Starch is the major energy reserve of photosynthetic eukaryotes and the most common 
carbohydrate in the human diet.25 It is formed as insoluble, semi-crystalline granules which 
consist of two polysaccharide fractions: amylose and amylopectin.26 Amylose contains very 
few α-1,6 branches and is typically folded as single, left-handed helix, denoted V-amylose, 
although A and B double helical structures are also known.27 Amylopectin usually accounts 
for at least 70% of the granule and contains numerous α-1,6 branches, which are arranged 
in clusters at regular intervals along the main chain. Double helices form between cluster 
strands and these pack together to form lamellae within the granule, Figure 1.6.25 Amyloses 
are typically reported to have average chain lengths of DP 200-700, whereas amylopectin 
has average chain lengths of DP 20-25, corresponding to 4-5% α-1,6 linkages in the 
molecule.28 
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Figure 1.6 Starch structure.  A) The arrangement of amylose and amylopectin; B) A cross-
section of a starch granule from potato. Adapted from Zeeman SC, et al. 2010,25 with 
permission. 
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1.2.4 Glycogen 
Glycogen is the analogous carbohydrate energy store in animals, fungi and bacteria.23 
Glycogen has an arboreal structure, with branches dispersed more evenly through the 
molecule. Average branch lengths are typically DP 10-12, giving a higher overall percentage 
of α-1,6 linkages (8-10%).29 It forms dendrimeric β-particles with a diameter of 10-100 nm, 
and these can aggregate to give larger α-particles, 100s of nm in diameter, Figure 1.7. 
Unlike its botanic counterpart, glycogen is largely soluble and can be dissolved in water at 
ambient temperature.30 In mammals, a priming protein, glycogenin, initiates glycogen 
synthesis through covalent attachment of glucose molecules to its Tyr195 residue. Until 
very recently this was assumed to be essential, however, glycogenin-deficient mice were 
recently shown to accumulate high levels of glycogen.31 
 
Figure 1.7 Glycogen structure. A) Representation of the molecular structure of 
mammalian glycogen originating from a glycogenin dimer. Image by Mikael Häggström. B) 
β-particles of E. coli glycogen.32 C) α-particles of rat liver glycogen.30 All images used with 
permission. 
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1.2.5 Bacterial glycogen synthesis 
Classical glycogen biosynthesis in bacteria does not require glycogenin and takes place via 
the GlgABC pathway, which was first described in Escherichia coli. In this pathway, a 
glucose unit is activated by the addition of ADP via the action of GlgC on α-glucose-1-
phosphate, using an AMP unit from ATP. ADP-glucose is then polymerised via α-1,4 
glucosidic linkages by glycogen synthase, GlgA, to generate a linear α-glucan. Finally, α-
1,6 branches are introduced by the branching enzyme, GlgB, which cleaves 
oligosaccharides at the non-reducing end and transfers them to a C6-hydroxyl group within 
or between chains,29 Figure 1.8. Glycogen can be degraded to α-glucose-1-phosphate by 
the action of glycogen phosphorylase, GlgP,33 and the debranching enzyme, GlgX,34 thus 
completing the metabolic cycle. These enzymes have been biochemically characterised 
from a number of different bacteria, but their structure-activity relationships remain poorly 
understood. 
 
Figure 1.8 Classical glycogen synthesis pathway. Glucose-1-phosphate is converted 
into ADP-glucose by GlgC. This activated sugar is a substrate for the α-1,4 polymerase 
GlgA and GlgB introduces α-1,6 branches. Pyranose units are represented as blue 
hexagons. 
Glycogen synthesis by this route is controlled by allosteric regulation of GlgC whereby 
glycolytic intermediates activate GlgC activity and where ADP, AMP and Pi are common 
inhibitors. For M. smegmatis GlgC, fructose-1,6-bisphosphate and fructose-6-phosphate 
were found to be activators, and AMP and ADP found to be inhibitors.35 
1.3 α-Glucan metabolism in M. tuberculosis 
1.3.1 α-Glucans in M. tuberculosis 
It had long been established that, in common with many other bacteria,22 mycobacteria 
accumulated a glycogen-like α-glucan polysaccharide in nitrogen-limiting growth 
conditions.36 More recently, it was found that α-glucan is the main component of the loosely 
associated capsule, the outermost layer of the mycobacterial cell envelope.37 Here, it 
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functions as a virulence factor and mutant M. tuberculosis strains lacking α-glucan had 
significantly attenuated growth in the both the acute and chronic phases of infection in a 
murine model.38 M. tuberculosis α-glucan binds to the human immune receptors DC-SIGN 
and CR3 in vitro, and the interaction which each is mediated by internal glucosyl residues.39 
The capsular α-glucan has also been implicated in the persistence of M. tuberculosis in 
mice40 and can induce monocytes to differentiate into altered dendritic cells, allowing 
mycobacteria to evade the immune host response.41 
A further type of α-glucan found in mycobacteria and some Nocardia species are the 6-O-
methylglucose lipopolysaccharides (MGLPs), whose metabolism was thought to be linked 
to capsular α-glucan metabolism. MGLPs consist of a predominantly 6-O-methylated α-1,4 
backbone, 15-20 carbons in length, with an α-1,6 linked di-glucosylglycerate moeity at the 
reducing end.42 Two β-1,3-glucose branches are found near the reducing end and there is 
extensive acylation across the molecule, Figure 1.9. MGLPs are thought to function as 
regulators/chaperones of fatty acid biosynthesis, with the nature of acylation determining 
fatty acid binding specificity.43 
 
Figure 1.9 The structure of MGLP The molecule consists of an α-1,4 chain linked by an 
α-1,6 bond to glycosylglycerate at the reducing end. Two β-D-glucose branches emanate 
from the second and fourth residues in the chain. R = isobutyrate; R' = propionate, Rʹ = 
acetate, R''' = succinate.43-44 
1.3.2 The GlgE pathway 
It had been presumed that M. tuberculosis α-glucan synthesis was analogous to that in 
other bacteria, because homologues of the E. coli genes glgA, glgB and glgC had been 
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identified.40, 45 However, unlike in E. coli, glgB was found on a separate operon with other 
genes implicated in α-glucan metabolism, including glgE.40 The homologue of glgE in M. 
smegmatis was thought to encode for a glucanase, due to a perceived increase in glycogen 
accumulation when the activity of GlgE was impaired by a temperature sensitive mutation.46 
The glgB and glgE genes also clustered with treS and pep2, mirroring a similar arrangement 
of genes previously seen in duplicated operons in Streptomyces coelicolor.47 TreS was 
known to interconvert trehalose and maltose48 and had previously been proposed to 
function as a link between trehalose and glycogen metabolism.49-50 This was finally 
confirmed by the discovery of the novel GlgE-mediated α-glucan synthesis pathway,51 
Figure 1.10. 
  
Figure 1.10 The GlgE pathway. Trehalose is isomerised to maltose by TreS and this is 
then phosphorylated by Pep2 to make maltose-1-phosphate. This is the substrate for the α-
1,4 polymerase GlgE and α-1,6 branches are subsequently introduced by the branching 
enzyme GlgB. Pyranose units are represented as blue hexagons. 
 
In this pathway trehalose is firstly isomerised to α-maltose by TreS. Interestingly, the 
equilibrium position of TreS in isolation lies towards trehalose, however the flux in vivo is in 
the α-maltose direction.52 α-Maltose is then phosphorylated by the maltokinase Pep2, to 
generate α-maltose-1-phosphate (M1P). TreS and Pep2 act together in a hetero-octameric 
complex.53 M1P is then the substrate for GlgE, which is in fact a maltosyltransferase that 
uses M1P as a donor to extend α-1,4-glucan chains, releasing phosphate in the process.51 
Once the maltooligosaccharides reach a DP ≥ ~16, GlgB can introduce an α-1,6 branch. 
The enzymes GlgE and GlgB work in tandem to create the α-glucan polysaccharide, 
analogous to the GlgA and GlgB pair in E. coli.32 Genetic knockouts of glgE or glgB are 
lethal in M. tuberculosis in vitro and in mouse models, due to the accumulation of the M1P 
substrate, which leads to a pleiotropic stress response, including inhibition of respiration, 
down-regulation of ATP synthase genes and the induction of DNA damage. Moreover, this 
effect is exacerbated by an upregulated feedback loop, whereby trehalose production is 
increased in an apparent attempt to compensate for the attenuated α-glucan synthesis, 
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leading to self-poisoning. GlgE and GlgB were therefore validated as M. tuberculosis drug 
targets and this is discussed in more detail below.51 
The discovery of the GlgE pathway presented a number of questions. The first was the 
contrary function of GlgE compared to its original annotation as a glucanase in M. 
smegmatis. This can be attributed to the assay that the earlier study used to measure the 
accumulation of glycogen, as this simply measured the glucose released after 
amyloglucosidase treatment. It would therefore not discriminate between M1P and 
glycogen, resulting in the erroneous assignment of GlgE function. More recently, work by 
myself, K. Syson and colleagues confirmed this was the case, by demonstrating a build-up 
of M1P in a M. smegmatis strain with the temperature sensitive glgE mutation which was 
investigated in the previous study, Figure 1.11. 
 
Figure 1.11 Accumulation of M1P in M. smegmatis with temperature sensitive glgE 
mutation. NMR spectra in the region of 5.0 – 5.5 ppm. Peaks corresponding to trehalose 
anomeric protons seen at 5.15 ppm for the WT (first panel). When GlgE function is abolished 
M1P accumulates with peaks corresponding to its anomeric protons being observed 
between 5.3 and 5.4 ppm (second panel). A strain with the temperature sensitive glgE 
mutation accumulates M1P when grown at a non-permissive temperature of 42 °C (fourth 
panel) but not at 30 °C (third panel). This confirms that the suggested glycogen 
accumulation in the original study was in fact a build-up of M1P. I generated these data and 
figure using strains provided by R. Kalscheuer. 
The presence of the glgA and glgC genes in M. tuberculosis raised a second question: do 
multiple α-glucan synthesis pathways co-exist in this bacterium? This was answered during 
the investigation of the unexplained presence of M1P in a ΔglgE Δpep2 mutant strain. 
Characterisation of M. tuberculosis GlgA revealed that, contrary to its annotated function as 
an α-1,4 glucan synthase, it in fact produced M1P from the condensation of α-glucose-1-
phosphate and ADP-glucose, and accordingly the enzyme was renamed as GlgM. The 
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function of GlgC is as predicted and, as in E. coli, this enzyme generates ADP-glucose from 
glucose-1-phosphate. However, this is instead used to make M1P and the formation of M1P 
by GlgA was confirmed to be dependent on GlgC. This represents a significant 
reconfiguration of α-glucan synthesis in M. tuberculosis relative to E.coli, Figure 1.12. 
A further potential complication was the proposed interplay between the MGLP and α-
glucan synthetic pathways. In the synthesis of MGLP, di-glucosylglycerate is thought to be 
extended by Rv3032, using a UDP-glucose donor.54 Rv3032 was initially implicated in α-
glucan synthesis because its deletion appeared to reduce intracellular α-glucan content and 
the combined ΔglgA ΔRv3032 was said to be not viable.40 However, both of these findings 
were recently refuted, suggesting that Rv3032 has no role in α-glucan synthesis and that 
MGLP synthesis is an independent process.38 
 
Figure 1.12 Synthesis of α-glucan in M. tuberculosis.  M1P can be generated by either 
TreS/Pep2 or GlgM, converging to one unified route to α-glucan in mycobacteria. Pyranose 
units are represented as blue hexagons. 
The complete GlgE pathway has been identified in 14% of sequenced bacterial genomes 
and is especially common in Streptomyces, Mycobacterium and Corynebacterium 
species.42 Some organisms contain only this set of α-glucan synthesis genes, for example, 
Streptomyces venezuelae, and the GlgE pathway has been confirmed as the sole α-glucan 
synthetic pathway in this species.43 
1.3.3 Mycobacterial α-glucan structure 
Since α-glucan is made by a different biosynthetic pathway in actinomycetes, it follows that 
it might have altered structural properties. Recently, an in-depth analysis of M. tuberculosis 
α-glucan structure was carried out and it was compared to α-glucan originating from the 
classical glycogen synthesis pathways, such as in E. coli.32 Interestingly, M. tuberculosis 
had an average chain length of DP 7.1 ± 2.0, markedly shorter than classical bacterial and 
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mammalian glycogen, which had average chain lengths of 11.0 ± 2.9 and 10.8 ± 4.6, 
respectively. The internal chain length of M. tuberculosis α-glucan was 4.7 ± 1.6, with an 
A:BC chain ratio of 0.6, compared to 8.3 ± 3.3 and 0.8 for E. coli glycogen. M. tuberculosis 
α-glucans extracted from the cytosol or capsule were essentially identical, consistent with 
their singular biosynthetic origin. Furthermore, α-glucan extracted from S. venezuelae had 
very similar properties to that from mycobacteria, consistent with the hypothesis that α-
glucan made via the GlgE pathway has notably shorter average branch lengths, internal 
chain lengths and a lower A:BC chain ratio, compared to classical glycogen.32 
Comparison of the known types of α-glucan polysaccharide demonstrates that 
mycobacterial α-glucan has the shortest branches, with the corresponding highest 
percentage of branching, Table 1.1. 
Table 1.1 Features of different types of α-glucan. Data from Tester et al.28 and Rashid 
et al.32 Decreasing chain length correlates with increased aqueous solubility and an 
increased percentage branching. 
 
However, this work does not provide direct evidence for the formation of mycobacterial α-
glucan by GlgE and GlgB alone, and without this, the distinct structure of mycobacterial α-
glucan cannot be directly linked to these enzymes. 
1.3.4 Determinants of mycobacterial α-glucan branch length specificity 
The shorter average chain length of α-glucan derived from the GlgE pathway implies that 
the actinomycete GlgB enzymes generate shorter branches than those from the classical 
glycogen synthesis pathways, such as E. coli GlgB. It would therefore be interesting to 
understand the underlying basis of these different specificities. However, whilst a wide 
range of substrate preferences, branch length specificities and branchpoint positions have 
α-Glucan type Aqueous 
solubility 
Mean chain 
length (DP) % Branching 
Biological 
role 
Amylose X 50 – 1,000 <1 Energy 
storage 
Amylopectin X 20 – 25 ~4 Energy 
storage 
Classical 
glycogen ✓ 10 – 12 ~9 
Energy 
storage 
M. tuberculosis 
 α-glucan ✓ 7 – 8 ~14 
Energy 
storage 
Virulence 
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been reported for different α-1,6 branching enzymes,55 the factors controlling these have 
not yet been identified. 
Most branching enzymes belong to the GH13 CAZy family, and are further classified into 
the GH13_8 or GH13_9 subfamilies, which usually correlates with a eukaryotic or 
prokaryotic origin, respectively, however there are some exceptions.55 More recently, 
branching enzymes have been discovered that are classified into the GH57 CAZy family.56-
57 All GH13 branching enzymes share the GH13 family (β/α)8 barrel, which contains the 
catalytic aspartate and glutamate, along with a further aspartate and arginine that typically 
coordinate the pyranose in the -1 subsite.58 The catalytic domain is flanked by the CBM48 
and C-terminal β-sandwich domains, along with an N-terminal β-sandwich domain in many 
species.55 This domain has been linked to branch length specificity, with some N-terminal 
truncations increasing branch length in E.coli GlgB, although overall there was not a clear 
relationship between truncation size and glucan properties.59 The lack of a clear correlation 
between amino acid sequence and branch length specificity implies that the structural 
features responsible are not directly distinguishable from protein sequence. It is therefore 
necessary to consider the three-dimensional structures of branching enzymes, some of 
which have been determined with X-ray crystallography. 
 
Figure 1.13 Domains and sequence motifs of GH13 family branching enzymes. GH13 
branching enzymes consist of domain N, which is absent in some enzymes, CBM48, the 
catalytic domain A, which contains the (β/α)8 barrel, and domain C. Conserved sequence 
regions are numbered I-VII, with the catalytic Asp and Glu residues located in II and III, 
respectively. Adapted from Suzuki and Suzuki, 2010,55 with permission. 
The crystal structure of full length M. tuberculosis GlgB (MtGlgB) has been solved,60 along 
with that of E. coli,61 human62 and rice,63 all lacking domain N. Recently, the full length 
structure of a cyanobacterial branching enzyme was also solved by Hayashi et al., which 
had domain N located at the back of the protein,64 in contrast to the linear arrangement of 
domains along the longitudinal axis in the M. tuberculosis enzyme. Structures of the E. coli, 
Chapter 1 
17 
human and rice enzymes in complex with maltooligosaccharides or cyclodextrins have been 
solved, but these ligands are all located at a significant distance from the active site, 62-63, 65-
66 therefore their influence on the branch length specificity is unclear.The recently 
characterised cyanobacterial branching enzyme is the only branching enzyme structure with 
a maltooligosaccharide bound at the active site cleft, identifying the donor subsites.64 
Unusually, this GH13_9 enzyme is involved in the synthesis of starch, and generates branch 
lengths of DP 6-7.67 Hayashi et al. proposed an acceptor site based on other 
maltooligosaccharide binding sites in the C-terminal domain, both at a distance of ~30 Å 
from the catalytic nucleophile. Site-directed mutagenesis of some of the residues at these 
distal sites resulted in decreased activity of the enzyme or slight shifts in the distribution of 
branch lengths in the products. However, it was not determined whether these directly result 
from the disruption of maltooligosaccharide binding at these sites or whether mutagenesis 
results in conformational changes in the protein. The suggested model does not fully explain 
the reported branch length specificity of DP 6-7, since the B chains created by this extended 
acceptor site are DP10, Figure 1.14. 
 
Figure 1.14 Proposed substrate binding model in cyanobacterial branching enzyme.  
The donor site is coloured dark grey and bound pyranose units are represented by black 
hexagons and numbered according to the donor (-) subsites. The proposed acceptor site is 
coloured white and is based on binding at the A1 and A2 sites in domain C, with interacting 
protein residues labelled. The predicted acceptor maltooligosaccharide is represented by 
grey hexagons, with the reducing end marked by a slash. The expected reaction product is 
shown on the right, which has an A chain of DP6 and B chain of DP10. Adapted from 
Hayashi et al. with permission.64 
 
For the M. tuberculosis enzyme, only the apo crystal structure exists60 and therefore the 
donor and acceptor subsites have not yet been identified. It is therefore not yet possible to 
compare the structural features involved in substrate binding that might underlie the branch 
length specificity in mycobacteria. 
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1.4 Trehalose metabolism in M. tuberculosis 
Trehalose is a non-reducing disaccharide consisting of two α-D-glucose units linked by a 
1,1-glycosidic bond, Figure 1.15. It is biosynthesised by bacteria, fungi, plants and 
invertebrates, but not mammals, and is known to play an important role in energy storage 
in insects, as well as protection from desiccation, cold and oxidation stress in bacteria.68 
Trehalose metabolism in mycobacteria has previously attracted considerable interest due 
to the incorporation of trehalose into cell wall glycolipids, such as trehalose-6,6'-dimycolate 
(TDM), which plays an important role in the virulence and persistence of M. tuberculosis 
within the host, as well as the structural integrity of the M. tuberculosis cell wall.69-72 
 
Figure 1.15 Trehalose Structures. A) Trehalose consists of two α-D-glucopyranose units 
linked by an α-1,1 glycosidic bond B) TDM consists of two mycolate groups attached at the 
6 and 6' positions of trehalose. 
Classical trehalose biosynthesis occurs via the OtsAB pathway whereby a nucleotide 
diphosphate-activated glucose unit is transferred onto glucose-6-phosphate by trehalose 
phosphate synthase, OtsA. The resultant trehalose-6-phosphate is then converted into free 
trehalose by trehalose phosphate phosphatase, OtsB. OtsA enzymes identified in yeast, 
insects and Streptomyces are specific for either UDP-glucose or GDP-glucose, whereas 
those in mycobacteria have much broader substrate specificities and can utilise all of the 
naturally occurring glucose nucleotides.68 This pathway is the predominant trehalose 
synthesis route in M. tuberculosis.73 
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Trehalose can also be generated by the degradation of cytosolic α-glucan via the TreXYZ 
pathway, which was first identified in Sulfolobus acidocaldarius.74 In this route, a glycosyl 
residue at the reducing end of an α-1,4-glucan is inverted by TreY to form a trehalose moiety 
at the end of the chain which is cleaved by TreZ to release free trehalose.75 This process 
would have to be aided by the glycogen debranching enzyme GlgX (also called TreX) to 
get past branchpoints.76 The discovery that trehalose is also the starting point for the GlgE 
pathway underlines the importance of trehalose as a metabolic hub in mycobacteria. 
 
1.5 Tuberculosis 
Tuberculosis (TB) is an infectious disease that has plagued humanity  for millennia.77 It is 
still the second most common cause of death worldwide due to a single infectious agent 
after HIV/AIDS. It is estimated that one third of the world’s population is infected by M. 
tuberculosis and that 5 – 10% of these cases will go on to develop the active form of TB, 
with 1.8 million dying each year as a result. It is an airborne infection, which is typically 
spread through the transmission of respiratory fluids via coughs and sneezes. Upon 
inhalation, M. tuberculosis infects alveolar macrophages. In an immunocompetent host 
these are physically contained in granulomas consisting of tiny collections of modified 
macrophages that surround the TB bacilli. These structures present one of the major 
barriers for complete TB elimination by antibiotics, leading to progressive chronic disease.78 
Immunocompromised patients by contrast are also particularly vulnerable to acute TB 
infection, and TB is therefore the leading cause of death for HIV patients. Poverty is the 
other key risk factor associated with developing the disease.79 
1.5.1 The tubercle bacillus 
M. tuberculosis was first identified as the aetiological agent of TB in 1882 by Robert Koch, 
for which he received the 1905 Nobel Prize in Physiology or Medicine.80 Mycobacteria are 
a type of actinobacteria, a group of Gram-positive bacteria, which contain a high level of 
guanine and cytosine in their DNA. As well as M. tuberculosis, the genus also includes 
Mycobacterium leprae, which is the causative agent of leprosy. The M. tuberculosis 
complex comprises at least five distinct members: M. tuberculosis, Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium canettii and Mycobacterium microti, all of which 
are pathogenic, slow growing species. The rapidly growing, non-pathogenic species, 
Mycobacterium smegmatis, is commonly used as a model organism for the study of M. 
Chapter 1 
20 
tuberculosis.81 The complete genome sequence of the H37Rv strain of M. tuberculosis was 
published in 1998,82 and represented a significant milestone in over a century of TB study. 
Although mycobacteria are classified among the Gram-positive bacteria, they possess a 
cell envelope structurally related to, but arguably more complex than that of, Gram-negative 
bacteria.83 The mycobacterial envelope consists of an inner plasma membrane and a thick 
cell wall comprised of peptidoglycan (PG) covalently linked to arabinogalactan (AG), which 
is esterified by mycolic acids. The outermost compartment consists of the loosely bound 
capsule structure and this surface forms the interface with the host.84 This cell envelope 
structure confers impermeability to small molecules and presents a further obstacle to TB 
therapeutics,85 Figure 1.16. 
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Figure 1.16 The M. tuberculosis cell envelope. The innermost layer is the phospholipid 
plasma membrane, separated from the outer membrane (phospholipids not shown) by the 
periplasmic space. This space is divided into the inner wall and medial zones, which are 
separated by a PG layer. The final, outermost layer attached to the outer membrane is the 
capsule. The cell wall core consists of the PG layer attached to the mycolate layer of the 
outer membrane via AG. Used with permission from Jackson et al. 2013.84 
Key: Medial Zone: PG, black with coloured peptides; galactofuranosyl residues, blue; 
arabinofuranosyl residues in AG, red. Outer Membrane: mycolic acids attached to arabinan, 
black; mycolic acids attached to trehalose, pink. Capsule: α-glucan (not structurally 
representative), black; mannan, purple; arabinomannan, purple and red. 
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1.5.2 TB treatments 
The attenuated M. bovis bacillus Calmette-Guérin (BCG) strain has been used as an anti-
TB vaccine for the last century, however its efficacy is highly variable.86 Since the 1970s, 
TB has been routinely treated with the first line drugs isoniazid (INH) and rifampicin (RIF) 
which target fatty acid metabolism and RNA synthesis respectively. Second line treatments 
include the injectable antibiotics kanamycin, capreomycin and amikacin, which target 
protein synthesis, as well as the fluoroquinolones, which target DNA gyrase.78 Lengthy and 
expensive treatment regimens have been streamlined into the 6-month directly observed 
treatment short-course therapy, which has been successful in improving patient compliance 
and completion of the full course of drugs.87 
Multi-drug resistant TB (MDR-TB) is defined as strains that are resistant to INH and RIF 
and accounted for 3.6% of the 8.6 million new cases of TB in 2012, and 20% of previously 
treated cases. Worst affected countries include South Africa and India, along with most of 
Eastern Europe. Extensively-drug resistant TB (XDR-TB) is defined as strains resistant to 
at least one of the three injectable antibiotics and a member of the quinolone family, in 
addition to INH and RIF. There was at least one case of XDR-TB in all the countries 
surveyed by WHO in 2013 and it makes up about 10% of all MDR-TB cases.79 Despite 
receiving considerable research investment and attention, only one new anti-TB drug has 
been approved in the last 40 years: bedaquiline, which has been shown to be active against 
MDR-TB.88 There is clearly an urgent need to develop novel anti-TB treatments with new 
targets. 
1.6 Targeting α-glucan metabolism in M. tuberculosis 
The α-glucan metabolic pathways in M. tuberculosis present a number of potential routes 
for the development of novel therapeutic agents. GlgE and GlgB are attractive drug targets, 
with a dual mechanism of action.89 Inhibition leads to the lethal accumulation of M1P that is 
escalated in an upregulated feedback loop,51 as well as the loss of the capsular α-glucan 
virulence factor.38 As there are two biosynthetic routes to M1P, mutations in both branches 
of the pathway would be required to prevent M1P build-up, and even if both routes are 
blocked, the reduced virulence resulting from the loss of capsular α-glucan remains. 
Trehalose metabolism in M. tuberculosis has already been targeted for inhibition or the 
incorporation of diagnostic probes, and its link with α-glucan metabolism may provide an 
indirect route to target the enzymes of the GlgE pathway. 
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1.6.1 Targeting GlgE 
The biochemistry, structure and mechanism of GlgE have been extensively characterised 
by K. Syson et al.. As high-resolution structures of M. tuberculosis GlgE have been difficult 
to obtain, S. coelicolor GlgE isoform 1 has been used as a structural model.90 These two 
enzymes have highly similar active site architectures and catalytic properties, with S. 
coelicolor GlgEI having 𝑘cat
app
 values an order of magnitude greater than M. tuberculosis 
GlgE, and the latter enzyme having a slightly lower optimum acceptor chain length of DP5 
vs. DP6.91 GlgE is the defining member of the GH13_3 subfamily and exists as a homodimer 
in solution,91-92 with a disulphide bridge between the two monomers in the M. tuberculosis 
structure.90 The predicted α-retaining double displacement mechanism is supported by a 
covalent catalytic intermediate, which could be trapped with a 2-deoxy-2-fluoro-α-maltosyl 
fluoride substrate analogue, aided by the removal of the catalytic acid/base residue.92 The 
carbohydrate binding sites -2 to +6 have been defined, along with secondary binding sites 
that can accommodate branched α-glucans.93 The structure of Mycobacterium 
thermoresistible GlgE revealed that the enzyme can adopt different conformational states, 
which are predicted to be important for the enzyme’s activity.94 GlgE conforms to a ping-
pong enzyme mechanism, whereby the donor and acceptor binding is sequential and not 
simultaneous.91 The enzyme is negatively regulated by PknB via Ser/Thr phosphorylation.95 
However, despite the detailed knowledge of the enzyme’s structure and activity, only a few 
inhibitors of GlgE have been reported to date. These are substrate and transition state 
analogues, which have been shown to bind to GlgE in vitro. Maltose C-phosphonate is a 
non-hydrolysable and isosteric analogue of M1P, which bound to GlgE and had an IC50 
value of 230 ± 24 µM. The transition state analogue 2,5-dideoxy-3-O-α-D-glucopyranosyl-
2,5-imino-D-mannitol had a Ki value of 237 ± 27 µM for M. tuberculosis GlgE, and had an 
approximately two-fold higher affinity for the S. coelicolor enzyme. The addition of a 
phosphonate moiety improved the Ki to 45 ± 4 µM and, whilst this is relatively weak, it is the 
most effective GlgE inhibitor reported to date. Maltosyl fluorides also bind to GlgE, but are 
slow substrates rather than inhibitors,92, 96 Table 1.2. Other putative GlgE inhibitors have 
been predicted by virtual docking, however these have not been verified experimentally.97 
Screening of small-molecule compound libraries was carried out by K. Syson in 
collaboration with MRCT, but also yielded no hit compounds (K. Syson, personal 
communication with permission). 
Whilst substrate analogues have been the most promising avenue for the development of 
GlgE inhibitors in vitro, carbohydrate uptake is highly limited in M. tuberculosis and it lacks 
the capacity to import maltose-based compounds. Therefore, the compounds shown in 
Chapter 1 
24 
Table 1.2 will be ineffective in vivo as they cannot reach the cytosolic GlgE target. The 
development of a M. tuberculosis carbohydrate-based inhibitor is limited to the known 
specificities of carbohydrate importers, namely for glycerophosphocholine, amino sugars 
and trehalose.98-100 
 
Table 1.2 Analogues that bind to and/or inhibit GlgE. a = IC50 value, b = Ki value, * = WT 
S. coelicolor GlgEI; nd = not determined. 
Compound 
S. coelicolor GlgEI V279S 
M. 
tuberculosis 
GlgE 
Ki (µM) 
Crystal 
Structure 
(Å) 
IC50/ Ki (µM) 
 
 
 
 
 
 
 
 
Maltose C-phosphonate 
nd 1.9 90 230 ± 24a 101 
 
 
 
 
 
 
 
R = H 102 ± 8 102 2.5 90 237 ± 27b 102 
  R =  45 ± 4 103 3.2 103 nd 
  R =  
95 ± 16 103 2.5 103 nd 
2,5-dideoxy-3-O-α-D-glucopyranosyl-
2,5-imino-D-mannitol compounds 
   
 
 
 
 
 
 
 
R = H 
Slow 
substrate* 92 
2.4* 92 nd 
R = F 
No 
 inhibition 96 
2.3 96 nd 
Maltosyl fluoride compounds    
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1.6.2 Targeting trehalose metabolism 
Trehalose metabolism has attracted attention as a target for anti-TB agents due to its 
absence in mammals and the integral role trehalose plays in cell wall glycolipids. The 
specificity of trehalose for mycobacteria has also been utilised to target therapeutics to the 
bacteria in vivo, using functionalised nanoparticles.104 Unlike almost all other types of 
carbohydrates, trehalose is readily taken up into the bacterium via the LpqY-SugABC 
transporter. This is highly specific for the α-1,1 linkage, but can accommodate a wide range 
of modified trehaloses.98 This has been exploited to incorporate fluorescent or radioactive 
labels for diagnostic imaging.105-108 Inhibiting the synthesis of trehalose is more challenging 
due to the multiple routes for trehalose biosynthesis. Efforts have instead focused on the 
inhibition of trehalose mycolate processing enzymes, such as Pks13, MmpL3 and Ag85, 
with a number of highly potent inhibitors identified.89 One approach that has not yet been 
considered is the indirect inhibition of GlgE via trehalose analogues, which could be taken 
into the cell and converted to GlgE inhibitors by the enzymes of the GlgE pathway. 
1.6.3 Targeting GlgB 
MtGlgB has been biochemically characterised and is a monomeric protein with an optimal 
activity at 30 °C, which is surprisingly low for a human pathogen.45 Due to exposed cysteine 
residues, different redox forms of the protein were proposed, however the redox 
environment does not affect enzymatic activity.109 One challenge for the development of 
GlgB inhibitors is the inherent difficulty in determining kinetic parameters, since branching 
reactions are difficult to monitor directly. Indirect kinetic parameters were previously 
determined by monitoring the amylase side reaction of the enzyme,60 which may not directly 
relate to the branching activity. Furthermore, this study used long-chain, linear amyloses 
that are not representative of GlgB substrates in vivo and therefore may not reflect the 
activity of the enzyme in vivo. 
MtGlgB has received less attention as a drug target due to the existence of a human 
homologue.62 However, these enzymes only share 27% sequence identity, therefore the 
development of a selective inhibitor is feasible. Other known inhibitors of GH13 enzymes 
such as ADP, ADP-glucose, tunicamycin, casternospermine, nojirimycin and acarbose 
were ineffective against GlgB.60 So far, high-throughput screening to identify inhibitors of 
GlgB has not been carried out. Some potential inhibitors of GlgB were claimed to have been 
identified through a computational docking approach and two of these also showed 
inhibition in whole-cell assays.110 However, the hit compounds were not validated using 
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counter-screens, whereby the effect of the compound on the amylose-iodine interaction is 
assessed to rule out false positives. The binding of compounds to the enzyme was not 
confirmed with any other method, therefore it cannot be ascertained whether the reported 
in vivo activity is specific for MtGlgB. 
As discussed above, the apo M. tuberculosis MtGlgB crystal structure exists, but it is low 
quality, which may preclude the determination of detailed SAR for future GlgB inhibitors. An 
improved structural model of mycobacterial GlgB would aid the rational design of inhibitors 
with increased potency or specificity. Additionally, substrate-bound structures would identify 
specific sites in the protein that can be targeted, such as the substrate donor or acceptor 
sites. 
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1.7 Project aims 
The main goals of this work were: to firstly improve the understanding of mycobacterial α-
glucan synthesis through structural studies, secondly to identify a small-molecule inhibitor 
of GlgB and thirdly to investigate targeting GlgE using trehalose analogues. These were 
achieved by addressing the following questions: 
Mycobacterial α-glucan synthesis (Chapter 2) 
• Are GlgE and GlgB sufficient to generate α-glucan in vitro? 
• Can the structural model of mycobacterial GlgB be improved? 
• Can mycobacterial GlgB substrate binding sites be identified? 
Targeting GlgB (Chapters 3 and 4) 
• Can an inhibitor of GlgB be identified by high-throughput screening? 
• Can SAR be established with a selection of modified compounds? 
• How do GlgB inhibitors behave in vivo? 
Targeting GlgE (Chapter 5) 
• Can a synthetic route to 4-deoxy trehalose analogues be established? 
• Are 4-deoxy trehalose compounds taken up in mycobacterial cells? 
• Can 4-deoxy trehalose analogues be processed in the GlgE pathway? 
Finally, the broader conclusions and implications of these results are discussed, along with 
future work. 
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2. Structural insights into the control of branch lengths in 
mycobacterial α-glucan 
2.1 Introduction 
α-Glucans are important energy storage polysaccharides in bacteria, plants and animals. In 
M. tuberculosis α-glucan also functions as a virulence factor that is exported to the capsular 
layer of the mycobacterial cell envelope, where it can interact with human immune 
receptors.1-2 In M. tuberculosis and other actinomycetes, α-glucan is synthesised from M1P, 
by the maltosyl transferase GlgE and the α-1,6-branching enzyme GlgB.3 Prior to the work 
described in this chapter, α-glucans from different actinomycete sources were extracted 
and analysed, demonstrating that actinomycete α-glucan is structurally distinct from 
classical E. coli or mammalian glycogen. It had shorter average branch lengths of DP ~7, 
compared to DP ~11 for classical glycogen. Mycobacterial α-glucan also had shorter 
internal chain lengths of DP ~5.0 and a smaller A:BC chain ratios of 0.2-0.6, compared to 
DP ~8 and 0.8 for classical glycogen.4 However, it had not been shown that GlgE and GlgB 
were directly responsible for the distinct α-glucan architecture. Therefore, I aimed to answer 
the question: Are GlgE and GlgB sufficient to generate α-glucan in vitro? 
Following this, I wanted to investigate the structural features of mycobacterial GlgB, to 
improve the understanding of how this enzyme generates the distinct architecture of the α-
glucan product. This would also be useful in order to identify target sites for MtGlgB 
inhibitors and help with the determination of structure-activity relationships of potential 
inhibitors. The structural determinants that control the product architecture would also be 
relevant to the general understanding of branching enzymes, as these had not been clearly 
established for any enzyme of this type. Whilst all GH13 branching enzymes share the same 
domains, motifs and GH α-retaining mechanism, Figure 2.1, there is no obvious correlation 
with amino acid sequence and branch length specificity.5 Crystal structures of branching 
enzymes from E. coli, rice, human, M. tuberculosis and cyanobacteria have been solved,6-
11 however only the latter has a maltooligosaccharide bound at the donor site, which allowed 
the identification of the donor subsites. Several maltooligosaccharide binding sites were 
also identified in the E. coli, rice and human enzymes,7-8, 11-12 but these were far removed 
from the catalytic residues. An acceptor site was proposed for the cyanobacterial enzyme, 
based on similar distal maltooligosaccharide binding sites, however no 
maltooligosaccharides bound closer than ~30 Å to the catalytic residues were seen in this 
region.10 
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For the M. tuberculosis homologue only a low quality, apo structure had been reported,9 so 
it was not yet possible to relate substrate binding to branch length control. Therefore, I firstly 
aimed to answer the question: Can the structural model of mycobacterial GlgB be 
improved? Secondly, I aimed to answer the question: can mycobacterial GlgB substrate 
binding sites be identified? This would not only serve as a tool to investigate the structural 
determinants of branch length specificity, but would also reveal new target sites for small-
molecule GlgB inhibitors. 
 
Figure 2.1 Branching enzyme mechanism. The branching enzyme GlgB cleaves an α-
1,4 glucan chain and transfers the non-reducing end on to a 6-OH of another glucose 
residue, creating a branchpoint. GH13 branching enzymes utilise an α-retaining 
mechanism, with the catalytic residues of an Asp nucleophile and a Glu acid/base. The 
reaction proceeds via a covalent intermediate (middle panel). 
 
  
Chapter 2 
38 
2.2 GlgB enzymes from actinomycetes generate α-glucan branch lengths 
of DP 7-8 in vitro 
Some of the work described in this section has been published as part of Rashid et al. 
20164. Appendix 1, and appears with permission. 
2.2.1 Production of recombinant GlgB enzymes 
To investigate the activity of actinomycete branching enzymes in vitro, I firstly produced 
recombinant GlgB proteins. I optimised the expression and purification protocols to produce 
MtGlgB and MsGlgB each with an N-terminal His6 tag in high yield, Figure 2.2. Other GlgB 
enzymes from S. coelicolor, S. venezuelae and M. tuberculosis CCDC5180 had been 
previously produced by A. Rashid.4 
 
Figure 2.2 Production of recombinant GlgB proteins.A) M. tuberculosis H37Rv GlgB; 
B) M. smegmatis mc2 155 GlgB. Proteins were purified by Ni+ affinity and size exclusion 
chromatographies, which showed one major peak. The protein purity was confirmed by 
analysing fractions with SDS-PAGE and Coomassie staining. The expected mass of the 
recombinant GlgB protein is shown with a red arrow adjacent to the major component in 
both cases. For each protein, the fractions indicated with a red bracket were combined and 
concentrated for use in further experiments. 
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2.2.2 Synthesis of α-glucan in vitro 
The GlgB enzyme was hypothesised to work in tandem with GlgE, which extends α-1,4 
oligosaccharides using M1P to generate α-1,4 glucan substrates for branching.3 It was 
previously established that M. tuberculosis and S. coelicolor GlgE enzymes have similar 
kinetic properties, apart from an order of magnitude lower 𝑘cat
app
 for the M. tuberculosis 
enzyme.13 Therefore, to generate α-glucan in vitro, I incubated M1P and a maltohexaose 
acceptor with either M. tuberculosis or S. coelicolor GlgE along with MtGlgB. To ensure 
completion of the reactions, two further aliquots of M1P were added over the course of the 
90 h incubation period. Residual low molecular weight oligosaccharides of mass ≤ 5 kDa 
were removed by filtration and the resultant α-glucan particles were imaged with 
transmission electron microscopy (TEM) by E. Barclay, Figure 2.3. Similar spherical 
particles were observed, with average sizes of 32 ± 14 nm and 30 ± 15 nm for M. 
tuberculosis GlgE and S. coelicolor GlgE respectively, indicating that the source of GlgE 
does not affect α-glucan particle size in these conditions. Particles were slightly smaller than 
in α-glucan extracted from M. tuberculosis, which had an average size of 58 ± 2 nm. I went 
on to generate in vitro α-glucan with the other actinomycete GlgB enzymes detailed above, 
in combination with S. coelicolor GlgE due to its higher catalytic activity. 
 
 
Figure 2.3 Synthetic α-Glucan particles. A) α-Glucan particles generated by M. 
tuberculosis GlgE and MtGlgB. Mean particle size ± standard deviation: 32 ± 14 from 48 
measurements. B) α-Glucan particles generated by S. coelicolor GlgE and MtGlgB. Mean 
particle size 30 ± 15 nm from 40 measurements. Branch lengths DP 8.1 ± 2.7 (MALDI mass 
spectrometry) or 7.5 ± 3.5 (CE). 
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2.2.3 Synthetic α-glucan has branch lengths of DP 7-8 
α-Glucan branch lengths were then determined by debranching with isoamylase and 
analysis by matrix assisted laser desorption / ionisation (MALDI) mass spectrometry. 
Results were verified by capillary electrophoresis (CE), which gave very similar branch 
lengths, showing that MALDI mass spectrometry was reliable for these analyses. 
Comparison of reactions of M. tuberculosis GlgE or S. coelicolor GlgE in combination with 
MtGlgB showed similar branch lengths of DP 8.6 ± 2.5 and 8.1 ± 2.7 respectively, 
demonstrating the source of GlgE also has no discernible effect on α-glucan branch lengths. 
The branch length specificities of the other actinomycete GlgB enzymes were then 
determined, Table 2.1. Branch lengths ranged from DP 7-8, which correlated with those of 
α-glucan extracted from actinomycete cells, therefore, GlgE and GlgB are sufficient for 
synthesis of an α-glucan which is representative of the polysaccharide in vivo. This work 
confirms that these enzymes are responsible for the notably shorter branches in 
actinomycete α-glucan compared to those in classical glycogen, which has branch lengths 
of 10.8 ± 4.6 (rabbit liver) and 11.0 ± 2.9 (E. coli).4 
Table 2.1 α-Glucan branch lengths generated by actinomycete GlgB enzymes. α-
Glucan was generated as described above, debranched with isoamylase and branch 
lengths were analysed by MALDI mass spectrometry and CE. Length distributions are 
shown as mean ± standard deviation of products DP ≥ 4. Each result is representative of at 
least two independent experiments. 
Source of GlgB Source of GlgE 
Branch Length DP 
MALDI 
Mass Spectrometry 
CE 
M. tuberculosis 
M. tuberculosis 8.6 ± 2.5 8.0 ± 3.1 
S. coelicolor 8.1 ± 2.7 7.5 ± 3.5 
M. tuberculosis CCDC5180 
S. coelicolor 
8.4 ± 2.5 - 
M. smegmatis 8.5 ± 2.5 - 
S. venezuelae 7.9 ± 2.4 - 
S. coelicolor 7.2 ± 2.2 7.1 ± 3.1 
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2.3 A high-resolution structural model of MtGlgB 
Having established that MtGlgB and other actinomycete glucan branching enzymes 
generate markedly shorter branches than those of classical glycogen, my next goal was to 
investigate the structural basis for this differing branching activity. This firstly required the 
generation of high-resolution GlgB crystal structures, with which substrate binding could 
be investigated. 
2.3.1 Crystallisation of MtGlgB 
The crystal structure of apo MtGlgB at 2.33 Å was previously solved by Pal and co-workers 
(PDB code 3K1D),9 however no substrate-bound structures had been reported for this 
enzyme. I therefore initially set out to replicate the crystallisation of MtGlgB, according to 
the reported conditions, comprising a precipitant solution of 30% polyethylene glycol (PEG) 
4,000 and 0.1 M MES at pH 6.5 with 12 mg/mL protein. The MtGlgB protein with an N-
terminal His6 tag was produced as described above, and crystallisation trials were set up 
with these conditions, but no protein crystals were observed. Systematic variation of the 
components of the precipitant solution, pH and protein concentration, along with the addition 
of reducing agents, metal ions or maltooligosaccharides did not improve protein 
crystallisation. The MtGlgB protein was then subjected to crystallisation trials with a range 
of different commercial screens, which also yielded no protein crystals. Cleavage of the N-
terminal His6 tag did not improve protein crystallisation under any of the investigated 
conditions. 
I then explored the possibility that the tags used for protein production affected the protein 
crystallisation. The MtGlgB protein produced by Pal and co-workers included an N-terminal 
S-tag and a C-terminal His6 tag, compared with a single N-terminal His6 tag in my construct. 
Modifying the expression construct to locate the His6 tag at the C terminus resulted in much 
a lower yield of protein that was mostly insoluble. Investigation of the plasmid stability 
indicated a higher proportion than expected of mutants that had lost the ability to produce 
MtGlgB-CHis6, Figure 2.4A. This normally suggests that the target protein is toxic to the 
cell, although it is difficult to rationalise how this would result from such a small modification 
to the protein. Both the solubility and overall yield were not improved with different E. coli 
expression strains. 
Subsequently, I investigated truncating the protein sequence as an approach to enable 
protein crystallisation. Firstly, I tested the removal of amino acid residues 1-108, to remove 
domain N, because this is the most disordered region in the protein according to predictions 
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generated with XtalPred-RF,14 and this approach has been successful for the crystallisation 
of other branching enzymes.6 In contrast to the previous expression construct, plasmid 
stability tests indicated that the resultant recombinant protein had no detrimental effect on 
E. coli growth, Figure 2.4A. Whilst it was produced in relatively high yield, it was insoluble 
in all expression conditions tested. I then tested the removal of just the first nine amino 
acids, which were predicted to be the most disordered region in domain N, by both XtalPred-
RF14 and their absence in the MtGlgB electron density map. The resulting protein was both 
soluble and could be produced in high yield. Gratifyingly, crystallisation trials with various 
commercial screens resulted in protein crystals with two different precipitant solutions, 
namely 12.5% polyacrylate 2100 with 0.5 M NH4H2PO4 and 30% Sokalan® CP42 with 0.1 
M Tris-HCl at pH 8.5. Sokalan® is also an acrylic polymer, suggesting that this reagent may 
play an essential role the crystallisation of ΔN9-MtGlgB. Protein crystallisation strategies 
are summarised in Table 2.2 and crystal images are shown in Figure 2.4. 
Table 2.2 Summary of approaches for MtGlgB crystallisation. Full length MtGlgB with 
either an N or C-terminal His6 tag did not crystallise. Removal of the N domain resulted in 
insoluble protein, whereas removal of only the first nine amino acids gave protein crystals, 
however these diffracted very weakly. 
Protein ID Vector Tag Soluble Protein Crystallisation Diffraction 
MtGlgB pET21a N-His6 ✓ × - 
MtGlgB-CHis6 pET101a C-His6   ✓ (low) × - 
ΔN9-MtGlgB pET21a N-His6 ✓ ✓ × 
ΔN108-MtGlgB pOPINA C-His6 × - - 
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Figure 2.4 Crystallisation of MtGlgB. A) Plasmid stability tests for MtGlgB-C-His6 ΔN108-
MtGlgB-C-His6. Colonies on IPTG + antibiotic (AB) plate for MtGlgB-C-His6 indicates that 
production of this protein has an unexplained detrimental effect on cell function, whereas 
the absence of colonies on the equivalent plate for ΔN108-MtGlgB-C-His6 demonstrates 
that this protein is non-toxic. B) Images of (i) ΔN9-MtGlgB crystals generated with 
polyacrylate precipitant imaged with a polarising optic; (ii) rod-shaped crystal in cryoloop; 
(iii) part of the diffraction pattern, showing very weak diffraction. 
I attempted to optimise the production of protein crystals by varying the components of the 
precipitant solutions and micro-seeding with crystal fragments. Any modifications to the 
polyacrylate precipitant solution decreased the quality of the crystals. For the other 
crystallisation condition, decreasing the proportion of Sokalan to ~10% increased the size 
of the crystals. A protein concentration of ~5 mg/mL was found to be optimal as higher or 
lower concentrations resulted in precipitation or no crystals, respectively. In all cases, 
cleavage of the N-terminal His6 tag, addition of maltooligosaccharides and varying the ratio 
of protein and precipitant solution had no discernible effect on the crystals generated. 
Likewise, a commercial additive screen did not lead to any improvements or variations in 
the type or quality of crystals produced. Finally, crystallisation trials with commercial screens 
that did not previously yield crystals were repeated using seeding with crystal fragments. 
This resulted in protein crystallisation in two further conditions, however the crystals were 
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too small to be used in X-ray diffraction experiments and were not improved by 
optimisations. 
2.3.2 The structure of MtGlgB could not be solved 
Crystals of MtGlgB were cryoprotected, frozen and X-ray diffraction data were collected. In 
general, the diffraction was very poor, with crystals from the polyacrylate condition 
diffracting slightly more strongly. Data processing was attempted for the best data set, for 
which the solvent content was estimated at 65%. Attempts to process the data with the 
given cell parameters resulted in two overlapped molecules with large gaps in the P2 crystal 
lattice. Doubling the b axis resulted in a reasonable solution with no overlaps, which 
contained four molecules per asymmetric unit. However, attempts to refine this model were 
unsuccessful and an Rfree value of less than 45% could not be obtained. Crystals from the 
attempted optimisations described above gave similar or worse data. I concluded that it was 
not feasible to investigate the structural determinants of branching activity with MtGlgB. 
2.3.3 Crystallisation of MsGlgB 
Since it was not possible to obtain structural data for MtGlgB, I went on to investigate the 
MsGlgB homologue. These two proteins share 82% amino acid sequence identity and 
earlier in this chapter I showed they have very similar branch length specificities. Therefore, 
it was reasonable to expect that the M. smegmatis homologue would provide a good 
structural model for MtGlgB. The MsGlgB protein was produced as described in section 
2.2.1 and subjected to crystallisation trials with a range of commercial screens. After one 
week, crystals were observed with precipitant solution: 0.06 M MgCl2, 0.06 M CaCl2, 20% 
glycerol, 10% PEG 4,000, 0.1 M imidazole, 0.1 M MES at pH 6.5. Variation of the 
components of the precipitant solution did not improve the quality of crystals, but micro-
seeding did lead to improvements in the crystal size and morphology, Figure 2.5. 
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Figure 2.5 Crystallisation of MsGlgB. A) Initial crystals observed for MsGlgB with and 
without UV imaging. B) Optimised crystals of MsGlgB imaged with a polarising optic. C) 
Diamond-shaped crystal in cryoloop. D) Section of the diffraction pattern showing strong 
diffraction. 
2.3.4 The structure of MsGlgB was solved at 1.72 Å resolution 
Crystals of MsGlgB were flash-frozen without additional cryoprotectant and X-ray diffraction 
data were recorded. The data sets were processed in the P21212 space group, with cell 
parameters of approximately a = 98, b = 164, c = 54 Å. The initial structure was solved by 
molecular replacement in PHASER,15 using MtGlgB (PDB code 3K1D) as a template. One 
molecule was placed in the asymmetric unit, corresponding to the monomeric nature of the 
protein in solution. The structure was rebuilt and completed through several iterations of 
refinement with REFMAC5,16 and manual model building with COOT.17 This model was 
used as a starting point to refine further MsGlgB structures, and the best data set for the 
apo wildtype (WT) protein, Apo-WT-MsGlgB, was solved at 1.72 Å resolution, Figure 2.6 
and Table 2.4. 
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Figure 2.6 Structure of MsGlgB coloured by domain. Apo-WT-MsGlgB structure shown 
as A) surface model and B) ribbon model. Cyan = domain N, yellow = CBM48, lilac= domain 
A, dark purple = domain C. Catalytic residues D416 and E469 are indicated with arrows. 
2.3.5 Comparison of MsGlgB and MtGlgB apo structures 
In common with MtGlgB and other branching enzymes, 6-8, 10 MsGlgB comprised domain N 
(residues 9-110), CBM48 (111-231), the catalytic domain A (232-635) and domain C (637-
736), arranged sequentially along the longitudinal axis of the protein, Figure 2.6. Reflecting 
their conserved amino acid sequences and catalytic specificities, the 3D structures of the 
enzymes were highly similar, with a C-α root mean square deviation (RMSD) of 0.49 Å. 
Differences were mainly concentrated in domain N and some surface loops, Figure 2.7. 
Overall, this work validated MsGlgB as a high-resolution structural model for MtGlgB. This 
model represents a significant improvement on the previously published structure, and can 
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be used for both the rational design of GlgB inhibitors and to investigate the structural 
determinants of the branch length specificity. 
 
Figure 2.7 MsGlgB is structurally equivalent to MtGlgB. A) Surface model of MsGlgB 
coloured by amino acid sequence conservation with MtGlgB. Green = identical, yellow = 
similar, red = different. The proteins share 82% sequence identity, with most differences 
found in their N-termini. B) Superposition of MsGlgB (cyan) and MtGlgB (coral) structures, 
shown as ribbon models. As would be expected from their high sequence conservation, the 
structures are very similar, with a Cα RMSD of 0.49 Å. 
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2.4 Identification of oligosaccharide binding sites in MsGlgB 
Having obtained a high-resolution model for mycobacterial GlgB, my next objective was to 
identify oligosaccharide binding sites to understand how this enzyme binds to its substrate 
and creates branches of a specific length. In total, 10 distinct binding sites could be identified 
from five oligosaccharide-bound crystal structures of wild type and modified GlgB proteins. 
An overview of oligosaccharide binding is shown in Figure 2.8 and the identification of these 
sites is detailed in the following sections. For clarity, the structures referred to in this section 
are summarised in Table 2.3. 
 
Table 2.3 Summary of structures discussed in Section 2.4. Ligand binding sites are 
defined and colour-coded according to Figure 2.7 and the identity of the 
maltooligosaccharide ligands is given in parenthesis. 
* DP3-ACR binds across the N3 and A1 sites in DP3-ACR-MsGlgB. 
 
Structure ID 
X-ray data collection 
statistics 
Ligand binding sites 
Apo-WT-MsGlgB Table 2.4 None 
DP4-WT-MsGlgB 
Table 2.4 
C4 (DP4) 
Apo-D416A-MsGlgB 
Appendix 2 
 
None 
Apo-E469A-MsGlgB Appendix 2 None 
Apo-D416A-E469A-MsGlgB Appendix 2 None 
DP8-D416A-MsGlgB Table 2.5 
N1 (DP1), N2 (DP2), N3 
(DP2), Donor (DP8), C1 
(DP6), C2 (DP6), C3 
(DP3), C4 (DP7) 
DP8-D416A-E469A-MsGlgB Appendix 2 
N1 (DP1), N2 (DP2), N3 
(DP2), Donor (DP8), C1 
(DP6), C2 (DP6), C3 
(DP3), C4 (CP7) 
ACR-E469A-MsGlgB Table 2.5 
N2 (DP3), A2 (ACR), C3 
(ACR) 
DP3-ACR-MsGlgB Table 2.5 
N2 (DP2), N3 (DP3*), A1 
(ACR*), C2 (ACR) 
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Figure 2.8 Overview of oligosaccharide binding in MsGlgB. Ribbon model of Apo-WT-MsGlgB superposed with all oligosaccharide binding 
sites observed in the crystal structures DP8-D416A-MsGlgB, ACR-E469A-MsGlgB and DP3-ACR-E469A-MsGlgB described in Table 2.5 and 
the text below. Bindings sites comprise: N1 (1), N2 (2), N3 (3), A1 (4), A2 (4), Donor (8), C1 (6), C2 (6), C3 (3) and C4 (7), with the maximum 
number of glucose units or pseudoglucose units accommodated specified in parentheses. Colour scheme according to Figure 2.6.
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2.4.1 Identification of surface binding sites in WT MsGlgB 
MsGlgB WT protein crystals were subjected to soaks and/or co-crystallisations with various 
commercially available α-glucans, including maltose, maltooligosaccharides, maltodextrin, 
amyloses from different plant sources and cyclodextrins at concentrations of up to ~10 mM. 
In most cases these did not yield oligosaccharide-bound structures, with the exception of 
weak density C4 or N2 sites. Only by soaking crystals with much greater concentrations of 
maltooligosaccharides or maltodextrin (≥ 100 mM) could binding sites N1-N3 and C1-C4 be 
distinguished. The binding of oligosaccharides tended to improve the resolution of the 
structures and a structure with a tetrasaccharide bound at the C4 site was determined at 
1.46 Å resolution, Table 2.4, the highest reported for any branching enzyme. However, no 
binding of oligosaccharides at or near the active site was observed in the WT protein and 
therefore I investigated whether this could be achieved using mutagenesis. 
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Table 2.4 X-ray data collection and refinement statistics for WT MsGlgB structures. 
Values in parentheses are for the outer resolution shell; r.m.s., root mean square. 
 
 
 
 
 
  
Dataset ID Apo-WT-MsGlgB DP4-WT-MsGlgB 
Data Collection   
Beamline I04-1 I03 
Wavelength (Å) 0.9282 0.9763 
Detector Pilatus 6M Pilatus3 6 M 
Resolution range (Å) 84.49-1.72 (1.75-1.72) 54.10-1.46 (1.48-1.46) 
Space group P21212 P21212 
a, b, c (Å)  98.49, 164.41, 54.52 97.36, 162.31, 53.75  
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Total observations 912,423 (46,131) 1,949,958 (86,737)  
Unique reflections 94,955 (4,676) 148,349 (7219) 
Multiplicity 9.6 (9.9) 13.1 (12.0) 
Mean I/σ(I) 9.6 (1.2) 16.3 (1.2) 
Completeness (%) 100.0 (100.00) 100.0 (99.9) 
Rmergea 0.152 (1.846) 0.073 (2.015) 
Rmeasb 0.161 (1.949) 0.076 (2.105) 
CC1/2
c 0.998 (0.606) 1.000 (0.738) 
Wilson B value (Å2) 20.7 21.0 
Refinement   
Resolution range (Å) 84.49-1.72 (1.75-1.72) 54.10-1.46 (1.48-1.46) 
Reflections: working/freed 90,195/4,684 140,775/7,483 
Final Rwork 0.164 0.125 
Final Rfreee 0.186 0.160 
Estimated coordinate error (Å)f 0.089 0.052 
r.m.s bond distance deviation (Å) 0.0152 0.0103 
r.m.s. bond angle deviation (°) 1.511 1.411 
No. of protein residues per chain (ranges) 723 (9-375; 380-736) 723 (9-375; 380-736) 
No. of heterogen residues: sugar/water/otherg 0/759/9 4/737/9 
Mean B factors: protein/ligands/water/overall (Å2) 25/34/37/25 27/36/41/27 
Ramachandran: favoured/allowed/disallowedh (%) 97.6/2.3/0.1 98.2/1.7/0.1 
Protein Data Bank accession code N/A N/A 
a Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl). 
b Rmeas = ∑hkl [N/(N  1)]1/2 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith observation of 
reflection hkl, I(hkl) is the weighted average intensity for all observations i of reflection hkl and N 
is the number of observations of reflection hkl. 
c CC1/2 is the correlation coefficient between symmetry equivalent intensities from random halves 
of the data set. 
d The data set was split into “working” and “free” sets consisting of 95 and 5% of the data, 
respectively. The free set was not used for refinement. 
e The R factors Rwork and Rfree were calculated as follows: R = (| Fobs - Fcalc |)/| Fobs |where 
Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively. 
f Based on Rfree as calculated by REFMAC5.1 
g “Other” includes glycerol and sodium ions 
h As calculated using MolProbity.2 
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2.4.2 Crystallisation of MsGlgB proteins with mutated active site residues 
One approach that has been successfully used to generate substrate-bound crystal 
structures of CAZymes is the mutation of active site residues. I investigated this by 
generating modified GlgB proteins in which either or both of the catalytic residues D416 and 
E469 were mutated to alanine. MsGlgB expression plasmids were modified using a 
QuikChange Lightning site-directed mutagenesis kit and proteins D416A-MsGlgB, E469A-
MsGlgB and D416A-E469A-MsGlgB were produced as described previously, Figure 2.9. 
As would be expected, no enzymatic activity was detected for any of the modified proteins. 
In addition, no negative effects on protein production were observed as a result of these 
changes. In fact, modification of D416 increased protein thermostability, as determined by 
nano differential scanning fluorimetry (DSF), for which differences in melting temperatures 
(Tm) ≥ 0.5 °C are considered significant. Tms were 65.0 °C for D416A-MsGlgB and 64.4 °C 
for D416A-E469A-MsGlgB, compared with 63.9 °C for the WT protein and 62.9 °C for 
E469A-MsGlgB. The proteins were crystallised, X-ray diffraction data were recorded and 
models were refined as previously, Figure 2.9 and Appendix 2. The electron density maps 
were consistent with the expected amino acid substitutions. Overall the structures were very 
similar to that of the WT protein, apart from a slight rearrangement of residues adjacent to 
E469A in E469A-MsGlgB and D416A-E469A-MsGlgB. 
 
Figure 2.9 Production and crystallisation of MsGlgB proteins with mutated active site 
residues. Proteins were produced and crystallised as described above. Analysis of 
fractions by SDS-PAGE and the corresponding protein crystals imaged with polarised light 
are shown for each MsGlgB protein. 
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2.4.3 Attempts to trap a covalent intermediate with 2-deoxy-2-fluoro 
maltosyl fluoride oligosaccharides 
Having solved the structures of GlgB proteins with the activity of either or both of the 
catalytic residues abolished, I firstly attempted to use E469A-MsGlgB and a fluorinated 
substrate mimic to obtain structures with oligosaccharides covalently bound at the active 
site. This was achieved previously for S. coelicolor GlgE, whereby a covalent intermediate 
was trapped using 2-deoxy-2-fluoro-α-maltosyl fluoride and a modified GlgE protein with 
the acid/base residue substituted for Ala, equivalent to E469A-MsGlgB.18 With this 
substrate, the electron withdrawing character of the 2-fluoro substituent destabilises the 
oxocarbenium transition states in the α-retaining double displacement mechanism, Figure 
1.2. In the formation of the covalent bond with the nucleophilic residue, this is partly 
compensated for by the presence of the anomeric fluoride, which is a better leaving group 
relative to hydroxyl in the normal glucan substrate. However, formation of the α-1,4-
glycosidic bond in the second step is much slower, impeding the overall reaction 
mechanism. With WT GlgE 2-deoxy-2-fluoro-α-maltosyl fluoride served as a slow substrate 
that could be used to extend maltotetraose.13 The additional loss of the acid/base catalysis 
in the modified GlgE protein further slows the formation of the α-1,4-glycosidic bond, 
effectively trapping the covalent intermediate, which was then detected by X-ray 
crystallography, Figure 2.10A.18 
Initially, I soaked crystals of E469A-MsGlgB with high concentrations of 2-deoxy-2-fluoro-
α-maltosyl fluoride, but this did not result in any detectable ligand binding in the active site 
or anywhere else in the protein. Previous studies have suggested that 
maltooligosaccharides ≥ DP4 are required to detect any binding to branching enzymes.8, 11 
I hypothesised that extended 2-deoxy-2-fluoro-α-maltosyl fluorides could provide the 
additional binding interactions that may be needed to trap a covalent enzyme intermediate 
in E469A-MsGlgB. I then tested whether 2-deoxy-2-fluoro-α-maltosyl fluoride could be 
extended by S. coelicolor GlgE in the absence of a DP4 acceptor. MALDI spectra of the 
reaction products demonstrated that this was the case and peaks had an m/z value of DPn 
+ (n + 2), where n is an even integer up to DP24, Figure 2.10B. This is consistent with a 2-
deoxy-2-fluoro substitution on alternate glucose residues and the retention of the reducing 
end fluoride, which might have otherwise been hydrolysed. After removal of GlgE by 
precipitation and filtration, the product mixture was used for E469A-MsGlgB crystal soaks. 
However, as before, no additional density was observed in the crystal structures, and 
therefore this approach to generate active site bound GlgB structures was not pursued 
further. 
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Figure 2.10 Using 2-deoxy-2-fluoro maltosyl fluoride oligosaccharides to trap 
covalent intermediates. A) Reaction of 2-deoxy-2-fluoro maltosyl fluoride moiety in the 
active site of an GH13 α-retaining enzymes with and without mutation of acid/base residue 
to alanine. B) MALDI mass spectrum of products from the incubation of 2-deoxy-2-fluoro-
α-maltosyl fluoride with WT S. coelicolor GlgE. The m/z values are increased by two for 
each fluorine atom, with the general formulae of m/z = DPn + (n + 2), indicating that the 
reducing end fluorine atom was retained. Crystal soaks with this mixture did not yield 
substrate-bound structures. 
2.4.4 Identification of donor site with maltooctaose-bound D416A-MsGlgB 
I subsequently carried out crystal soaks of D416A-MsGlgB, E469A-MsGlgB and D416A-
E469A-MsGlgB with high concentrations of maltooctaose and maltodextrin. For D416A-
MsGlgB and D416A-E469A-MsGlgB maltooligosaccharides were observed bound in the 
active cleft, but not in E469A-MsGlgB. Maltooligosaccharide binding at the N1-N3 and C1-
C4 sites was observed in all of the modified proteins, indicating that, under these conditions, 
the presence of the nucleophilic residue D416 was the main barrier to binding at the active 
site. The best data sets were processed to give DP8-D416A-MsGlgB and DP8-D416A-
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E469A-MsGlgB, both with maltooctaose-bound at the active site, at resolutions of 1.88 Å 
and 1.42 Å, respectively, Table 2.5. Comparison with other GH13 enzyme structures clearly 
indicated that maltooctaose occupied the donor binding site. 
Interestingly, the reducing end pyranose occupying donor subsite -1 had a different 
configuration in each structure. In DP8-D416A-MsGlgB this pyranose has a β-
configuration, with O1 positioned towards the D416A residue, consistent with the orientation 
in the covalent intermediate present in the α-retaining mechanism. The O1 forms a 
hydrogen bonding interaction with the acid/base catalytic residue E469 as would be 
expected from the branching enzyme catalytic mechanism. Conversely, in the DP8-D416A-
E469A-MsGlgB structure the reducing end pyranose has an α-configuration. The 
rearrangement around E469A, described above for the apo-E469A-MsGlgB structure, 
allows E470 to coordinate to the α-O1, Figure 2.11. Since this is unlikely to be relevant to 
the catalytic mechanism, only DP8-D416A-MsGlgB was used in further analyses of ligand 
binding. 
 
Figure 2.11 Alternative configurations of the reducing end pyranose observed in DP8-
D416A-MsGlgB and DP8-D416A-E469A-MsGlgB. Superposition of Apo-WT-MsGlgB, 
(coral, no ligand-bound) DP8-D416A-MsGlgB (cyan, β-maltooctaose-bound) and DP8-
D416A-E469A-MsGlgB (pink, α-maltooctaose-bound) structures, showing the reducing 
end pyranose in ball and stick form and the main chain of residues 400-420 and 460-490 
as a ribbon model. Rearrangement of residues E469A - A471 in DP8-D416A-E469A-
MsGlgB allows E470 to coordinate to α-O1, whereas in DP8-D416A-MsGlgB E469 
coordinates to β-O1. 
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The electron density of the oligosaccharide ligand was clearly resolved, so I could 
unambiguously assign donor subsites -1 to -8, Figure 2.12. In total, 17 amino acid residues 
coordinate to maltooctaose in DP8-D416A-MsGlgB via hydrogen bonding or van der Waals 
interactions, Figure 2.13. The bound maltooctaose adopts a twisted “S” conformation, as 
seen previously in Chlamydomonas reinhardtii isoamyase (ISA) (CrISA; pdb code 4OKD)19 
and Cyanothece sp. ATCC 51142 BE1 (CceBE1; pdb code 5GQX), the only other known 
branching enzyme structure with a maltooligosaccharide bound at the active site.10 In the 
latter structure, an unusual 91 ° rotation of the reducing end pyranose was observed. On 
the other hand, I observed an orientation of this ring that corresponds to the covalently 
bound glycosyl enzyme intermediate of the CrISA, Figure 2.12, suggesting that this 
structure reflects the orientation of the sugar in the covalent intermediate. Accordingly, the 
distance between the Cα of D416A and the C1 of pyranose is 4.42 Å, compared to 4.59 Å 
in the covalently bound CrISA structure. 
In the -1 subsite, there are hydrogen bonding interactions with His351 (O6), His536 (O3), 
Asp337 (O2 & O3) and Arg414 coordinates O1 & O2 via a water molecule. These residues 
are highly conserved across GH13 family enzymes.20 A further CH/π stacking interaction 
with Tyr311 coordinates this reducing-end pyranose. Subsites -2 to -6 are mainly conserved 
between DP8-D416A-MsGlgB and CceBE1. However, in CceBE1 the pyranose in subsite 
-7 is rotated at a slightly different angle. Whilst both pyranoses in the -7 subsites are 
coordinated to a C-α NH via O2, that of CceBE1 is additionally coordinated by Arg216 side 
chain (equivalent to Pro227 in DP8-D416A-MsGlgB), Asp324 (Gly306 in DP8-D416A-
MsGlgB) and Val282 C=O, in an extra loop not found in DP8-D416A-MsGlgB. The 
pyranose in the MsGlgB -8 subsite is coordinated by Glu591 and Glu592, residues that are 
not conserved in CceBE1. The O4 of pyranose in the -8 subsite points into solvent, meaning 
that it is possible that oligosaccharides longer than DP8 can extend from the MsGlgB donor 
site.
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Figure 2.12 Maltooctaose-bound in the donor site of D416A-MsGlgB. A) Maltooctaose-bound in the donor site of MsGlgB showing hydrogen 
bonding and coordinating residues, also shown in Figure 2.13. Protein shown in cyan, maltooligosaccharide carbons in green, oxygen atoms in 
red and nitrogen atoms in blue. Catalytic residues D416A and E469A are indicated. B) The omit electron density map (1.88-Å resolution; contoured 
at ~3.0σ) indicating the binding of β-maltooctaose. Donor subsites are labelled -1 to -8. 
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Figure 2.13 Interactions between maltooctaose and D416A-MsGlgB. 2D plot of 
maltooctaose-bound in donor site in a “twisted-S” conformation and protein residue side 
chains. Hydrogen bonds are shown by dashed lines and dashed arc indicate hydrophobic 
interactions. Catalytic residues are shown in blue and donor subsites labelled in red. 
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Figure 2.14 MsGlgB and Cce BE1 donor sites are similar. A) Superposition of DP8-D416A-MsGlgB and DP7-CceBE1 donor binding sites, 
showing interacting protein side chains. For DP8-D416A-MsGlgB protein is shown in cyan and the maltooligosaccharide in green. For DP7-
CceBE1 the protein is shown in coral and the maltooligosaccharide is shown in purple. Catalytic residues are labelled in blue for DP8-D416A-
MsGlgB and orange for DP7-CceBE1. B) Superposition of maltooligosaccharides only, with MsGlgB donor subsites labelled. 
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The structures of Apo-D416A-MsGlgB and DP8-D416A-MsGlgB were then directly 
compared, to ascertain whether maltooligosaccharide binding at the donor site is facilitated 
by conformational changes in the protein. In DP8-D416A-MsGlgB there was a slight shift 
in the main chain between residues 350-355, with His351 NH moving 2.2 Å to accommodate 
the reducing end pyranose and allow H-bonding to O6, which is precluded by proximity in 
the apo structure. Rotation of Gln312 was also observed, with Oδ moving 3.13 Å to allow a 
H-bonding interaction between it and the O4 of the glycosidic bond between pyranoses in 
the -3 and -4 subsites. In Apo-D416A-MsGlgB Phe305 has an alternate conformation that 
overlaps with the pyranose in the -6 subsite; this is not seen in the ligand-bound structure. 
Additionally, Glu591 shifts in DP8-D416A-MsGlgB to accommodate the pyranose in the -8 
subsite and allow H-bonding to O2 and O3, with Oδ moving 2.85 Å. 
2.4.5 Acarbose soaks reveal additional binding sites in the catalytic domain 
Having assigned the donor site of MsGlgB, my next objective was to identify the acceptor 
site. To this end, crystals of D416A-MsGlgB, E469A-MsGlgB and D416A-E469A-MsGlgB 
were soaked with α-glucans that contained α-1,6 bonds, including pullulan, β-limit dextrin, 
rabbit liver glycogen, amylopectin and maltotriosyl maltotriose. Mostly, very weak or no 
additional density was detected, though for the latter soak, maltotriose was observed in the 
donor subsites -1 to -3 in D416A-MsGlgB and D416A-E469A-MsGlgB. I subsequently 
investigated the binding of the pseudotetrasaccharide acarbose, a widely-used inhibitor of 
α-amylase enzymes,21 even though this had previously been shown not to inhibit MtGlgB.9 
Surprisingly, this revealed a new binding site in the catalytic domain of E469A-MsGlgB, site 
A2. In D416A-MsGlgB and D416A-E469A-MsGlgB, acarbose instead bound at the donor 
site, suggesting that when binding is not obstructed by the presence of nucleophile D416, 
this is the preferred binding site. In ACR-E469A-MsGlgB O4 at the non-reducing end of 
acarbose was located 19.5 Å from the D416 Oδ, in an orientation that suggested the A2 
site could be a distal part of the main acceptor site, Figure 2.15. 
In an attempt to extend binding towards the catalytic residues I soaked E469A-MsGlgB 
crystals with acarbose that had been extended by six glucose units at the non-reducing end 
(DP6-ACR). However, this molecule was instead orientated such that the acarbose moiety 
was rotated ~180° and located in the adjacent A1 site, with three of the glucose units bound 
at the N3 site. Superposition of ACR-E469A-MsGlgB and DP3-ACR-E469A-MsGlgB 
suggested that these binding sites could represent an α-1,6 branchpoint between the O1 of 
acarbose in the A2 site and an O6 of acarbose in the A1 site, Figure 2.15. The O1 and the 
carbon of the O6 were 3.2 Å apart. 
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Table 2.5 X-ray data collection and refinement statistics for MsGlgB complexes 
Values in parentheses are for the outer resolution shell, r.m.s., root mean square 
 
 
 
 
 
 
 
Dataset ID DP8-D416A-MsGlgB ACR-E469A-MsGlgB DP3-ACR-MsGlgB 
Data Collection    
Beamline I04-1 I03 I04 
Wavelength (Å) 0.9282 0.9762 0.9795 
Detector Pilatus 6M Pilatus3 6 M Pilatus 6M 
Resolution range (Å) 84.7-1.88 (1.92-1.88) 48.50-1.60 (1.63-1.60) 62.28-1.45 (1.47-1.45) 
Space group P21212 P21212 P21212 
a, b, c (Å)  98.79, 164.57, 54.42 97.00, 162.04, 53.64 97.67, 161.69, 53.79 
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Total observations 972,120 (60,979) 729,137 (37,025) 2,005,551 (97,080) 
Unique reflections 73,128 (4,408) 111,249 (5,452) 151,467 (7,404) 
Multiplicity 13.3 (13.8) 6.6 (6.8) 13.2 (13.1) 
Mean I/σ(I) 11.3 (1.5) 9.7 (1.3) 16.8 (1.4) 
Completeness (%) 100.0 (100.0) 99.2 (98.8) 100.0 (99.9) 
Rmerge
a 0.184 (1.851) 0.095 (1.688) 0.082 (1.779) 
Rmeas
b 0.192 (1.922) 0.104 (1.828) 0.086 (1.874) 
CC1/2
c 0.998 (0.753) 0.998 (0.463) 1.000 (0.685) 
Wilson B value (Å2) 25.0 22.0 25.0 
Refinement    
Resolution range (Å) 84.7-1.88 (1.92-1.88) 48.50-1.60 (1.63-1.60) 62.28-1.45 (1.47-1.45) 
Reflections: working/freed 69,343/3,715 105,686/5501 143,858/7,518 
Final Rwork 0.173 0.176 0.124 
Final Rfree
e 0.206 0.192 0.161 
Estimated coordinate error (Å)f 0.125 0.078 0.054 
r.m.s bond distance deviation (Å) 0.0102 0.0102 0.0099 
r.m.s. bond angle deviation (°) 1.393 1.394 1.484 
No. of protein residues per chain (ranges) 722 (9-94; 99-736) 722 (9-94; 101-736) 722 (9-94; 100-736) 
No. of heterogen residues: 
sugar/water/otherg 
35/636/6 13/411/15 17/901/18 
Mean B factors: 
protein/ligands/water/overall (Å2) 
13/42/40/30 32/41/40/32 23/35/39/23 
Ramachandran: 
favoured/allowed/disallowedh (%) 
98.5/1.4/0.1 97.8/2.1/0.1 98.0/1.9/0.1 
Protein Data Bank accession code N/A N/A N/A 
a Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl). 
b Rmeas = ∑hkl [N/(N  1)]
1/2 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, I(hkl) is 
the weighted average intensity for all observations i of reflection hkl and N is the number of observations of reflection hkl. 
c CC1/2 is the correlation coefficient between symmetry equivalent intensities from random halves of the data set. 
d The data set was split into “working” and “free” sets consisting of 95 and 5% of the data, respectively. The free set was 
not used for refinement. 
e The R factors Rwork and Rfree were calculated as follows: R = (| Fobs - Fcalc |)/| Fobs |where Fobs and Fcalc are the 
observed and calculated structure factor amplitudes, respectively. 
f Based on Rfree as calculated by REFMAC5.
16 
g Sugars includes acarbose as four residues. “Other” includes glycerol, imidazole, sodium, calcium, nickel and chloride 
ions. 
h As calculated using MolProbity.22 
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Figure 2.15 Binding at the A1 and A2 sites suggests coordination of an α-1,6-
branchpoint. A) Superposition of DP8-6416A-MsGlgB, ACR-E469A-MsGlgB, DP3-
E469A-MsGlgB and structures showing binding of maltooctaose at the donor site, acarbose 
at the A2 site and DP3-acarbose at the N3 and A1 sites. Reducing ends of the 
oligosaccharaides are indicated by ø. A black dashed line indicates the distance of 19.5 Å 
between the non-reducing end of acarbose in A2 and the D416 catalytic residue, which is 
marked by a black arrow. An orange solid line shows the putative α-1,6 branchpoint. B) A 
closer view of the N3, A1 and A2 sites rotated ~180° relative to A. The O1 and the carbon 
of the O6 were 3.2 Å apart. Protein and oligosaccharides are coloured according to Figure 
2.8. 
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2.4.6 Residues 370-383 form a flexible loop that is involved in substrate 
binding 
Comparison of crystal structures with oligosaccharides bound at different sites revealed that 
residues 370-383 formed a loop that could adopt different conformations, Figure 2.16. In 
apo structures, this loop is disordered, with no or very weak electron density detected. When 
an oligosaccharide is bound in the donor site, such as in DP8-D416A-MsGlgB, the loop 
adopts a fixed conformation that can be clearly resolved for most residues. This allows 
coordination of Trp381 to the oligosaccharide, both via CH/π stacking between the 
tryptophan side chain and pyranose in the -2 subsite, as well as hydrogen bonding of the 
Trp381 backbone carbonyl to the -3 pyranose O3 and the -4 pyranose O2. Conversely, 
when acarbose is bound at the A2 site in ACR-E469A-MsGlgB, I observed an alternative 
conformation of this loop, which instead allows coordination of His370 and Arg375 to 
acarbose. Surprisingly, in this latter conformation, the loop occupies the same space as the 
maltooligosaccharide units bound at the -3 and -4 subsites in DP8-D416A-MsGlgB, 
indicating that this would obstruct binding at the donor site. 
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Figure 2.16 Residues 370-383 make up a flexible loop region that adopts distinct conformations in oligosaccharide-bound structures. 
The top three panels show the same view of residues 364-392 and bound oligosaccharides in DP8-D416A-MsGlgB (cyan), Apo-WT-MsGlgB 
(orange) and ACR-E469A-MsGlgB (lilac). The hinge points of the loop at residues 369 and 383 indicated by grey spheres and residues 364-369 
and 383-392 are shown in light blue. In Apo-WT-MsGlgB residues 374-381 are disordered and represented by a dashed orange line. In DP8-
D416A-MsGlgB the loop adopts the conformation shown in cyan that allows coordination of the oligosaccharide in the donor site and Trp381. In 
ACR-E469A-MsGlgB the loop adopts the conformation shown in lilac that allows coordination of His370 and Arg375 to acarbose. The lower 
panel shows a superposition of the top three panels.
Chapter 2 
65 
2.4.7 There is extensive maltooligosaccharide binding in domain C of 
MsGlgB 
Examination of domain C across all crystal structures demonstrated that of the four distinct 
binding sites, C1 can accommodate an oligosaccharide up to DP6, C2 DP7, C3 DP3 and 
C4 DP6. Although these sites are adjacent to each other, the orientation of the sugars and 
the positions of the atoms do not allow for the possibility of α-1,6 linkages between the 
oligosaccharides in any pairs of sites, Figure 2.17. This pattern of binding sites may only 
make sense in the context of a much larger α-glucan polysaccharide. Under the 
crystallography conditions, oligosaccharides were most commonly bound at the C4 site and 
oligosaccharides here were most consistently and clearly resolved. However, this may 
simply be the most accessible site in the crystal structure and this does not necessarily 
reflect the affinity of this site for maltooligosaccharide binding in vivo. 
 
Figure 2.17 C-terminal surface binding sites. Maltooligosaccharide binding at the 
interface of domain A and C reveals four distinct sites, C1- C4, accommodating 
maltooligosaccharides of DP 6, 7, 3 and 6 respectively. Domains are coloured according to 
Figure 2.6, with the view along the longitudinal axis of the protein. The reducing ends of 
the oligosaccharides are indicated by Ø. 
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2.4.8 Amino acid residues that coordinate oligosaccharides are largely 
conserved between MsGlgB and MtGlgB 
Having identified numerous amino acid residues that interact with oligosaccharides in 
MsGlgB, I investigated the conservation of these residues in MtGlgB, Figure 2.18. As would 
be expected from the 82% sequence identity, residues that interacted with carbohydrates 
were generally highly conserved. Interacting amino acid residues in donor subsites -1 to -6 
were completely conserved. In the -7 subsite, glycine (Gly306 MsGlgB) was changed to 
alanine (Ala301 MtGlgB), however as this interaction with the O2 of this pyranose is via the 
backbone NH, this is likely to be unchanged. Likewise, there is a glutamate (Glu592 
MsGlgB) to glutamine (Gln587 MtGlgB) change in the -8 subsite, but this is again unlikely 
to change the interaction with the side chain carbonyl and O6 of the final pyranose. The 
flexible loop region was conserved between the two sequences, apart from a change of 
arginine (Arg374 MsGlgB) to lysine (Lys369 MtGlgB), which is unlikely to have much effect 
as these residues are very similar. Overall, this analysis suggests that, with the exception 
of some minor modifications, all of the identified binding sites are conserved between the 
M. smegmatis and M. tuberculosis branching enzymes. 
This work represents a significant step forward in the understanding of how a mycobacterial 
branching enzyme binds to its α-glucan substrate. The wider implications of these results 
are discussed below. 
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Figure 2.18 Alignment of MtGlgB and MsGlgB amino acid sequences. Numbering 
refers to the MsGlgB sequence. Secondary structural features are indicated with 
consecutive numbering. Domains are indicated with coloured bars and residues interacting 
with oligosaccharides are marked with coloured circles. Conserved residues are boxed with 
identity shown with a red background and similarity with red lettering. The alignment was 
generated with CLUSTALW223 and displayed with ESPript.24 
 
2.5 Discussion 
The overarching aim of this chapter was to develop the understanding of the action of the 
branching enzyme GlgB in the synthesis of mycobacterial α-glucan. This was achieved by 
both the investigation of GlgB activity in vitro and the generation of oligosaccharide-bound 
crystal structures. 
Firstly, I investigated the in vitro activity of GlgB enzymes from mycobacteria and other 
actinomycetes by generating synthetic α-glucan with GlgE and different GlgB enzymes, 
then determining the average branch lengths, which ranged from DP 7.2 ± 2.2 to 8.6 ± 2.5. 
This could be directly compared to α-glucan generated in vivo, that had previously been 
extracted from M. tuberculosis and S. venezuelae cells, which had average branch lengths 
of DP 7.0 ± 2.0 – 7.3 ± 1.8. Therefore, whilst the synthetic α-glucan tended to have slightly 
higher average branch lengths, they were overall very similar and clearly distinct from the 
longer branch lengths seen in E. coli and mammalian glycogen, of ~DP11. My results 
confirmed that GlgE and GlgB are necessary and sufficient to generate the α-glucan 
polysaccharide. This work is part of a suite of experimental analyses that determine the fine 
detail of the actinomycete α-glucan structure, Appendix 1.4 
It is noteworthy that I determined very similar average branch lengths by MALDI mass 
spectrometry and CE. The latter method is considered the gold standard for quantitative 
analysis of oligosaccharides,25 but requires lengthy derivatisation steps with expensive 
reagents and typically 30-60 min to analyse each sample. In contrast, MALDI mass 
spectrometry is a rapid method, that does not require derivatisation, but has been reported 
to be not suitable for quantitative analyses without internal standards that have been 
properly calibrated.26 Furthermore, MALDI mass spectrometry allows the direct 
identification of the DP, whereas with CE, the identity of peaks is inferred by comparison to 
standards. This work supports the use of MALDI mass spectrometry for the analysis of the 
proportions of linear α-1,4 oligosaccharides and suggests that, at least in this DP range, the 
method is more quantifiable than previously thought. 
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The in vitro characterisation of GlgB enzymes led directly on to the structural investigation 
of the mycobacterial GlgB enzyme, to understand the structural basis for the shorter branch 
lengths created by actinomycete GlgB enzymes relative to other bacterial and eukaryotic 
homologues. The crystallisation of MtGlgB proved challenging, despite the existence of a 
previously solved structure.9 Crystallisation could only be achieved by the removal of the 
first nine amino acid residues, however these crystals diffracted poorly and the structure 
could not be solved. Fortuitously, MsGlgB crystallised without the need for modifications of 
the recombinant protein and the structure was solved at high-resolution. Importantly, the 3D 
structures of MsGlgB and MtGlgB were highly similar, with an RMSD of just 0.49 Å, 
validating MsGlgB as an equivalent structural model. This also provides the means to 
generate inhibitor-bound GlgB structures, which will inform structure-activity relationships 
for the development of lead compounds active against GlgB. 
Other researchers have also found it difficult to replicate the published MtGlgB structure 
(Geiger and co-workers, personal communication). Therefore, it appears that MsGlgB 
provides a more tractable model for crystallographic studies. This difference is reflected in 
the higher thermostability of MsGlgB, with a Tm of 64.0 °C compared to 57.7 °C for MtGlgB, 
as determined by nano DSF. The predicted disulphide bonds in MtGlgB,27 which are absent 
in MsGlgB, may lead to different populations of MtGlgB molecules, creating disorder that 
impedes crystallisation. It is interesting to note that PEG 4,000 and 0.1 M MES at pH 6.5 
are present in both final crystallisation conditions, and these components may play a role in 
formation of the crystal lattice, but neither were detected in electron density maps. Although 
the crystal structure of MsGlgB was obtained much more readily relative to MtGlgB, protein 
crystals were observed in only one condition out of the 768 tested and required a number 
of optimisation steps before high-quality X-ray diffraction data could be reliably obtained. 
This is consistent with branching enzymes being challenging to crystallise, and there are a 
low number of reported structures, even though they are widely studied. 
Using the MsGlgB model I went on to solve the first reported ligand-bound structures for an 
actinomycete branching enzyme. Carbohydrate-bound structures could only be determined 
using very high concentrations of oligosaccharides, ≥ 0.1 M, as was seen previously for the 
cyanobacterial BE1.10 Generally, soaks with polysaccharides did not result in any ligand 
binding, most likely because the shorter fragments that could be detected by 
crystallographic studies were not present at high enough concentrations. The approach of 
using 2-deoxy-2-fluoro-maltosyl fluoride oligosaccharides in combination with the MsGlgB-
E469A protein also did not yield donor-bound structures. This could be attributed to the 
alternate 2-deoxy-2-fluoro substitutions in the pseudooligosaccharide interfering with 
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binding or, more likely, that maltooligosaccharides ≤ DP8, which can be accommodated in 
the donor site, were present at too low concentrations in the reaction mixture for this to be 
achieved. Further optimisation of reaction and purification conditions to increase the 
proportion of products of appropriate DP might result in a fluorinated oligosaccharide 
product mixture suitable for structural studies of other GH enzymes. 
Oligosaccharides were only bound in the donor site of MsGlgB when the aspartate 
nucleophile was mutated to alanine. This suggests that the presence of the aspartate 
residue precluded ligand binding, most likely by blocking the binding at the -1 subsite, which 
appeared to be necessary for binding at any of the other donor subsites. This contrasts with 
CceBE1, in which oligosaccharides bound at only subsites -2 to -6, and, when they did also 
bind at the -1 subsite, the reducing-end pyranose was rotated by an unusual angle. This 
necessitated a W610N modification, whereas this was not the case in MsGlgB, and the 
equivalent residue Glu592 coordinated the pyranose in the -8 subsite, suggesting that 
longer oligosaccharides are more easily accommodated in MsGlgB. Donor subsites -1 to -
6 are almost completely conserved between MsGlgB and CceBE1, and sequence 
alignments suggest these may be conserved more widely across the bacterial species, 
Figure 2.19. 
 
Figure 2.19 Alignment of bacterial branching enzyme sequences. Protein sequence 
alignment of MsGlgB, S. coelicolor GlgB, E. coli GlgB and CceBE1, with residues in the 
MsGlgB donor site highlighted in green. With the exception of a couple of residues these 
are conserved between these species, suggesting that this site may be conserved across 
different bacterial species. 
The relative orientations of the A1 and A2 sites suggested that MsGlgB can coordinate an 
α-1,6 branched structure at a distance from the active site. Previously, analysis of 
mycobacterial α-glucan structure showed that branches in mycobacterial α-glucan are 
accommodated on the 4th or 5th glucose units from an existing branch point and that most 
B chains carry one or two branches.4 Therefore, if O1 of acarbose at the A2 site was linked 
in a branch then the subsequent branchpoint would emanate from the O6 of the non-
reducing end pyranose. The next branchpoint would be expected 4-5 residues from here, 
at approximately the site of catalytic residues, where a new branchpoint would be formed, 
Figure 2.20. In this model, the branch emanating from the non-reducing end of acarbose in 
A2 is therefore a proximal branchpoint, and the A1/A2 1,6 linkage therefore represents a 
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distal branchpoint. Whilst this remains speculative without more substrate-bound structures, 
the coordination of a distal branchpoint could have interesting implications for the activity of 
MsGlgB. Coordination to a distal branchpoint might be suggestive of a mechanism whereby 
a substrate with ≥ two existing branches is more likely to be branched again. It would make 
sense for MsGlgB to prefer branched substrates as this would mean it would tend to act to 
create larger α-glucan molecules, rather than generate many smaller branched 
oligosaccharides. 
 
Figure 2.20 Proposed model of substrate binding for MsGlgB. Protein and bound 
oligosaccharirdes shown as in Figure 2.15A. Maltooligosaccharide binding in the proposed 
acceptor site is symbolised by blue circles, with each representing an α-glucopyranose unit. 
Suggested substrate branchpoints are labelled and indicated by red circles. 
The acceptor subsites were not identified by this work, but the A2 site is a promising 
candidate for a distal acceptor site. Acarbose was bound at the A2 site, with a distance of 
19.5 Å between the non-reducing end of the pseudotetrasaccharide and the nucleophilic 
residue D416. The acceptor site could be modelled by a 4-5 glucose unit extension from 
the non-reducing end of the A2 acarbose, Figure 2.20. In this model, MsGlgB residues 470-
475 would be implicated in binding the acceptor oligosaccharide. This contrasts with the 
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acceptor cleft proposed for cyanobacterial BE1 based on oligosaccharide binding site near 
domain C, Figure 2.21 and Figure 2.22. Although CceBE1 and MsGlgB generate similar 
average branch lengths of DP 6-7 and DP 7-8 respectively, they are involved in the 
synthesis of different α-glucan products, namely starch and glycogen and this could explain 
the different acceptor sites that have been proposed. 
One other aspect of the branching enzyme mechanism is whether transfer is intra or inter 
chain. For MtGlgB chain transfer was shown to be strictly intrachain with a short 
oligosaccharide substrate in vitro.4 Based on the average branch lengths of DP7-8 and 
internal chain lengths of DP4.6-5.0, intrachain transfer necessitates an average movement 
of a newly cleaved chain by ~3 glucose residues. This would require a significant 
conformational change in the acceptor binding cleft and/or strained binding of the substrate 
to create the optimal orientation for chain transfer. A cartoon of a possible mechanism for 
the strained orientation of an acceptor substrate facilitating intrachain branch formation is 
shown in Figure 2.22. This may mean that identifying maltooligosaccharides bound at the 
MsGlgB proximal acceptor site will be challenging due to the inherent disorder these 
mechanisms entail. 
  
Figure 2.21 Comparison of maltooligosaccharide binding in MsGlgB and CceBE1. 
Superposition of MsGlgB and CceBE1 structures showing all maltooligosaccharide binding 
sites. Proteins are shown as ribbon models, oligosaccharides as ball and stick models. 
MsGlgB: protein = cyan, oligosaccharide = green; CceBE1: protein = orange, 
oligosaccharide = dark purple. The paths of the donor site and proposed acceptor sites for 
each enzyme are indicated by coloured lines. 
Chapter 2 
73 
 
Figure 2.22 Comparison of the branching mechanisms of MsGlgB and CceBE1. A) Branching mechanism proposed for MsGlgB based on 
intrachain transfer facilitated by a strained oligosaccharide conformation in the proximal acceptor site, marked by *. Oligosaccharides are 
represented by blue circles for each glucose unit, with filled circles representing those observed in crystal structures and striped circles for 
predicted binding. B) Proposed mechanism of CceBE1, labelled according to Figure 1.14. Adapted from Hayashi et al.10 with permission.
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2.6 Summary 
This chapter describes the biochemical and structural characterisation of mycobacterial 
GlgB. Biochemical analyses demonstrated that these enzymes generate notably shorter 
branches than their E. coli or mammalian counterparts, consistent with what is seen in the 
in vivo α-glucan product. The existing MtGlgB structural model was greatly improved with 
high-resolution, substrate-bound MsGlgB structures. These enabled the identification of a 
number of structural features, including the donor site, a flexible loop region and the putative 
distal acceptor site. 
2.7 Materials and methods 
Unless otherwise specified, all chemicals were purchased from Sigma Aldrich Company 
Ltd. 
2.7.1 Growth media 
All bacterial growth was carried out using lysogeny broth (LB) consisting of tryptone (10 
g/L), yeast extract (5 g/L), NaCl (10 g/L) in dH2O, with the addition of agar (10 g/L) for solid 
media. The antibiotics carbenicillin (100 µg/mL) or kanamycin (50 µg/mL) (ForMedium) 
were added as appropriate to select for bacterial strains. 
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2.7.2 Primers 
Oligonucleotide sequences used in molecular biology experiments are listed in Table 2.6. 
Table 2.6 Oligonucleotide sequences. 
Oligonucleotide ID Sequence (5ʹ - 3ʹ) Notes 
T7 TAATACGACTCACTATAGGG For plasmid sequencing 
T7 terminal TAGTTATTGCTCAGCGGTGG 
MtGlgB-Internal1 GTGACCGATCGTGCAGATCC For plasmid sequencing 
MtGlgB-Internal2 GCTACGATACACCGGATCACG 
MtGlgB-Internal3 CATCATGAAATGACCTTTAG 
MtGlgB-Nterm-DT CACCATGAGCCGTAGCGAAAAA
CTGACCG 
To generate PCR fragments for 
Directional TOPO® cloning to make 
MtGlgB-CHis6 expression construct MtGlgB-CHis6-DT TTAGTGGTGGTGGTGGTGGTGC
GCCGGGGTCAGCCACAG 
MtGlgB-ΔN9-QC-F GAAAACCTGTATTTTCAGGGTGA
ACATCTGGCCCCG 
To remove the region encoding for amino 
acids 2-8 using the QuikChange 
Lightning kit to make ΔN9-MtGlgB 
expression construct 
MtGlgB-ΔN9-QC-R CGGGGCCAGATGTTCACCCTGA
AAATACAGGTTTTC 
MtGlgB-ΔN108-IF AGGAGATATACCATGACCCTGG
GCGAAGTGGATCT 
To generate PCR fragments for In-
Fusion® HD cloning to make ΔN108-
MtGlgB expression construct MtGlgB-C-His6-IF GTGGTGGTGGTGTTTCGCCGGG
GTCAGCCACAGCG 
MsGlgB-Internal1 GTGGGAACTGTTTTGGCCG For plasmid sequencing 
MsGlgB-Internal2 GTGACTAATCGGCAGCACG 
D416A-MsGlgB-F CAGGACGTACTTTCTGCGGCAAC
GGTCACGA 
To change codon for Asp416 to Ala in 
MsGlgB using the QuikChange Lightning 
kit D416A-MsGlgB-R GTCTGCGCGTTGCCGCGGTCGC
CAG 
E469A-MsGlgB-F TCGTGACCGTTGCCGCAGAAAG
TACGTCCTG 
To change codon for Glu469 to Ala in 
MsGlgB using the QuikChange Lightning 
kit E469A-MsGlgB-R CTGGCGACCGCGGCAACGCGCA
GAC 
 
2.7.3 Cloning methods 
DNA fragments were amplified by PCR thermal cycling using Phusion® High-fidelity DNA 
polymerase (NEB). DNA was analysed by DNA gel electrophoresis using a 1% (w/v) TAE 
agarose gel with 1 µg/mL ethidium bromide with UV visualisation. DNA fragments were 
purified using a QIAquick PCR purification kit (Qiagen) and concentrations were determined 
using the Nanodrop spectrophotometer (Nanodrop®). DNA fragments were incorporated 
into vectors using Directional TOPO® cloning with transformation into One Shot® TOP10 
competent cells (Invitrogen) or In-Fusion® HD cloning with transformation into Stellar 
Competent cells (Takara) according to the protocols set out in the relevant user manuals. 
Site-directed mutagenesis was carried out using a QuikChange Lightning kit (Agilent) 
following the protocols for thermal cycling, DpnI digestion and transformation of XL10-Gold 
ultracompetent cells as set out in the user manual. 
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To verify successful transformants, a single colony from the resultant transformation plate 
was used to inoculate LB media supplemented with the appropriate antibiotic and incubated 
at 37 °C with shaking for 18 h. Plasmids were purified using a QIAprep Spin Miniprep kit 
(Qiagen) and quantified using the Nanodrop spectrophotometer as above. All modifications 
were confirmed by DNA sequencing (Eurofins), using the T7 and T7 terminal primers, as 
well as internal glgB primers, Table 2.6. Sequencing data were analysed using Chromas 
Lite (Technelysium). 
2.7.4 Plasmids for protein expression 
Expression plasmids for producing GlgB and GlgE proteins with an N-terminal, TEV 
cleavable His6 tag had previously been prepared by K. Syson as follows. Codon-optimised 
DNA sequences of glgB and glgE genes from M. tuberculosis H37Rv and S. coelicolor A3(2) 
(isoform 1 of glgB and glgE), and the glgB gene from M. smegmatis mc2 155 were ligated 
into a pET-21a(+) vector (Novagen). The glgB gene from S. venezuelae ATCC 10712 was 
ligated into a pBAD43 vector (Novagen). The M. tuberculosis H37Rv glgB gene sequence 
was mutated into that of M. tuberculosis CCDC5180 by changing the codon for Ser470 into 
one for Pro using a QuikChange Lightning kit (Agilent). 
All modifications to the M. tuberculosis and M. smegmatis glgB expression plasmids were 
carried out by myself as follows. The construct for the expression of ΔN9-MtGlgB was 
generated using QuikChange Lightning as above to remove the region encoding the first 
nine amino acids from the MtGlgB expression construct described above. The construct for 
the expression of MtGlgB-C-His6 was made by incorporating the M. tuberculosis glgB gene 
with an extension for a C-terminal His6 tag into a pET101 vector (Invitrogen) using 
Directional TOPO® cloning. To make the construct for the expression of ΔN108-MtGlgB with 
a C-His6 tag, the M. tuberculosis glgB gene sequence was incorporated into a pOPINA 
vector (OPPF-UK) using In-FusionTM cloning. For the modified MsGlgB expression 
constructs the M. smegmatis glgB gene sequence was mutated with QuikChange Lightning 
to either change the codon for Asp416 into Ala or Glu469 into Ala or both. 
2.7.5 Production of recombinant proteins 
Plasmids for protein expression were transformed into either One ShotTM BL21 (DE3), One 
ShotTM BL21 StarTM (DE3) (Invitrogen) or soluBL21TM (DE3) (Genlantis) chemically 
competent E. coli. Cells containing the expression plasmid were cultured in LB containing 
appropriate antibiotic at 37 °C. Expression was induced when the cells reached an OD600nm 
of 0.6, by the addition of 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG). After 
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incubation at 30 °C for 2 h and then 16 °C for 18 h, the cells were harvested by centrifugation 
at 5,000 × g for 10 min at 4 °C and resuspended in 50 mM Tris-HCl, pH 8.0, containing 15 
mM imidazole, 300 mM NaCl, DNase 1, and a complete protease inhibitor cocktail tablet 
(Roche). The cells were disrupted with a TS Series Benchtop 1.1 kW cell disruptor 
(Constant Systems Ltd.) at 25 kPSI. The resulting cell lysate was separated from the cell 
debris by centrifugation at 18,000 × g for 25 min at 4 °C. 
Proteins were purified from each cell lysate by application onto a 1 mL FF HisTrap column 
(GE Healthcare). Protein was eluted with a 15–300 mM imidazole gradient and further 
purified using a HiLoad 26/60 Superdex 200 gel filtration column (GE healthcare) 
equilibrated with 20 mM sodium phosphate buffer, pH 7.0, 50 mM NaCl. The eluate was 
collected in fractions, which were analysed by SDS-polyacrylamide gel electrophoresis 
(PAGE) using pre-cast 12% (w/v) SDS-PAGE gels and staining with InstantBlue (Expedeon 
Ltd). Fractions containing the desired recombinant protein were combined and concentrated 
using an Amicon Ultra-15 centrifugal filter unit with a 10 kDa cut-off (MerckMillipore) and 
centrifugation at 5,000 × g. Aliquots of protein were flash-frozen in liquid N2 and stored at -
80 °C. Protein concentrations were determined using a Direct Detect® infrared spectrometer 
(Merck). 
In some cases, the His6 tag was cleaved by incubating the recombinant protein with TEV 
protease in a buffer containing 50 mM Tris, pH 8 and 150 mM NaCl. This was followed by 
the addition of imidazole at a final concentration of 30 mM and the solution was applied onto 
a FF HisTrap column to remove TEV protease. The flow-through was collected, 
concentrated and then solvent exchanged by dialysis. 
2.7.6 Plasmid stability test 
Plasmid stability tests were carried out according to the pET system manual (Novagen). 
Bacterial strains transformed with an expression plasmid were cultured in LB and grown at 
37 °C until the cells reached an OD600nm of 0.6. Serial dilutions of the cell suspension were 
then prepared up to 10-6 dilution. The 10-6 dilution was plated on LB-agar (allowing growth 
of all viable cells) and LB-agar with antibiotic (allowing growth of cells retaining the plasmid). 
The 10-6 dilution was plated on LB-agar with 1 mM IPTG (allowing growth of cells that have 
lost the plasmid or the ability to express the gene) and LB-agar with 1 mM IPTG and 
antibiotic (allowing growth of cells that retain the plasmid but cannot express the gene). 
After incubation at 37 °C the number of colonies on each plate was counted. It was expected 
<2% of cells will form a colony on the plate containing IPTG and < 0.01% on the plate 
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containing IPTG and antibiotic. Higher values were indicative of plasmid instability and 
hence a toxic gene product. 
2.7.7 Nano differential scanning fluorimetry 
Nano DSF experiments were performed on the Prometheus NT.Plex (NanoTemper 
Technologies Ltd.). For each protein sample 10 µL was loaded into a glass capillary and 
subjected to a temperature ramp of 2 °C/min from 20 °C to 95 °C. Fluorescence at 350 nm 
and 330 nm was constantly monitored and data were analysed with PR.ThermControl 
software (NanoTemper Technologies Ltd.). A difference ≥ 0.5 °C is considered significant. 
2.7.8 In vitro glucan synthesis 
To generate synthetic α-glucan 1 mM maltohexaose and 10.1 mM M1P (synthesised by A. 
Rashid as previously described13) were incubated with 7 μg each of recombinant GlgE and 
GlgB (giving < 2 μM final concentrations) in 100 mM bis-Tris propane, pH 7.0, containing 
50 mM sodium chloride in a total volume of 50 μL. After 18 h at 22 °C, a second aliquot of 
M1P was added. After a further 90 h, the sample was heated at 95 °C for 5 min, cooled, 
and washed five times using a 10 kDa cut-off membrane with 100 mM sodium acetate 
buffer, pH 4.0, to remove small maltooligosaccharides. The sample was analysed by TEM, 
MALDI mass spectrometry, or CE with or without debranching as appropriate. 
2.7.9 Transmission electron microscopy 
TEM imaging was carried out by E. Barclay as follows. Aqueous polymer samples (typically 
0.1 mg/mL) were allowed to settle briefly onto a 400 mesh copper grid with a carbon-coated 
pyroxylin support film before being negatively stained. α-Glucan was stained with 2% (w/v) 
aqueous uranyl acetate, pH 4.5. The grids were viewed in a FEI Tecnai 20 transmission 
electron microscope (Eindhoven, Netherlands) at 200 kV, and digital TIFF images were 
taken using an AMT XR60B digital camera (Deben). 
2.7.10 Debranching α-glucans with isoamylase 
Polymer samples (typically in 25 μL) were debranched using Pseudomonas sp. isoamylase 
(with typically 2 μL of a 1,000 U/mL stock solution) from Megazyme in 100 mM sodium 
acetate buffer, pH 4.0, at 37 °C for 4 h. Reactions were terminated by heating at 95 °C for 
5 min, and the products were analysed either directly or after precipitation with ethanol (5 
vol). Precipitated samples were dissolved in water (50 μL) and freeze-dried to yield an 
amorphous powder. 
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2.7.11 MALDI mass spectrometry 
Matrix assisted laser desorption/ionisation mass spectra were acquired on Bruker Ultraflex 
or Autoflex Speed MALDI-Time of flight (TOF)/TOF mass spectrometers, equipped with a 
pulsed nitrogen laser emitting at 337 nm or Smartbeam-II 2 kHz laser, respectively. 
Samples were typically mixed 1:2 v/v with a 20 mg/mL solution of 2,5-dihydroxybenzoic acid 
in 50% aqueous acetonitrile and spotted on a target plate (Bruker MTP 384 Polished Steel 
TF Target). Data were processed using Bruker flexAnalysis software. The relative 
abundance of maltooligosaccharides of DP ≥ 4 was determined at least in duplicate by 
measuring the area under the peaks of all isotopes associated with each species of a given 
degree of polymerisation using the Sophisticated Numerical Annotation Procedure with 
sugar-sodium adduct average composition. 
2.7.12 Capillary electrophoresis 
Reducing saccharides were labelled with 8-aminopyrene-1,3,6-trisulphonic acid to facilitate 
their separation on the basis of charge and their detection by fluorescence 
spectrophotometry. Samples (typically 5 μL) were treated with 8-aminopyrene-1,3,6-
trisuphonic acid (1 μL of 50 mM in 15% aqueous glacial acetic acid) and freshly prepared 
NaCNBH3 in tetrahydrofuran (1 μL of 1 M). Reaction mixtures were incubated at 37 °C for 
4 h and diluted 10-fold with water. Samples were subjected to capillary electrophoresis 
using a Beckman Coulter PA800 ProteomeLab Protein Characterisation System using 
laser-induced fluorescence detection with an excitation wavelength of 488 nm and an 
emission band-pass filter of 520 nm ±10 nm. An SCIEX N-CHO capillary (50 μm internal 
diameter × 50.2 cm; 40 cm effective length to detector) was used with a constant voltage of 
−30 kV, the anode at the detector, and a temperature of 25 °C. The capillary was rinsed 
with SCIEX N-CHO buffer, and the samples were introduced at a pressure of 0.5 psi for 5 
s. 
2.7.13 Protein crystallisation 
Proteins were concentrated to 5-12 mg/mL using Amicon Ultra-0.5 centrifugal filter unit with 
a 10 kDa cut-off (MerckMillipore) and subsequently filtered using a 0.1 µm Ultrafree® filter 
(MerckMillipore). Protein crystallisation trials were carried out using the sitting drop vapour-
diffusion method in a 96-well MRC plate (Molecular Dimensions) format using the following 
screens: KISS (John Innes Centre), JCSG-plus, PACT premier, Structure, Morpheus, Midas 
(Molecular Dimensions), Ammonium sulphate and PEG suite (Qiagen). A volume of 40 µL 
was transferred to each well using the Freedom evo liquid handling robot (Tecan). Drops 
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were dispensed using the OryxNano robot (Douglas Instruments Ltd.) comprising 0.3 µL of 
precipitant solution and 0.3 µL of protein solution. The plates were sealed and stored at 19 
°C in a crystal hotel (CrystlPro, TriTek Corp.) and crystal formation was monitored by 
imaging plates with and without UV light. Crystals were optimised by varying the protein 
concentration, varying the components of the precipitant solution, varying the ratio of 
precipitant and protein solutions in each drop, and adding micro-seed solution, which was 
prepared by crushing existing crystals and preparing serial dilutions using the precipitant 
solution in the well reservoir. Crystals were imaged using a SMZ800 microscope (Nikon) 
with and without a polarising filter to observe birefringence. Photographs were taken with a 
Nikon Coolpix E995 digital camera (Nikon). 
2.7.14 Crystal soaks 
Crystal soaks were carried out using maltohexaose (Sigma Aldrich), maltoheptaose, 
maltooctaose (Carbosynth), β-cyclodextrin (Sigma Aldrich), γ-cyclodextrin (Wacker Chemie 
AG), cycloamylose (DP26; Ezaki Glico Wako), maltodextrin (Sigma Aldrich), amylose 2800 
(av. molecular weight (MW) 2800; Tokyo Chemical Industry Ltd), amylose BAR-5K-1 (av. 
MW 4,500; PS-Biotec Inc), amylose EX-I (av. DP17; Hayashibara Co. Ltd), amylose from 
potato (av. MW 150,000; Sigma), glucosyl maltotriosyl maltotriose (Megazyme), rabbit liver 
glycogen (Megazyme), amylopectin from potato (Sigma Aldrich), pullulan (Sigma Aldrich), 
β-limit dextrin (Megazyme), acarbose (Toronto Research Chemicals), DP6-acarbose 
(prepared by M. Rejzek as described previously28) and 2-deoxy-2-fluoro maltosyl fluoride 
(prepared by A. Rashid as described previously18). 2-Deoxy-2-fluoro maltosyl fluoride (5 – 
50 mM) was extended by incubation with S. coelicolor GlgEI (~1 µM) in a 100 mM bis-Tris 
propane, pH 7.0, 50 mM NaCl buffer. The reaction was terminated by heating at 95 °C for 
5 min and GlgE was removed by filtration or amberlite resin. 
Solutions for crystal soaks were prepared by dissolving oligosaccharides in MsGlgB 
crystallisation solution: 0.06 M MgCl2, 0.06 M CaCl2, 20% glycerol, 10% PEG 4,000, 0.1 M 
imidazole, 0.1 M MES at pH 6.5, without additional cryoprotection agents. Initially, 
oligosaccharide concentrations of 1 mM – 50 mM were prepared, which were then 
increased to 100 - 500 mM, or saturating solutions in cases where solubility was limiting. 
Crystals were soaked for 15 min – 48 h prior to mounting. 
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2.7.15 Data collection 
In collaboration with C. Stevenson, crystals were collected in litho-loops (Molecular 
Dimensions) and, in the case of MtGlgB crystals, were soaked in cryo-protectant solution 
comprising the crystallisation solution with the addition of 25% ethylene glycol. All crystals 
were flash-cooled by plunging into liquid N2 and stored in Unipuck casettes (MiTeGen) for 
transport to Diamond Light Source (Oxfordshire, UK) for data collection. Crystals were then 
robotically mounted onto the geniostat on stations I02, I03, I04 or I04-1 and maintained at 
100 K with a Cryojet cryocooler (Oxford instruments). Diffraction data were recorded using 
a Pilatus 6M hybrid photon counting detector (Dectris). 
2.7.16 Data processing 
The resultant datasets were processed using the XIA2 expert system29 and merged using 
AIMLESS.30 For MsGlgB, the data sets were processed in the space group P21212 with cell 
parameters of approximately a = 98, b = 164, c = 54 Å. The initial structure was solved by 
molecular replacement in PHASER,14 using MtGlgB (PDB code 3K1D) as the template. One 
molecule was placed in the asymmetric unit, corresponding to the monomeric nature of the 
protein in solution. The model was rebuilt using BUCCANEER31 and completed through 
several iterations of refinement with REFMAC515 with isotropic thermal parameters and 
manual adjustment with COOT.16 In the later stages, translation libration screw (TLS) 
refinement was used with a total of five TLS domains, which were defined by the TLS motion 
determination server.32 This model was used for the refinement of subsequent datasets. For 
higher resolution data, anisotropic thermal parameters were used instead of TLS 
parameters. Electron density maps were consistent with expected point mutations and 
provided evidence of ligand binding at various sites in the protein. 
2.7.17 Structural validation 
Model geometries were validated using MOLPROBITY22 for protein residues and 
PRIVATEER33 for sugar ligands. To generate mFobs – dFcalc difference electron density 
maps ligands were deleted from the coordinates of the final models and these were used 
as input to REFMAC5.16 All structural figures were prepared using CCP4mg.34 
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3. Identification of a small-molecule inhibitor of MtGlgB 
3.1 Introduction 
MtGlgB is an α-1,6 branching enzyme that has been genetically validated as a drug target, 
with a novel mechanism of toxicity.1 A number of putative MtGlgB inhibitors have previously 
been identified by virtual screening, including two which inhibited M. tuberculosis growth.2 
However, questions remain over the validity of the in vitro evaluation of these compounds 
due to the lack of counter-screens or verification that the compounds bind to the enzyme. 
Other known inhibitors of GH13 enzymes such as ADP, ADP-glucose, tunicamycin, 
casternospermine, nojirimycin and acarbose were ineffective against MtGlgB.3 The only 
verified inhibitor of any α-1,6 branching enzyme reported to date is the 
pseudooligosaccharide BAY e4609, a fraction of glycosylated acarbose derivatives with DP 
9 – 32. This showed slow-binding inhibition of E. coli GlgB,4 but this heterogeneous mixture 
of large molecules is unsuitable for therapeutic application. Therefore, in this chapter I 
address the question: can an inhibitor of MtGlgB be identified by high-throughput screening 
of compound libraries? 
This firstly necessitates the establishment of an assay suitable for HTS. The branching 
enzyme reaction involves the cleavage of an α-1,4-glycosidic linkage and the formation of 
an α-1,6-glycosidic bond.5 Enzyme activity is typically monitored by treatment of the 
branched products with isoamylase and subsequent quantification of the increase in 
reducing ends with colorimetric methods, with one or more heating steps.6-8 These are 
therefore unattractive for HTS due to the variability associated with heating microplates and 
the multiple steps involved.9 A more simple method for monitoring branching activity uses 
iodine staining, which can be used to distinguish branched and unbranched α-glucan chains 
by colour.10 
The dark blue colour resulting from the addition of iodine solution to amylose was first 
described in 1814.11 The structure of the complex was established by Rundle and co-
workers in the 1940s as a left-handed amylose helix with six glucose residues per turn, with 
the iodine component arranged axially in the inner cavity.12-13 The nature of the polyiodide 
species has been investigated with numerous different methods, with the prevailing 
interpretation being a mixture of I3- and I5-,14-16 although more recently an infinite iodide 
species, I∞δ-, has been suggested.17 The relationship between the DP of amylose and λmax 
has been established, with λmax increasing from 500 – 650 nm with increasing DP.18 
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In branched α-glucans, such as amylopectin and glycogen, the glucan helices are disrupted, 
resulting in a lower λmax value and a reduced peak in the absorbance spectrum.19 The use 
of the amylose-iodine assay in monitoring the activity of branching enzymes is well-
documented,20-21 and therefore, I firstly aimed to optimise this assay for HTS of MtGlgB. 
3.2 Development of an amylose-iodine assay for HTS of MtGlgB 
The amylose-iodine assay is the most attractive for HTS because no other steps are 
required and the absorbance can be monitored directly in a microplate. The first step was 
to optimise the amylose and iodine components of the assay. 
3.2.1 Development of a MtGlgB amylose-iodine benchtop assay 
The first consideration was the amylose substrate. Amylose has a very low solubility in 
aqueous solution, with insolubility increasing with chain length.22 Assays to monitor BE 
activity typically use partially solubilised long-chain amyloses that are highly viscous and 
likely to precipitate.20 This would result in erroneous absorbance readings, and has the 
potential to block HTS equipment. Long-chain amyloses were therefore incompatible with 
HTS. It was previously shown that MtGlgB can act on amylose-2800, a shorter, more soluble 
type of amylose. This has a mean DP of 12.6 ± 5.3 and, after MtGlgB treatment and 
subsequent debranching, chains with DP 6-9 increased, whilst chains with DP > 15 were 
depleted, demonstrating the branching activity of the enzyme.23 I determined that 2 mg/mL 
amylose-2800, that was solubilised by heating, would remain in solution for over 48 h, giving 
a suitable window for screening many compounds. 
The next consideration was the iodine detection reagent. Lugol’s solution is an aqueous 
preparation of iodine named after the French chemist Jean Lugol, and has been used as a 
disinfectant or for the treatment for thyroid diseases since its discovery in 1829.24 It is a 2:1 
mixture of I2 and KI (aq), to create a solution of iodide ions that is commonly used to 
investigate amylose.25 Addition of Lugol’s solution to amylose-2800 gives a purple/red 
colour with an absorbance maximum around 530 nm, Figure 3.1 (green line). Addition of 
Lugol’s solution to amylose-2800 that had been incubated with MtGlgB for 1 h gave a lower 
absorbance signal, as expected from the branching activity Figure 3.1 (blue line). Relatively 
high concentrations of enzyme were required to see a clear shift, most likely reflecting that 
this is not an ideal substrate for GlgB, because chain lengths are around the minimum DP 
required for branching, ~DP 15.23 Aqueous dilutions of Lugol’s solution of 10-25% gave 
absorbance readings in a suitable range for microplate measurements. 
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Figure 3.1 Amylose-2800 before and after incubation with MtGlgB.Absorbance spectra 
of amylose-2800 before (green line) and after (blue line) incubation with ~500 nM MtGlgB 
for 1 h. A 10% aqueous solution prepared from commercial Lugol’s solution is used. 
Branching results in depletion of the absorbance signal and the loss of the peak at ~530 
nm. 
A titration of amylose-2800 with a set dilution of Lugol’s solution demonstrated an 
approximately linear relationship between amount of amylose-2800 and absorbance, 
Figure 3.2A. Once an aqueous dilution of Lugol’s solution was prepared, it gave consistent 
initial absorbance readings when added to the same preparation of amylose-2800 every 
hour, indicating that the diluted Lugol’s solution is stable over this time-period, Figure 3.2B. 
However, after initial addition of Lugol’s solution, I observed that the absorbance signal 
decreased over time. I determined that this decrease was linear, Figure 3.2C, and was 
unaffected by other factors, such as light or temperature. Therefore, this signal drift can be 
accounted for in the assay protocol by recording absorbance measurements at a set 
timepoint after the addition of Lugol’s solution. 
Time-course experiments demonstrated that the addition of Lugol’s solution was sufficient 
to stop the enzymatic reaction, and at 22 °C the optimal assay window was achieved after 
a 90 min incubation period. However, I found that when Lugol’s solution was added directly, 
with no incubation period, the absorbance signal decreased with increasing enzyme 
concentration. This suggested that the presence of enzyme was affecting the amylose-
iodine interaction independently of the enzymatic activity. This could be due to amino acid 
residues such as lysine interacting with iodine.26 A heat-inactivated preparation of the 
enzyme was found to serve as a convenient control that would account for these 
interactions, Figure 3.2D. Both the active and heat-inactivated enzyme preparations were 
found to give consistent absorbance reading when stored on ice over a time-period of at 
least four hours, Figure 3.2E. 
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Figure 3.2 Investigation of amylose-iodine assay parameters. A) Titration of amylose-
2800 with Lugol’s solution, demonstrating a linear relationship. B) Initial absorbance 
readings from the addition of diluted Lugol’s solution to amylose-2800, every hour after 
preparation, demonstrating stability of the diluted Lugol’s solution over time. C) Depletion 
of the absorbance signal over time after the initial addition of Lugol’s solution to amylose-
2800. D) Comparison of absorbance at t(0) with either active or heat-inactivated MtGlgB for 
increasing concentrations of MtGlgB, suggesting that MtGlgB is reducing the absorbance 
signal independently of its enzymatic activity. E) Absorbance readings at t(90) with 
preparations of active and heat-inactivated MtGlgB stored on ice, demonstrating their 
stability. F) Effect of DMSO % on absorbance signal for active and heat-inactivated MtGlgB 
at t(90). Unless otherwise stated: 0.8 mg/mL amylose-2800, absorbance read at 530 nm, 
30 min after addition of 10-25% (aq.) Lugol’s solution, 22 °C. At least three repeats were 
carried out for all data sets.  
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 Compound libraries for HTS are typically stored in DMSO and therefore the influence of 
DMSO on the assay was also tested. The presence of DMSO slightly decreased the 
amylose-iodine absorbance signal, Figure 3.2F, however up to 10% DMSO had no effect 
on the enzymatic activity of MtGlgB as the difference between the two signals remained the 
same. Therefore, a final concentration of 10% DMSO was used for testing compound 
inhibition with this assay. 
Considering the variables discussed above, assay conditions were optimised on a 96-well 
plate format for 100 µL reaction volumes with the subsequent addition of 50 µL aq. Lugol’s 
solution as the detection reagent. Final enzyme reactions comprised 0.8 mg/mL amylose-
2800, 860 nM GlgB (active or heat-inactivated) and 10% DMSO, in 100 µL. After 90 min 
incubation at 22 °C, 50 µL of 20% aq. Lugol’s solution was added with mixing, and after a 
further 30 min incubation at 22 °C, the absorbance was recorded at 530 nm. The 
approximate Km for MtGlgB under these conditions was determined as 2.2 mg/mL, Figure 
3.3. However, the limited solubility of amylose-2800 precluded more accurate calculations 
because the full extent of the hyperbolic curve could not be determined. 
Finally, the overall assay quality was assessed according to the Zʹ values, defined as:27 
Zʹ = 1 −
3(σp + σn)
|𝜇𝑝 − 𝜇𝑛|
 
where σp and σn= the standard deviation of the positive and negative controls, respectively, 
and 𝜇𝑝 and 𝜇𝑛 = the mean of the of the positive and negative controls, respectively. A value 
of Zʹ = 1 represents an ideal assay, 1 > Zʹ ≥ 0.5 represents an excellent assay, 0.5 > Zʹ > 0 
represents a marginal assay and Z < 0 means that the assay is essentially unusable. 
Values for the assay described above were consistently ≥ 0.5, demonstrating it was an 
excellent assay with a large signal to noise ratio, hence it could be taken forward for HTS. 
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Figure 3.3 MtGlgB has a Km of ~2.2 mg/mL with amylose-2800 under assay condtions. 
Determined by the difference between absorbance at 530 nm in positive (active MtGlgB) 
and negative (heat-inactivated MtGlgB) controls, with increasing concentrations of amylose-
2800. In 100 µL, 860 nM MtGlgB was added to amylose-2800 with 10% DMSO. After 90 
min incubation at 22 °C, 50 µL 20% aq. Lugol’s solution was added and the absorbance 
was measured after a further 30 min at 22 °C. As the full extent of the hyperbolic curve 
could not be determined, a Km value was estimated using Sigmaplot. Data were recorded 
in triplicate. 
3.2.2 Comparison with published MtGlgB amylose-iodine assay 
During the course of this work, Dkhar et al. published a study in which potential inhibitors of 
MtGlgB were identified by virtual screening. The inhibition of MtGlgB was tested 
experimentally and some compounds were also shown to inhibit the growth of M. 
tuberculosis H37Rv.2 Due to the lack of counter-screens or other methods to verify 
compound binding, questions remained about the conclusions of this work. To investigate 
this further, I replicated the amylose-iodine assay reported in the Dkhar et al. study, which 
utilised a long-chain amylose substrate that was solubilised in 1 M NaOH and neutralised 
with 1 M HCl. According to the protocol, this was incubated with MtGlgB for up to 30 min, 
then a preparation of iodine solution which contained HCl was added. Under these 
conditions, I observed little difference between positive and negative controls for reaction 
times up to 1 h, with corresponding Zʹ values of ~0. Furthermore, upon the addition of the 
acidic iodine solution a significant amount of amylose precipitation was observed, 
precluding accurate absorbance readings. Different preparations of MtGlgB gave similar 
results, and increased enzyme concentrations and/or reaction times made no significant 
difference. I therefore concluded that the amylose-iodine assay reported by Dkhar et al. was 
not suitable for accurate evaluation of MtGlgB inhibition. 
Chapter 3  
 
91 
3.2.3 Automation of amylose-iodine MtGlgB assay 
For screening the compound libraries at MRCT, it was necessary to miniaturise the assay 
to a 384-well plate format and develop an automated method. The assay volume was 
reduced to 20 µL and the assay protocol was adjusted so that enzyme and substrate 
solutions were mixed in approximately equal volumes to reduce errors resulting from the 
transfer of small volumes. Standard polystyrene 384-well plates were compared with 
Nonbinding Surface plates, which have been treated to prevent protein binding to the 
plastic. No differences between the two were found and therefore standard plates were 
used. Automation methods for the assay were developed for Biomek (Beckman Coulter) 
and Flexidrop (Perkin Elmer) instruments in collaboration with Puneet Khurana, MRCT. 
Several steps were required to optimise the transfer of the amylose-2800 solution, which 
tended to result in plate-striping due to its viscosity. The final method was again verified by 
calculating Zʹ values, which were in the range of 0.7 – 0.8, demonstrating an excellent 
signal:noise ratio. 
For testing compounds, a 20 min pre-incubation of the enzyme and compound before 
substrate-addition was used, to allow for slow binders. Pilot runs were carried out with a set 
of about 1,000 compounds (MRCT) at 10 µM, which gave a hit rate of 0.14%, indicating the 
assay was unlikely to give a high number of false positives. However, because this could 
also indicate that the assay had a low sensitivity I increased the concentration of compounds 
in further screening to 30 µM. The final parameters for screening are shown in Table 3.1. 
Table 3.1 Optimised amylose-iodine assay conditions for HTS of MtGlgB.
 Concentrations are given for the enzyme reaction in 20 µL before the addition of 10 µL 
Lugol’s solution. 
 
 
  
Component Condition 
Substrate 0.8 mg/mL amylose-2800 
Enzyme 860 nM recombinant MtGlgB 
DMSO 10% (v/v) 
Compound  30 µM 
Pre-incubation time 20 min 
Reaction time 90 min 
Detection reagent 20% Lugol (aq.), 30 min incubation 
Absorbance wavelength 530 nm 
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3.3 Screening compound libraries against MtGlgB 
3.3.1 Screening MRCT compound libraries 
The optimised assay protocol, Table 3.1, was used to screen MRCT compound libraries 
consisting of 13,472 compounds, at 30 µM. These were divided over 44 384-well plates, 
with each plate normalised to the positive and negative controls. The assay parameters 
were monitored over the course of the screening process and the Z’ values were maintained 
at 0.7 – 0.8 throughout. In total, there were 17 compounds with a percentage inhibition over 
25%, Figure 3.4, representing a hit rate of 0.13%. These compounds, alongside any library 
compounds with a similarity score over 0.5 were rescreened to identify consistent hitters. 
Two consistent hitters were identified, compounds 3a and 3b, Figure 3.5. The kinetic 
solubility of these were determined as 212 µM and 5 µM, respectively, by David Tickle 
(MRCT), indicating only 3a was suitable for further investigation. Counter-screens in the 
absence of enzyme demonstrated that compound 3a did not interfere with the amylose-
iodine interaction independently of MtGlgB. 
 
Figure 3.4 Inhibition of MtGlgB by compounds from MRCT libraries. Compounds (×) 
are plotted on the x-axis according to MRCT compound number (arbitrary, numbers not 
shown). Calculated % inhibition values lower than 0 are not shown. The cut-off for further 
testing at ≥25% inhibition is illustrated with a red dashed line. 
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Figure 3.5 Hit Compounds identified from screening of MtGlgB. Compound 3b was 
excluded due to low solubility, whereas 3a was investigated further. 
3.3.2 Screening compounds from open-source GSK libraries 
Recently, Glaxo-Smith-Kline made available two sets of potent M. tuberculosis H37Rv 
inhibitors that have favourable properties but unknown targets.28-29 These consisted of 227 
compounds, which were screened at 50 µM with the amylose-iodine assay in a 96-well plate 
format. No inhibitors of MtGlgB were identified. 
3.4 Validation of hit compound 3a 
3.4.1 IC50 estimation of 3a 
Firstly, I attempted to determine the IC50 of 3a. Due to the solubility limit of the compound it 
was not possible to prepare a stock solution that gave 100% inhibition of MtGlgB. An 
estimated IC50 value was therefore calculated as 71 µM by assuming 100% inhibition at an 
arbitrary high concentration, Figure 3.6. This estimate is comparable with the IC50 and Ki 
values of the published GlgE inhibitors and in the expected range for a primary hit from a 
screen. 
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Figure 3.6 Compound 3a has an approximate IC50 of 71 µM. The percentage inhibition 
was determined with the standard amylose-iodine assay conditions in a 96-well plate 
format, for increasing concentrations of 3a. An approximate IC50 value was calculated using 
Sigmaplot, with an artificial 100% inhibition data point added. Data recorded in triplicate. 
3.4.2 Isothermal titration calorimetry verifies the binding of 3a to MtGlgB 
Whilst the counter-screen data indicate that 3a does not appear to interfere with the iodine-
amylose interaction in the absence of enzyme, it cannot be ruled out that it has an indirect 
effect, for example by sequestering the amylose-2800 substrate such that it is less 
accessible to MtGlgB. To determine whether 3a interacted directly with GlgB, several 
methods to investigate protein-ligand interactions were explored, including surface plasma 
resonance (SPR). However, this was found to be not suitable for measuring the interaction 
because the size difference between an immobilized protein (~83 kDa) and ligand (268 Da) 
is too great for detection of a µM binding interaction. On the other hand, isothermal titration 
calorimetry (ITC) measurements are independent of size and ITC is considered the gold 
standard for the measurement of protein-ligand interactions.30 
ITC experiments showed a clear binding interaction between 3a and MtGlgB with an 
average molar binding ratio of 0.89, suggestive of 1:1 binding, and an average Kd of 3.1 ± 
0.7 µM (n = 3); representative data shown in Figure 3.7. Protein concentrations of 10 µM – 
50 µM were tested, with ratio of ligand:protein 10:1 – 16:1. Control experiments with buffer 
titrated into MtGlgB and 3a titrated into buffer or control proteins such as BSA, showed no 
heat change, confirming that this binding interaction was genuine. The shape of the curve 
and binding heats were consistent with a low value of the Wiseman “c” parameter,31 which 
ranged from 3-10.32 The average calculated thermodynamic energies for the binding were: 
ΔH: -3.30 kcal/mol, ΔS: 13.5 cal/mol/deg; -TΔS: -3.98 kcal/mol, to give ΔG: -7.28 kcal/mol, 
suggestive of binding dominated by hydrophobic interaction. Thus, 3a, is confirmed as a 
true binder of MtGlgB, with a binding affinity significantly lower than that suggested by the 
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estimated IC50, representing a reasonable start for compound development. The binding 
ratio is approximately 1:1 with the protein, suggestive of a single binding site. 
 
Figure 3.7 ITC confirms that 3a binds to MtGlgB. 3a binds to MtGlgB with an average Kd 
=3.1 ± 0.7 µM and 0.89 molar ratio, suggestive of ~1:1 binding. A representative dataset is 
shown here with a calculated Kd = 3.9 µM and a molar ratio of 0.80. 
3.4.3 Compound 3a inhibits MsGlgB in vitro 
To gain insight into the cross-species spectrum of 3a inhibition, I investigated the inhibition 
of MsGlgB. The benchtop amylose-iodine assay detailed in section 3.2.1 was adapted 
slightly to account for the slightly higher activity observed for MsGlgB, compared to MtGlgB. 
As a modified MsGlgB protein lacking the catalytic residues was available, direct 
comparison could be made between this and the heat-inactivated control. Absorbance 
measurements were found to be very similar in both negative controls, confirming each to 
be valid. The percentage inhibition of M. smegmatis and MtGlgB with 50 µM 3a was then 
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determined under comparable conditions. The average percentage inhibition was 41% for 
MtGlgB and 36% for MsGlgB, demonstrating that 3a inhibits MsGlgB similarly, Figure 3.8. 
 
Figure 3.8 The compound 3a inhibits both MtGlgB and MsGlgB in vitro. Assay 
conditions were as described for the benchtop amylose-iodine MtGlgB assay in section 
3.2.1. At least three repeats were carried out with each enzyme. 
3.5 Co-crystallisation trials of 3a and MsGlgB 
Since 3a also inhibited MsGlgB and crystals of this enzyme were readily available (as 
described in Chapter 2) I attempted to determine inhibitor-bound crystal structures. Initially 
co-crystallisation trials were explored, whereby MsGlgB and 3a were combined and pre-
incubated for 1 h, before being mixed with precipitant solution and dispensed in vapour-
diffusion sitting drop plates. This either prevented crystal formation, or resulted in small 
needle-like crystals that were not suitable for diffraction experiments. To avoid this, I 
generated MsGlgB crystals first, and then soaked them for up to 2 h with 3a, which was 
diluted in precipitant solution to give a final concentration of DMSO ≤ 5%. The crystals were 
collected, frozen and subject to X-ray diffraction experiments, as described previously. 
Crystals diffracted to resolutions of around 2 Å and the structure was solved as before. In 
all cases, no additional electron density that could correspond to 3a was detected. 
To increase the concentration of 3a in the crystal soak, I tested the tolerance of the MsGlgB 
crystal to increased concentrations of DMSO. I found that the MsGlgB crystals could tolerate 
a 1:1 DMSO:precipitant solution for up to 3 h before they could be seen to degrade. I then 
prepared 1:1 mixtures of 3a in DMSO and precipitant solution, to achieve final 
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concentrations of 3a up to 50 mM. These were used for crystal soaks of up to 3 h and 
crystals were then used for diffraction experiments as above. Again, no additional electron 
density that could correspond to 3a was detected and I concluded that it would not be 
possible to obtain a structure of 3a bound to MsGlgB by this approach. 
3.6 ITC shows that compound MB16695 does not bind to MtGlgB 
In section 3.2.2 I investigated the amylose-iodine MtGlgB assay previously described by 
Dhkar et al.2 and found that it was not possible to distinguish between positive and negative 
controls with their protocol. This casts doubt on the validity of the MtGlgB inhibition values 
reported in this study, therefore I investigated the interaction between one of the putative 
inhibitors and MtGlgB in more detail. Compound MB16695 was reported to inhibit MtGlgB 
by 36.5% at a concentration of 3 nM, with a reaction time of 10 min. Furthermore, it was 
stated to have a minimum inhibitory concentration (MIC) of 15.6 µg/mL in growth inhibition 
assays with M. tuberculosis H37Rv, which was assumed to be due to it targeting MtGlgB in 
the cell. 
Firstly, I tested the inhibition of MtGlgB by MB16695 with the benchtop amylose-iodine 
assay described in section 3.2.1. I did not observe any inhibition of MtGlgB up to 50 µM 
MB16695, and above this concentration there was significant bleaching of the purple colour. 
I then investigated a possible binding interaction between MB16695 and MtGlgB using ITC, 
which had previously been used to confirm the binding of 3a to MtGlgB. Under similar 
conditions I saw no binding curve for MB16695, Figure 3.9. These data suggest that 
MB16695 does not inhibit MtGlgB and therefore the growth inhibition of M. tuberculosis 
H37Rv by this compound was not specific for the MtGlgB target. Further investigation is 
required to determine whether the other inhibitors reported in this study truly inhibit MtGlgB. 
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Figure 3.9 MB16695 does not bind to MtGlgB. A) Structure of MB16695. B) No binding 
response was observed for MB16695 and MtGlgB. ITC experiments were carried out as 
described above. 
3.7 Discussion 
In this chapter I aimed to identify small-molecule inhibitors of MtGlgB using HTS, which was 
achieved by the identification of 3a. This firstly required the establishment of a HTS assay 
for MtGlgB. The branching enzyme reaction can be challenging to monitor, because 
substrates and products are indistinguishable by mass or functional group, and there is no 
release of side-products.5 The amylose-iodine assay takes advantage of the difference in 
absorbance with iodine between branched products and unbranched substrates. Whilst this 
method has a long history of use for amylolytic enzymes and branching enzymes,25 this is 
the first time the assay parameters have been systematically investigated to give an assay 
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with high Zʹ values that can be used to screen 1,000s of compounds in quick succession. 
Colorimetric assays are usually preferred for screening due to their inherent simplicity, 
however there are some drawbacks that must be considered. Most significant is the 
interference of compounds with absorbance measurements, independent of interactions 
with the enzyme;33 a particular problem for coloured compounds. Indeed, a number of the 
compounds identified as false positives were coloured compounds that artificially increased 
absorbance measurements at 530 nm. Likewise, it cannot be ruled out that there were false 
negatives that artificially reduced absorbance readings, for example by interacting with the 
iodine reagent. This is an important consideration for all colorimetric assays and must be 
taken into account when taking this assay forward. 
In the past, amylose-iodine assays have been perceived as non-quantitiative.7 This work 
may encourage other researchers that the amylose-iodine assay has utility as a quantitative 
method for investigating branching enzymes, as long as the appropriate controls are 
implemented. For example, previous assays have not checked for the potential interaction 
of the enzyme with the iodine reagent, was seen here for MtGlgB with Lugol’s solution. This 
is important to consider as would lead to enzyme activities being overestimated. One caveat 
for using this assay with other branching enzymes is that the reported minimum substrate 
specificity tends to be much longer than the DP range of amylose-2800. However, as for 
MtGlgB, it may be the case that whilst the shorter chain amylose is not an ideal substrate, 
it is sufficient in the context of the assay. 
 A previously published amylose-iodine assay for MtGlgB2 was not reproducible in my hands 
and the long-chain amylose led to significant precipitation. The amylose-2800 substrate was 
used because it is more soluble than higher molecular weight amyloses that are typically 
utilised, however the overall aqueous solubility is still limited. The Km of amylose-2800 with 
MtGlgB under the assay conditions was estimated as 2.2 mg/mL, with more accurate 
determination precluded by the limited solubility of amylose-2800 at high concentrations. 
The substrate concentration used in the assay was 0.8 mg/mL, approximately three-fold 
lower than Km, with a higher concentration again prohibited by the limited solubility. 
Typically, a substrate concentration at or close to the Km is used, however, a substrate 
concentration below Km still allows for the identification of competitive inhibitors, in addition 
to uncompetitive and mixed inhibitors.9 The substrate concentration therefore does not limit 
the capacity to identify inhibitors with this assay. 
Compound 3a was identified as a MtGlgB inhibitor and the binding of the compound to the 
enzyme was confirmed with ITC. There was a difference between the estimated IC50 value 
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of 71 µM determined with the assay and the Kd of 3.1 ± 0.7 µM determined by ITC. As the 
IC50 value was an estimation due to the limited solubility of 3a, the true value may well be 
closer to the Kd. The relationship between the IC50 and the Kd depends on the type of 
inhibition and the substrate concentration. Nevertheless, IC50 is always greater than or 
equal to Kd, as was seen here. 
 Since an inhibitor-bound crystal structure could not be obtained, the binding site of 3a 
remains unknown. ITC data suggest binding dominated by hydrophobic interaction. Since 
3a has a planar, quinazoline scaffold, it is possible to speculate that it interacts via CH(π) 
stacking with an aromatic residue such as phenylalanine, tyrosine or tryptophan. A number 
of these residues interact with maltooligosaccharides in the ligand-bound MsGlgB 
structures, hence this could be a mechanism to inhibit the action of the enzyme. Knowledge 
of the binding site will be invaluable to the future development of 3a, as this will allow rational 
design of 3a analogues with improved potency. As efforts to identify this with crystallography 
have been unsuccessful thus far, other methods such as STD-NMR could be utilised.34 
I also investigated the interaction of MB16695 with MtGlgB, since this compound had 
previously been reported to inhibit the enzyme at low nM concentrations.2 Conversely, I saw 
no inhibition of MtGlgB by MB16695 in my amylose-iodine assay, but did observe bleaching 
of the colour and hence lower absorbance readings at concentrations of MB16695 > 50 µM. 
Since this would actually give a false-negative result, it does not explain the reported 
inhibition in the Dkhar et al. study, especially as this was for much lower concentrations of 
MB16695. ITC data confirmed that MB16695 does not bind to MtGlgB. This finding, in 
addition to the unreproducible assay, suggests that the inhibition of MtGlgB reported for 
other compounds may also not be valid. Whilst there is no suggestion that there are 
inaccuracies in the M. tuberculosis H37Rv growth inhibition studies, the observed inhibition 
must be enacted via targets other than MtGlgB. 
These findings indicate that compound 3a represents the first true small-molecule inhibitor 
of MtGlgB. The next steps are the investigation of structure-activity relationships and in vivo 
activity: these are explored in Chapter 4. 
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3.8 Summary 
I developed an amylose-iodine assay for HTS of compounds against MtGlgB. This was used 
to screen compound libraries of approximately 13,500 compounds. Compound 3a was 
validated as an inhibitor of MtGlgB, and ITC experiments demonstrated a 1:1 molar ratio 
with a low µM Kd. This will be further investigated with medicinal chemistry and in vivo 
assays in the following chapter. 
3.9 Materials and methods 
Methods for protein production and purification, crystal soaks of MsGlgB, data collection 
and refinement were carried out as described in section 2.7. 
3.9.1 Amylose-iodine assay 
Amylose-2800 was purchased from Tokyo Chemical Industry. Compound 3a was 
purchased from Specs. Compound MB16695 was purchased from Ambinter. Lugol solution, 
amylose from potato (av. MW 150,000) DMSO and all other chemicals were purchased from 
Sigma Aldrich. 96-well, 384-well or 384-well Nonbinding Surface flat-bottom microplates 
were purchased from Corning. Amylose and MtGlgB stock solutions and dilutions were 
prepared in 20 mM sodium phosphate buffer, pH 7.0, containing 50 mM NaCl ( henceforth 
referred to as phosphate buffer), Lugol solution was diluted in ultrapure water (Milli-Q). The 
heat-inactivated MtGlgB was prepared by heating at 90 °C for 5 min. Absorbance 
measurement were recorded using a CLARIOstar® plate reader (BMG LabTech) and data 
were analysed in Microsoft Excel (Microsoft Office) or SigmaPlot (Systat Software Inc.). 
3.9.2 Screening conditions 
Compound libraries were provided by MRCT and included a range of compounds from 
commercial suppliers: Maybridge (Trevillett, UK), Interbioscreen (Moscow, Russia), SPECs 
(Delft, Netherlands), Peakdale (Chapel-en-le-Frith, UK) and Biofocus (Chesterford Pk, UK). 
Library compounds were solubilised in DMSO at 1 mM in 384-well plates in preparation for 
screening and dilutions were prepared in DMSO. Automation methods were developed 
using Biomek (Beckman Coulter) and Flexidrop (Perkin Elmer) instruments in collaboration 
with Puneet Khurana, MRCT. 
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3.9.3 Kinetic solubility 
The kinetic solubilities of 3a and 3b were determined by David Tickle (MRCT). A stock 
solution in DMSO was diluted with 1 × PBS (Sigma Aldrich) and the concentration at which 
precipitate is first observed was recorded 
3.9.4 Isothermal titration calorimetry 
ITC experiments were carried out using a MicroCal VP-ITC instrument (Malvern) and data 
were analysed using Origin® (Malvern). Aliquots of MtGlgB were thawed on ice, combined, 
thoroughly mixed and centrifuged, before the determination of the protein concentration 
using a Direct Detect® infrared spectrometer (Merck) and a Nanodrop spectrophotometer 
(Nanodrop®). Dilutions were made as appropriate with the same batch of phosphate buffer 
the protein was stored in. Protein solutions were allowed to warm to 25 °C shortly before 
initiating ITC experiments, which were all carried out at this temperature. Compound 3a was 
solubilised in the same batch of phosphate buffer at pH 7.0, using sonication and heating. 
The compound solution was monitored by eye and by absorbance measurements to check 
for precipitation over the course of the experiments. Typically, experiments consisted of 19 
injections of 2 µL every 2 min, with MtGlgB in the cell and 3a in the syringe. Protein 
concentration ranged from 10 – 50 µM, with the ratio to ligand ranging from 1:10 to 1:16. 
After experiments were complete, the cell solution was also checked for precipitation. 
Control experiments consisted of injections of phosphate buffer into MtGlgB, 3a into buffer 
and 3a into control proteins such as BSA, all of which resulted in consistent heat changes 
that were not suggestive of binding. 
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4. Structure-activity studies of MtGlgB inhibitor 3a 
4.1 Introduction 
The previous chapter describes the identification of a small-molecule inhibitor of MtGlgB 
from an amylose-iodine assay screen; compound 3a, Figure 4.1. This was validated by 
ITC, which gave a Kd of 3.1 ± 0.7 µM and showed a 0.89 molar binding ratio, suggestive of 
a single protein binding site. Compound 3a has a number of favourable properties, such as 
conforming to Lipinski’s rule of 5,1-2 a high weighted quantitative estimation of drug likeness 
(QED)3 and a ligand efficiency greater than 0.3,2 Figure 4.1. The quinazoline scaffold is 
also generally attractive as it is found in a number of marketed drugs.4 To investigate 3a 
further I addressed the question: Can structure-activity relationships be established with a 
selection of modified compounds? I aimed to investigate which features of 3a were 
important for inhibition, with a view to improving the efficacy and/or solubility of 3a. 
I also wanted to address the question: How do 3a and its analogues behave in vivo? I aimed 
to gain further insight into the activity of 3a and synthesised compounds by testing their 
effect on M. smegmatis growth. As discussed previously, this is commonly used as a faster 
growing and non-pathogenic model for M. tuberculosis.5-6 In Chapter 2, I demonstrated the 
high similarity of MtGlgB and MsGlgB and in Chapter 3, I showed that 3a inhibits MtGlgB 
and MsGlgB by a similar amount. M. smegmatis is therefore a relevant model for the GlgB 
target. 
 
 
 
 
 
 
 
Figure 4.1 Drug-like properties of compound 3a. Structure of 3a with properties 
calculated using DruLiTo.1-3 
Molecular weight 268.36 
Lipinski’s Ro5 ✓ 
QED (weighted)  0.781 
LogP (predicted) 2.24 ± 0.76 
Kd 3.1 ± 0.7 µM 
Ligand efficiency 0.364 
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4.2 Chemical synthesis of 3a analogues 
4.2.1 Selection of target compounds 
The structure of compound 3a comprises a quinazoline core, consisting of fused benzene 
and pyrimidine rings, with two pyrrolidine side groups at positions 2 and 4. The aim of 
chemical synthesis was therefore to create a range of compounds varied in both the 
aromatic core and amine side groups, Figure 4.2. Both the availability of commercial 
reagents and the predicted ease of synthesis were also considerations for the selection of 
target compounds. Since 2,4-dichloro pyrimidine compounds were commercially available 
and could theoretically be substituted at the 2 and 4 positions with amine groups via a 
nucleophilic addition/elimination,7 these were chosen as the basis for the synthesised 
compounds. 
Firstly, substitutions with a single amine group were explored, with the 4-amino 2-chloro 
compounds being more synthetically accessible. Then, to investigate both the effect of the 
ring size and cyclic nature of the amine group, pyrrolidine was substituted by either 
piperidine or butylamine. Further substitutions, to introduce more heteroatoms via 
piperazine and proline were considered, however these proved more challenging to 
synthesise, as discussed below. Finally, I wanted to investigate modifications to the 
quinazoline scaffold, by retaining the pyrimidine core without the additional benzene ring. I 
explored different pyrimidine substitutions with trifluromethane and thiophene. This 
proposed set of compounds would provide a good starting point for preliminary structure-
activity studies of 3a. 
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Figure 4.2 Proposed structural modifications for compound 3a. Compound 3a 
comprises a quinazoline core consisting of fused pyrimidine and benzene rings (green box) 
with pyrrolidine side groups at the 2 and 4 positions (blue boxes). Proposed modifications 
of these groups are shown in green and blue boxes respectively. 
 
4.2.2 Chemical synthesis 
The general synthetic strategy was nucleophilic substitution of 2,4-dichloro pyrimidine 
compounds with simple aliphatic amines. The 4-position is known to be much more reactive 
with respect to nucleophilic substitution, compared to substitution at the 2-position.8 This 
differential reactivity could be exploited in some cases, to sequentially add different amine 
groups to the pyrimidine scaffolds. 
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4.2.2.1 Synthesis of Quinazoline Compounds 
I initially explored substitution of 2,4-dichloroquinazoline at the 4-position with simple 
amines, Figure 4.3. Stirring with pyrrolidine in the presence of triethylamine (TEA) gave 4a, 
and none of the di-substituted product. Likewise, reaction with piperidine and TEA readily 
gave 4b. Reaction with n-butylamine was slower, therefore heat was used to drive the 
reaction and form 4c.1. Reactions with piperazine or proline were also slow and resulted in 
a complex mixture of products. The troubleshooting of the piperazine and proline reactions 
included exploration of different bases, solvents and temperatures, but no significant 
improvements were seen. These target molecules were therefore not pursued further and I 
moved on to the synthesis of di-substituted quinazolines. 
I firstly investigated 2-position substitutions of 4a with different amines, using higher 
temperatures and longer reaction times. Substitution with piperidine was successful, to form 
4d, however reaction with pyrrolidine to make 3a was much slower and required microwave 
radiation conditions to form the desired product. Substitution of 4a with n-butylamine could 
not be achieved despite considerably extended reaction times and temperatures. 
Consistent with previously attempted reactions, reaction of 4a with piperazine or proline did 
not give any of the desired products, and hence these reagents were not used in further 
synthesis of quinazoline derivatives. 
To create the di-piperidinyl quinazoline, 4b was further reacted with piperidine, which 
fortuitously gave 4e as a crystalline solid, that could be easily isolated by filtration. On the 
other hand, reaction of 4b with pyrrolidine surprisingly yielded no detectable product, 
despite exploring different reaction times and temperatures. As with 4a, reaction with n-
butylamine also did not give the desired product. The mono-substituted n-butylamine 
compound 4c.1 was then reacted with piperidine, which readily gave 4f. Unlike the previous 
sets of reactions, it was possible to substitute with n-butylamine at the 2-position to give the 
di-substituted n-butylamine compound 4g. However, as before, reaction with pyrrolidine did 
not yield the desired product. Interestingly, after purification of the reaction mixture by flash 
column chromatography, an inseparable mixture of 4c.1 and 4c.2 was isolated, indicating 
a possible migration of the n-butylamine group in 4c.1 under these conditions. 
Yields were generally modest, but sufficient for compound characterisation and further 
testing, and the reactions were therefore not optimised further. 
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Figure 4.3 Synthetic scheme for quinazoline-based compounds. All reactions carried out in ethanol with 1.5-2 equivalence of the respective 
amine and TEA, with heating if required. nd = not detected. Yields: a: 73%, b: 85%, c: 63%, f: 37%, g: 91%, l: 45%, o: 29%, p: 22%.
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For investigation of a pyrimidine-only scaffold, the commercially available compound 2-
chloro-4-pyrrolidin-1-yl pyrimidine was reacted with pyrrolidine or piperidine to give 4h and 
4i respectively. Surprisingly, unlike all previously attempted reaction with proline, it was 
possible to isolate the proline-substituted compound 4j. 
From 2,4-dichloro-5-trifluoromethyl pyrimidine, either of the 2- or 4- mono-substituted 
pyrrolidine compounds 4k.1 and 4k.2 could be generated, but the di-substituted compound 
was not attained, despite a number of attempts to optimise reaction conditions. Likewise, 
attempts to make 2,4-di-pyrrolidin-1-yl-thieno[3,2-d]pyrimidine were also unsuccessful, 
however the mono-substituted compound 4l could be isolated, Figure 4.4. Overall, 14 
compounds were purified in high enough yields for full characterisation and further testing, 
including two novel compounds: 4f and 4k.2. 
 
Figure 4.4 Synthetic scheme for pyrimidine-based compounds. All reactions carried 
out in ethanol with 1.5-2 equivalence of the respective amine and TEA, and heating with 
microwave radiation if required; nd = not detected. Yields: q: 84%, r: 60%, s: 31% t: 86% 
(4k.2) and 14% (4k.1); v: 78%. 
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4.3  Testing analogues of 3a with MtGlgB 
Fourteen of the synthesised compounds were tested for inhibition of MtGlgB at a 
concentration of 50 µM, using the amylose-iodine assay described in Chapter 3. The 
percentage inhibition observed was normalised to that of 3a, to more easily make 
comparisons. Previous ITC analyses indicated that the actual binding affinities may be 
higher than the percentage inhibition seen in the MtGlgB assay. However, none of the 
synthesised compounds showed higher levels of inhibition than 3a, suggesting that their 
binding affinities would also be worse than that of 3a. 
Broadly speaking, compounds that retained a quinazoline scaffold showed some level of 
inhibition, whereas those without this did not inhibit MtGlgB, with the notable exceptions of 
4d and 4k.2, which had lower and higher levels of inhibition, respectively. Comparing 3a 
and 4d, just switching the 2-pyrrolidine group for piperidine completely abolished inhibition. 
It was not possible to synthesise other quinazoline compounds with a 2-pyrrolidine 
substitution and so it is difficult to draw conclusions, although this could indicate that this 
group has the biggest contribution to the inhibition in a quinazoline scaffold. Most of the 
pyrimidine-based compounds showed no inhibition apart from 4k.2, which had higher 
inhibition than its isomer 4k.1. Again, this suggests the 2-pyrrolidine substitution is critical 
for inhibition, although compound 4h with a 2-pyrrolidine group showed no inhibition.  
The order of relative inhibition 4a > 4b > 4c.1 indicates that in the presence of a 2-chloro 
group, the level of inhibition with respect to the 4-position group is pyrrolidine > piperidine 
> n-butylamine. However, this trend is not seen in the di-substituted compounds, for 
example 4f, in which the pyrrolidine groups were replaced with 4-n-butylamine and 2-
piperidine, had a relatively high inhibition. The other 4-n-butylamine compounds 4c.1 and 
4g, and the other 2-piperidine compounds 4d and 4e, had lower levels of inhibition. The 
combination and relative position of the amine groups is important and it does not seem 
possible to consider the amine groups at each position in isolation.  
Overall, the trends between the identity of the amine groups were difficult to distinguish and 
it seems that more chemical space needs to be explored before trends can be clearly 
established. 
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Figure 4.5 Inhibition of MtGlgB by analogues of 3a. Percentage inhibition is normalised 
to that of 3a demonstrating that none of the structural modifications led to an improved 
efficacy. Compounds were tested at 50 µM with the 96-well plate format amylose-iodine 
assay detailed in section 3.2.2, with a minimum of three repeats for each compound. 
4.4 Testing effect of 3a on M. smegmatis growth 
M. smegmatis is a faster growing, non-pathogenic relative of M. tuberculosis, that is a 
commonly used surrogate for assessing the in vivo activity of potential tuberculosis 
therapeutics.6 A M. tuberculosis ΔglgB strain is not viable due to the lethal accumulation of 
M1P. On the other hand, a M. smegmatis, ΔglgB strain accumulates M1P, but is viable in 
normal growth conditions, unless the growth medium is supplemented with trehalose.9 
Therefore, to monitor inhibition of MsGlgB in M. smegmatis, it is necessary to add trehalose 
to the growth medium. This trehalose dependence is useful, as it provides a way to 
distinguish between growth inhibition specific for the GlgB target and off-target effects, 
simply by comparing growth in the presence and absence of trehalose. 
4.4.1 Developing a M. smegmatis assay to test compounds 
In the first instance, I explored the agar disk diffusion method,10 as a potentially quick and 
easy method to determine the effects of the compounds on mycobacterial growth. However, 
I observed inconsistent and/or hazy zones of inhibition with positive controls and therefore 
Chapter 4  
 
115 
this method was not pursued further. Instead, I opted for a liquid culture 96-well plate assay 
to continuously monitor M. smegmatis growth over a number of days in the presence of the 
compounds. This can be followed by the addition of the redox-sensitive dye resazurin, which 
turns from blue to pink when it is reduced in the presence of viable cells.11-12 Hence, by 
comparing growth and colour, compounds that are bactericidal can be distinguished from 
those that are bacteriostatic. To optimise the published protocol13 for my purposes I varied 
inoculum density, incubation time, DMSO percentage, trehalose concentration and 
incubation time with resazurin. Each plate included sterility controls and growth controls, 
comprising medium with and without inoculum. 
4.4.2 Three compounds were non-selective inhibitors of M. smegmatis 
growth at high concentrations 
Compounds were initially tested at a concentration of 500 µM in the presence and absence 
of trehalose. Each condition was tested at least in triplicate on every plate, and repeated on 
2-3 different plates, with a new mycobacterial inoculum for each plate. Compounds 4a, 4b, 
4h and 4l consistently showed no inhibition. Compounds 4c.1 and 4e initially showed some 
growth inhibition, but this was not consistent in repeat experiments. This could indicate that 
at this concentration they are borderline inhibitors and testing at higher concentrations could 
determine if this were the case. Compounds 3a, 4g and 4f were consistently bactericidal, 
however they were not selective for GlgB as there was no difference in growth inhibition 
with and without trehalose. The approximate MICs of these compounds was established 
using serial two-fold dilutions from 500 – 4 µM, according to the standard protocol.13 These 
were 125 µM for 4f, 125 µM for 3a and 250 µM for 4g, Figure 4.6. 
4.4.3 Compounds did not inhibit E. coli growth at the same concentrations 
To determine whether these compounds were effective against Gram-negative bacteria, I 
attempted to determine the MICs with E. coli ATCC 25922, a reference strain for antibiotic 
susceptibility testing.14 For all three compounds, growth was visible at the highest 
concentration tested, therefore the E. coli MICs with this strain were all ≥ 500 µM. However, 
there was a visible decrease in growth that correlated with increasing compound 
concentration, indicating that the compounds impeded E. coli growth by up to 20 - 30% at 
500 µM. Whilst these preliminary results indicate that these compounds may be more 
effective against mycobacteria than E. coli, further work is required to confirm this. 
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Figure 4.6 M. smegmatis growth assays with synthesised compounds. Growth assays 
are shown in the top panel, with 500 µM of each compound added to growth media lacking 
trehalose (-Tre) or supplemented with 500 µM trehalose (+Tre). Since the M. smegmatis 
glgB knockout is lethal only in the presence of trehalose, compounds that inhibit growth by 
targeting GlgB will be effective in the +Tre condition only. Colorimetric read-outs were 
determined using a resazurin assay. Pink wells contain viable bacteria and blue wells no 
viable cells. Compounds 3a, 4f and 4g showed non-selective inhibition and the MICs in 
normal growth media were determined by two-fold serial dilutions, bottom panel. Analysis 
of growth curves confirmed these were bactericidal, rather than bacteriostatic. Images are 
representative of at least three biological repeats. 
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4.5 Crystal soaks of MsGlgB with synthesised compounds 
Crystal soaks of MsGlgB and D416A-MsGlgB were carried out with all the compounds that 
showed > 10% relative inhibition in the in vitro assay. As with 3a, soaks with a mixture of 
compound in DMSO at ~50 mM and precipitant solution were used. After 3 h, crystals were 
frozen and diffraction data were collected, however no additional electron density 
corresponding to any of the compounds was observed. 
4.6 Discussion 
In this chapter I aimed to address structure-activity relationships of 3a with a selection of 
modified compounds. Compound 3a was identified as an inhibitor of MtGlgB from a high-
throughput screen and validated by ITC, which demonstrated a Kd of 3.1 ± 0.7 µM and a 
1:1 binding ratio. As the interactions with the protein and the mechanism of inhibition were 
unknown, my approach was to explore the effect of varying the main structural features. I 
defined these as a pyrimidine-containing quinazoline core and amine side groups located 
at the 2 and 4 positions of the pyrimidine ring, Figure 4.2. I aimed to make compounds that 
retained the pyrimidine ring and the position of the amine group substitutions, but had 
variations in both the type of amine groups and substitutions on the pyrimidine ring. 
Substitutions of 2,4-dichloro quinazoline provided a straightforward route to target 
compounds, taking advantage of the differential activity of each position to add different 
amine groups to the 2 and 4-positions. The greater rate of reaction at the 4-position 
compared with that at the 2-position with respect to nucleophilic displacement can be 
explained by the resonance forms of the respective reaction intermediates, Figure 4.7. The 
intermediate formed by nucleophilic substitution at the 4-position is stabilised by the 
resultant resonance structures. The resonance structures of the intermediate formed by 
nucleophilic substitution at the 2-position give less stability due to the o-quinoid resonance 
structure.8 
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Figure 4.7 Resonance forms in nucleophilic substitution of 2,4-dichloro quinazoline  
The resonance forms in the transition states in nucleophilic substitutions of 2,4-dichloro 
quinazoline at the 2 or 4 positions. The rate of substitution at the 4-position is much greater 
as these resonance forms (bottom panel) provide more stability than the o-quinoid structure 
(top right) in the 2-position substitution resonance forms. R= nucleophile. Adapted from The 
chemistry of heterocyclic compounds; part 1 fused pyrimidines.8 
 
The ease of substitution with pyrrolidine and piperidine at the 4-position of 2,4-dichloro 
quinazoline to make 4a and 4b was expected due to the high nucleophilicities of these 
secondary amines.15 The slower 4-position substitution reaction with the primary amine n-
butylamine to make 4c.1 can also be explained by its lower nucleophilicity. However, it is 
surprising that reactions with proline or piperazine in similar conditions were also slow, as 
these would be expected to react similarly to the other secondary amines. The formation of 
side-products in these reactions may be attributed to the additional functional groups in the 
nucleophiles. More controlled reactions may be achieved by the use of protecting groups 
such as silyl esters for the free carboxylic acid in proline or tert-butyloxycarbonyl (BOC) for 
the amino group in piperazine.16 
The substitution of 4a, 4b and 4c.1 at the 2-position required more forcing conditions, as 
expected. However, it is surprising that substitution with piperidine tended to be achieved 
more readily than that of pyrrolidine, as these have similar nucleophilicities.15 It is perhaps 
also surprising that the 2-position substitution of pyrimidine was achieved more easily as 
the transition state would be less stabilised in these compounds. The inconsistency in the 
reactivity of the amine groups to make the di-substituted compounds may be explained by 
other variables that were not fully considered at the time, such as the pH of the reaction 
mixture. Whilst there is certainly further scope for optimising the reaction conditions, the in 
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vitro and in vivo results with the compounds that could be successfully isolated indicate that 
future work should explore different structural modifications. 
The synthesised compounds were tested against MtGlgB using the amylose-iodine assay 
described in Chapter 3.  None of these showed greater inhibition than 3a, indicating that 
the interaction of 3a and MtGlgB is highly specific for this particular configuration of amine 
groups and quinazoline core. It appears that the changes explored here were therefore too 
great and future synthetic work should focus on adding groups to 3a, rather than 
modifications. Substitutions of the benzene ring, at the 5, 6, 7 and/or 8 positions are the 
obvious routes to explore. It was difficult to distinguish clear trends from the set of 
synthesised compounds. Broadly, the quinazoline scaffold and the 2-pyrrolidine group 
appeared to contribute to higher inhibition values, indicating that this edge of 3a is the most 
important for binding. However, there were exceptions to these trends, suggesting that 
other, as yet undetermined factors are involved in compound binding and inhibition. 
I also wanted to address the question: How do 3a and its analogues behave in vivo? I aimed 
to gain further insight into the activity of 3a and synthesised compounds by testing their 
effect on M. smegmatis growth. The trehalose-sensitivity of M. smegmatis ΔglgB meant that 
a simple in vivo assay could be established, which can be used to determine whether growth 
inhibition is specific for the GlgB target. This approach has not been explored previously 
and will be useful for other researchers investigating MtGlgB inhibitors. An alternative 
method for the same approach could be to compare growth inhibition in M. smegmatis WT 
and M. smegmatis ΔglgB strains. It is usually difficult to distinguish target-specific growth 
inhibition and this can be an erroneous assumption of inhibition studies, as the Dhkar et 
al.17 work discussed in Chapter 3 demonstrates. Future work, could include testing 
compounds with M. tuberculosis, as whilst M. smegmatis is a good model for this target, 
there could be some differences between compound uptake between the species. 
Testing the non-specific inhibitors with a clinical E. coli indicated that at the same 
concentration of compounds, growth inhibition was more pronounced in M. smegmatis. This 
is perhaps unexpected, due to the greater barrier for cellular uptake in mycobacteria 
compared to E. coli.18 Whilst this could be suggestive of mycobacteria-specific inhibition, 
these results are preliminary and further testing on other bacterial strains in required before 
any conclusions can be made.  
In addition to exploring more chemical space to improve the potency of 3a, the other target 
for further investigation of this compound is to achieve selectivity for GlgB in the 
mycobacterial cell. The other target or targets are unknown, although similar sets of 
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compounds have been shown to interfere with folate acid biosynthesis,19-20 which could be 
the actual target here.21 If this is established, future medicinal chemistry efforts can be 
focussed on exploiting differences in the binding mode of 3a, to add groups that obstruct 
binding in unwanted targets or create additional interactions that favour binding to GlgB. 
4.7 Summary 
I synthesised a selection of analogues of 3a, which were modified in the quinazoline core 
and the amine side groups. Fourteen compounds were tested in vitro with MtGlgB. Results 
suggested that one edge of 3a was important for inhibition, however no synthesised 
compound had improved potency. A M. smegmatis assay was established, which could 
determine whether growth inhibition was specific for the GlgB target. Three compounds 
inhibited M. smegmatis growth at high concentrations, but not via the GlgB target. Future 
synthetic work will aim to increase both potency and target selectivity. 
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4.8 Materials and methods 
4.8.1 Synthesis of 3a analogues 
4.8.1.1 General methods 
2,4-Dichloro quinazoline was purchased from Key Organics. All other solvents and reagents 
were purchased from Sigma Aldrich or Fisher Scientific and used without further purification. 
Analytical thin layer chromatography was carried out using Merck aluminium backed sheets 
coated with 60-F254 silica gel and spots were visualised with UV light. Compounds were 
purified by automated flash column chromatography using a Biotage Isolera™ Spektra One 
system with KP-Sil™ (Uppsala, Sweden). NMR spectra were recorded at 22 °C on a Bruker 
Avance III spectrometer at 400 MHz (1H), 100 MHz (13C) or 376 MHz (19F). Chemical shifts 
(𝛿) are reported in ppm using residual solvent signals from deuteriated solvents as 
references (CDCl3: 𝛿 1H 7.26 and 𝛿 13C 77.0). Assignments were made with the aid of COSY 
and HSQC experiments. Nominal m/z values are reported in Daltons. After classical work-
up of the reaction mixtures, organic layers were dried over MgSO4, filtered and then 
concentrated under vacuum. 
4.8.1.2 2-chloro-4-(pyrrolidin-1-yl)quinazoline (4a) 
 
To 2,4-dichloroquinazoline (1 g, 5.02 mmol) dissolved in THF (20 mL) were added 
pyrrolidine (495 µL, 6.03 mmol) and triethylamine (840 µL, 6.03 mmol). The solution was 
stirred for 3 h at room temperature, at which point TLC (4:1 hexane/EtOAc) showed 
conversion to product. The reaction mixture was poured on to ice and extracted three times 
with CH2Cl2 (3 × 30 mL), then the combined extracts were washed with water and 
concentrated. The crude residue was purified by column chromatography on silica gel (4:1 
hexane/EtOAc) to give 4a (850 mg, 73%) as a colourless solid. Rf 0.52 (4:1 Hexane/EtOAc); 
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1H NMR (400 MHz CDCl3): 𝛿 8.13 (dd, 1H, 3J7,8 8.5 Hz, 4J6,8 0.8 Hz, H-8), 7.74 (dd, 1H, 3J5,6 
8.4 Hz, 4J5,7 1.0 Hz, H-5), 7.67 (ddd, 1H, 3J7,8 8.3 Hz, 3J6,7 6.9 Hz, 
4J5,7 1.4 Hz, H-6), 7.36 
(ddd, 1H, 3J5,6 8.5 Hz, 3J6,7 6.9 Hz, 
4J6,8 1.5 Hz, H-7), 3.99-3.92 (m, 4H, 4 x H-1ʹʹ), 2.10-2.03 
(m, 4H, 4 x H-2ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 160.8 (C-2), 156.8 (C-4), 153.0 (C-8a), 
132.7 (C-6), 127.5 (C-5), 125.4 (C-8), 124.6 (C-7), 115.0 (C-4a), 51.3 (C-1ʹʹ), 25.6 (C-2ʹʹ); 
MS (ESI): [M + H]+ 234, found 234.4. 
4.8.1.3 2-chloro-4-(piperidin-1-yl)quinazoline (4b) 
 
 
To 2,4-dichloroquinazoline (50 mg, 0.251 mmol) dissolved in ethanol (1 mL) were added 
piperidine (30 µL, 0.301 mmol) and triethylamine (41 µL, 0.301 mmol). The solution was 
stirred for 3 h at room temperature, at which point TLC (4:1 hexane/EtOAc) showed 
conversion to product. The reaction mixture was poured on to ice and extracted three times 
with CH2Cl2 (3 × 2 mL) and the combined extracts washed with water and concentrated in 
vacuo. The crude residue was purified by column chromatography on silica gel (4:1 
hexane/EtOAc) to give 4b (52 mg, 85%) as a colourless solid. Rf 0.46 (4:1 Hexane/EtOAc); 
1H NMR (400 MHz CDCl3): 𝛿 8.05 (dd, 1H, 3J7,8 8.3 Hz, 4J6,8 1.4 Hz, H-8), 7.58 (ddd, 1H, 
3J7,8 8.3 Hz, 3J6,7 7.1 Hz, 
4J5,7 1.2 Hz, H-7), 7.38 (dd, 1H, 3J5,6 8.1 Hz, 
4J5,7 1.2 Hz, H-5), 7.13 
(ddd, 1H, 3J5,6 8.1 Hz, 3J6,7 7.1 Hz, 
4J6,8 1.4 Hz, H-6), 3.78-3.69 (m, 4H, 4 × H-1ʹʹ), 1.77-1.68 
(m, 6H, 4 x H-2ʹʹ, 2 × H-3ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 165.2 (C-2), 151.6 (C-4), 150.2 
(C-8a), 134.8 (C-6), 126.2 (C-5), 125.2 (C-8), 122.2 (C-7), 116.6 (C-4a), 46.2 (C-1ʹʹ), 25.7 
(C-2ʹʹ), 24.5 (C-3ʹʹ); MS (ESI): [M + H]+ 248, found 248.3. 
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4.8.1.4 n-butyl-2-chloro-quinazolin-4-amine (4c.1) 
 
To 2,4-dichloroquinazoline (50 mg, 0.251 mmol) dissolved in ethanol (1 mL) were added 
butylamine (30 µL, 0.301 mmol) and triethylamine (41 µL, 0.301 mmol). The solution was 
heated at 50 °C for 3 h, at which point TLC (4:1 hexane/EtOAc) showed conversion to 
product. The reaction mixture was poured on to ice and extracted three times with CH2Cl2 
(3 × 2 mL) and the combined extracts washed with water and concentrated. The crude 
residue was purified by column chromatography on silica gel (4:1 hexane/EtOAc) to give 
4c.1 (37 mg, 63%) as a colourless solid. Rf 0.35 (4:1 hexane/EtOAc); 1H NMR (400 MHz 
CDCl3): 𝛿 7.76 (dd, 1H, 3J7,8 8.3 Hz, 4J6,8 1.6 Hz, H-8), 7.72 (ddd, 1H, 3J7,8 8.3 Hz, 3J6,7 6.6 
Hz, 4J5,7 1.2 Hz, H-7), 7.67 (dd, 1H, 3J5,6 8.2 Hz, 
4J5,7 1.2 Hz, H-5), 7.45 (ddd, 1H, 3J5,6 8.2 
Hz, 3J6,7 6.6 Hz, 
4J6,8 1.6 Hz, H-6), 5.90 (s, 1H, N-H), 3.71-3.65 (m, 2H, 2 × H-1ʹʹ), 1.76-1.66 
(m, 2H, 2 × H-2ʹʹ), 1.52-1.41 (m, 2H, 2 × H-3ʹʹ); 0.99 (t, 3H, 3 x H-4ʹʹ); 13C NMR (100 MHz, 
CDCl3): 𝛿 161.0 (C-2), 157.9 (C-4), 150.8 (C-8a), 133.4 (C-6), 127.9 (C-5), 126.1 (C-8), 
120.6 (C-7), 113.2(C-4a), 41.4 (C-1ʹʹ), 31.3 (C-2ʹʹ), 20.2 (C-3ʹʹ), 13.8 (C-4ʹʹ); MS (ESI): [M + 
H]+ 236, found 236.3. 
4.8.1.5 2,4-di-pyrrolidinin-1-yl-quinazoline (3a) 
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To 4a (25 mg, 0.214 mmol) in ethanol (1 mL) were added pyrrolidine (13 µL, 0.321 mmol) 
and triethylamine (22 µL, 0.321 mmol). The solution was heated at 100 °C for 3 h using 
microwave radiation, at which point TLC (2:1 hexane/EtOAc) showed conversion to product. 
The reaction mixture was poured on to ice and extracted three times with CH2Cl2 (3 × 2 mL) 
and the combined extracts concentrated in vacuo. The crude residue was purified by 
column chromatography on silica gel (4:1 hexane/EtOAc) to give 3a (10 mg, 37%) as a 
colourless solid. Rf 0.42 (2:1 hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 7.96 (m, 1H, H-
8), 7.55-7.48 (m, 1H, H-5), 7.45 (ddd, 1H, 3J7,8 7.9 Hz, 3J6,7 6.5 Hz, 
4J5,7 1.2 Hz, H-6), 6.96 
(ddd, 1H, 3J5,6 8.2 Hz, 3J6,7 6.5 Hz, 
4J6,8 1.3 Hz, H-7), 3.91-3.86 (m, 4H, 4 x H-1ʹ), 3.69-3.63 
(m, 4H, 4 x H-1ʹʹ), 2.02-1.98-3 (m, 4H, 4 x H-2ʹ), 1.98-1.93 (m, 4H, 4 x H-2ʹʹ); 13C NMR (100 
MHz, CDCl3): 𝛿 160.4 (C-2), 153.5 (C-4), 148.2 (C-8a), 138.7 (C-6), 131.8 (C-5), 125.5 (C-
8), 119.2 (C-7), 112.0 (C-4a), 50.6 (C-1ʹ), 46.6 (C-1ʹʹ), 25.8 (C-2ʹ), 25.6 (C-2ʹʹ); MS (ESI): [M 
+ H]+ 269, found 269.3. 
4.8.1.6 2-(piperidin-1-yl)-4-(pyrrolidin-1-yl)quinazoline (4d) 
 
To 4a (50 mg, 0.214 mmol) in ethanol (2 mL) were added piperidine (32 µL, 0.321 mmol) 
and triethylamine (45 µL, 0.321 mmol). The solution was heated at reflux for 18 h, at which 
point TLC (3:1 hexane/EtOAc) showed conversion to product. The reaction mixture was 
poured on to ice and extracted three times with CH2Cl2 (3 × 30 mL) and the combined 
extracts were concentrated in vacuo. The crude residue was purified by column 
chromatography on silica gel (4:1 hexane/EtOAc) to give 4d (55 mg, 91%) as a colourless 
solid. Rf 0.73 (3:1 hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 7.92 (d, 1H, 3J7,8 8.4 Hz, H-
8), 7.49-7.41 (m, 2H, H-5, H-7), 6.99-6.93 (m, 1H, H-6), 3.89-3.82 (m, 8H, 4 x H-1ʹ, 4x H-
1ʹʹ), 2.03-1.95 (m, 4H, 4 x H-2ʹʹ), 1.68-1.57 (m, 6H, 4 x H-2ʹ, 2 x H-3ʹ); 13C NMR (100 MHz, 
CDCl3): 𝛿 160.5 (C-2), 158.7 (C-4), 154.5 (C-8a), 131.6 (C-6), 125.7 (C-5), 125.4 (C-8), 
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119.3 (C-7), 112.1 (C-4a), 50.6 (C-1ʹ), 44.9 (C-1ʹʹ), 26.1 (C-2ʹ), 25.7 (C-2ʹʹ), 25.1 (C-3ʹ); MS 
(ESI): [M + H]+ 283, found 283.1. 
4.8.1.7 2,4-di-piperidin-1-yl-quinazoline (4e) 
 
To 4b (25 mg, 0.101 mmol) dissolved in ethanol (1 mL) were added piperidine (12 µL, 0.121 
mmol) and triethylamine (17 µL, 0.121 mmol). The solution was heated in with microwave 
radiation at 100 °C for 1 h, at which point a crystalline precipitate had formed. The precipitate 
was removed by filtration and washed three times with ethanol (3 × 2 mL) to give pure 4e 
(13 mg, 45%) as a colourless solid. Rf 0.72 (4:1 hexane/EtOAc); 1H NMR (400 MHz CDCl3): 
𝛿 7.69-7.62 (m 1H, H-8), 7.50-7.44 (m, 2H, H-5, H-7), 7.03-6.97 (m, 1H, H-6), 3.92-3.81 (m, 
4H, 4 × H-1ʹ), 3.63-3.54 (m, 4H, 4 × H-1ʹʹ), 1.81-1.69 (m, 6H, 4 x H-2ʹʹ, 2 × H-3ʹʹ), 1.69-1.56 
(m, 6H, 4 x H-2ʹʹ, 2 × H-3ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 166.1 (C-2), 158.6 (C-4), 154.6 
(C-8a), 132.0 (C-6), 126.0 (C-5), 125.3 (C-8), 119.9 (C-7), 112.0 (C-4a), 51.1 (C-1ʹ), 45.0 
(C-1ʹʹ), 26.0 (C-2ʹ), 25.9(C-2ʹʹ), 25.1 (C-3ʹ), 25.0 (C-3ʹʹ); MS (ESI): [M + H]+ 297, found 297.5. 
4.8.1.8 n-butyl-2-(piperidin-1-yl) quinazolin-4-amine (4f) 
 
To 4c.1 (20 mg, 0.0851 mmol) dissolved in ethanol (1 mL) were added piperidine (10 µL, 
0.102 mmol) and triethylamine (14 µL, 0.102 mmol). The solution was heated with 
microwave radiation at 100 °C for 1 h, at which point TLC (2:1 hexane/EtOAc) showed 
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conversion to product. The reaction mixture was poured on to ice and extracted three times 
with CH2Cl2 (3 × 2 mL) and the combined extracts were washed with water and 
concentrated. The crude residue was purified by column chromatography on silica gel (4:1 
hexane/EtOAc) to give 4f (7 mg, 29%) as a colourless solid. Rf 0.42 (2:1 hexane/EtOAc); 
1H NMR (400 MHz CDCl3): 𝛿 7.45-7.43 (m, 3H, H-5, H-7, H-8), 7.05-6.98 (m, 1H, H-6), 5.60 
(s, 1H, N-H), 3.91-3.83 (m, 4H, 4 × H-1ʹ), 3.59 (ddd, 2H, 3J1ʹʹ,2ʹʹ 7.1 Hz, 3J1ʹʹ,2ʹʹ 7.1 Hz, 
2J1ʹʹa,1’ʹb 
5.6 Hz, H-1ʹʹ), 1.73-1.59 (m, 8H, 4 × H-2ʹ, 2 x 2ʹʹ, 2 × H-3ʹ) 1.45 (sxt, 2H, H-3ʹʹ), 0.98 (t, 3H, 
H-4ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 159.7 (C-2), 158.4 (C-4) 132.4 (C-8a), 127.9 (C-6), 
126.0 (C-5), 125.0 (C-8), 120.8 (C-7), 110.2 (C-4a), 45.1 (C-1ʹ), 40.9 (C-1ʹʹ), 31.4 (C-2ʹ), 
26.0 (C-2ʹʹ), 25.0 (C-3ʹ) 20.3 (C-2ʹʹ), 13.9 (C-4ʹʹ); MS (ESI): [M + H]+ 285, found 285.5. 
4.8.1.9 N2,N4-dibutylquinazoline-2,4-diamine (4g) 
 
To 4c.1 (20 mg, 0.0851 mmol) dissolved in ethanol (1 mL) were added n-butylamine (10 
µL, 0.102 mmol) and triethylamine (14 µL, 0.102 mmol). The solution was heated with 
microwave radiation at 100 °C for 3 h, at which point TLC (3:1 hexane/EtOAc) showed 
conversion to product. The reaction mixture was poured on to ice and extracted with CH2Cl2 
(3 × 2 mL) and the combined extracts were washed with water and concentrated. The crude 
residue was purified by column chromatography on silica gel (3:1 hexane/EtOAc) to give 4f 
(5 mg, 22%) as a colourless solid. Rf 0.36 (3:1 hexane/EtOAc); 1H NMR (400 MHz CDCl3): 
𝛿 8.05 (d, 1H, 3J7,8 7.9 Hz, H-8), 7.62-7.51 (m, 1H, H-7), 7.40-7.35 (m, 1H, H-6), 7.15-7.12 
(m, 1H, H-6), 3.88-3.83 (m, 1H, 1 × H-1ʹ), 3.73-3.66 (m, 1H, 1 × H-1ʹ), 3.60-3.53 (m, 1H, 1 
× H-1ʹʹ), 3.44-3.40 (m, 1H, 1 × H-1ʹʹ), 1.75-1.59 (m, 8H, 2 × H-2ʹ, 2 × H-2ʹʹ, 2 × H-3ʹ, 2 × H-
3ʹʹ), 1.49-1.36 (m, 3H, 3 × H-4ʹ), 1.00-0.89 (m, 3H, 3 × H-4ʹʹ); 13C NMR (100 MHz, CDCl3): 
𝛿 166.1 (C-2), 158.6 (C-4), 154.6 (C-8a), 132.0 (C-6), 126.0 (C-5), 125.3 (C-8), 119.9 (C-7), 
112.0 (C-4a), 46.2 (C-1ʹ), 41.0 (C-1ʹʹ), 31.4 (C-2ʹ), 26.0 (C-2ʹʹ), 24.9 (C-3ʹ), 24.4 (C-3ʹʹ), 20.3 
(C-4ʹ), 13.8 (C-4ʹʹ); MS (ESI): [M + H]+ 273, found 273.4. 
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4.8.1.10 2,4-dipyrrolidin-1-yl pyrimidine (4h) 
 
To 2-chloro-4-pyrrolidin-1-yl pyrimidine (13 mg, 0.0710 mmol) in ethanol (1 mL) were 
added pyrrolidine (9 µL, 0.107 mmol) and triethylamine (15 µL, 0.107 mmol). The solution 
was heated with microwave radiation for 100 °C for 3 h at which point TLC (4:1 
hexane/EtOAc) showed conversion to product. The reaction mixture was poured on to ice 
and extracted three times with CH2Cl2 (3 × 2 mL) and the combined extracts were 
concentrated in vacuo. The crude residue was purified by column chromatography on silica 
gel (4:1 hexane/EtOAc) to give 4h (13 mg, 84%) as a solid. Rf 0.73 (4:1 hexane/EtOAc); 1H 
NMR (400 MHz CDCl3): 𝛿 7.89 (d, 1H, 3J5,6 5.9 Hz, H-6), 5.62 (d, 2H, 3J5,6 5.9 Hz H-5), 3.58-
3.51 (m, 4H, 4 × H-1ʹ), 3.53 – 3.33 (m, 4H, 4 × H-1ʹʹ), 2.00-1.89 (m, 8H, 4 × H-2ʹ, 4 x H-2ʹʹ); 
13C NMR (100 MHz, CDCl3): 𝛿 160.5 (C-2), 160.4 (C-4), 155.5 (C-6), 92.8 (C-5), 46.3 (C-
1ʹ), 45.9 (C-1ʹʹ), 25.6 (C-2ʹ), 25.3 (C-2ʹʹ); MS (ESI): [M + H]+ 219, found 219.4. 
4.8.1.11 2-piperidin-1-yl-4-pyrrolidin-1-yl pyrimidine (4i) 
 
 
To 2-chloro-4-pyrrolidin-1-yl pyrimidine (50 mg, 0.273 mmol) in ethanol (2 mL) were 
added piperidine (41 µL, 0.410 mmol) and triethylamine (57 µL, 0.410 mmol). The solution 
was heated at reflux for 18 h at which point TLC (3:1 hexane/EtOAc) showed conversion to 
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product. The reaction mixture was diluted with water and extracted three times with CH2Cl2 
(3 x 3 mL) and the combined extracts washed with water and brine, dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by column chromatography on silica 
gel (3:1 hexane/EtOAc) to give 4i (38 mg, 60%) as a colourless solid. Rf 0.66 (3:1 
hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 7.88 (d, 1H, 3J5,6 5.8 Hz, H-6), 5.61 (d, 1H, 
3J5,6 5.8 Hz, H-5), 3.77-3.69 (m, 4H, 4 x H-1ʹ), 3.59–3.23 (m, 4H, 4x H-1ʹʹ), 2.00-1.88 (m, 
4H, 4 x H-2ʹ)) 1.67-1.53 (m, 6H, 4 x H-2ʹʹ, 2 x H-3ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 161.5 
(C-2), 160.5 (C-4), 155.4 (C-6), 93.1 (C-5), 45.9 (C-1ʹ), 44.7 (C-1ʹʹ), 25.9 (C-2’), 25.2 (C-2ʹʹ), 
25.1 (C-3ʹ); MS (ESI): [M + H]+ 233, found 233.1. 
4.8.1.12 (2S)-1-(4-pyrrolidin-1-ylpyrimidin-2-yl)pyrrolidine-2-carboxylic  acid 
(4j) 
 
To 2-chloro-4-pyrrolidin-1-yl pyrimidine (50 mg, 0.273 mmol) in ethanol (2 mL) were 
added proline (38 mg, 0.327 mmol) and triethylamine (46 µL, 0.327 mmol). The solution 
was heated at reflux for 18 h at which point TLC (3:1 hexane/EtOAc) showed conversion to 
product. The reaction mixture was diluted with water and extracted three times with CH2Cl2 
(3 × 3 mL) and the combined extracts washed with water, dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by column chromatography on silica 
gel (3:1 hexane/EtOAc) to give 4j (22 mg, 31%) as a colourless solid. Rf 0.05 (3:1 
hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 7.46 (d, 1H, 3J5,6 7.5 Hz, H-6), 5.61 (d, 1H, 
3J5,6 7.5 Hz, H-5), 4.47-4.04 (m, 1H, 4 × H-4ʹ), 3.56–3.39 (m, 4H, 2 × H-1ʹ, 2 x H-2ʹ), 3.12-
3.01 (m, 4H, 4 × H-1ʹʹ), 2.36-2.23 (m, 2H, H-3ʹʹ), 1.97-1.75 (m, 4H, 4 × H-2ʹʹʹ); 13C NMR (100 
MHz, CDCl3): 𝛿 173.1 (C-5ʹ), 158.7 (C-2), 150.4 (C-4), 141.8 (C-6), 95.9 (C-5), 60.8 (C-4ʹ), 
58.2 (C-3ʹ), 48.3 (C-1ʹ), 47.4 (C-1ʹʹ), 29.6 (C-2’), 25.5 (C-2ʹʹ); MS (ESI): [M + H]+ 263, found 
263.4. 
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4.8.1.13 4-chloro-2-(pyrrolidin-1-yl)-5-(trifluoromethyl)pyrimidine (4k.1) 
 
To 2-chloro-4-(pyrrolidin-1-yl)-5-(trifluoromethyl) (62 µL, 0.461 mmol) in methanol (0.5 
mL) on ice were added pyrrolidine (39 µL, 0.461 mmol) and triethylamine (63 µL, 0.461 
mmol). The solution was allowed to warm to room temperature and stirred overnight, at 
which point TLC (100% hexane) showed conversion to product. The reaction mixture was 
extracted three times with CH2Cl2 (3 × 30 mL) and the combined extracts washed with water 
and concentrated in vacuo. The crude residue was purified by column chromatography on 
silica gel (4:1 hexane/EtOAc) to give two products: firstly 4k.1 (100 mg, 86%) as a colourless 
solid. Rf 0.42 (9:1 hexane/EtOAc) 1H NMR (400 MHz CDCl3): 𝛿 8.37 (s, 1H, H-6), 3.70-3.64 
(m, 4H, 4 x H-1ʹʹ), 2.06–1.94 (m, 4H, 4x H-2ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 162.0 (C-2), 
157.4 (C-6), 125.3 (C-4), 122.6 (C-5), 105.2 (C-7), 49.6 (C-1ʹ), 25.2 (C-2ʹ); 19F NMR ( MHz 
CDCl3) 𝛿 53.0 (3 x F); MS (ESI): [M + H]+ 252, found 252.2. 
4.8.1.14 2-chloro-4-(pyrrolidin-1-yl)-5-(trifluoromethyl)pyrimidine (4k.2) 
 
The second product was 4k.2 (16 mg, 14%) as a colourless solid. Rf 0.46 (9:1 
hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 8.43 (s, 1H, H-6), 3.65-3.58 (m, 4H, 4 × H-
1ʹʹ), 2.07–1.97 (m, 4H, 4 × H-2ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 160.1 (C-2), 158.6 (C-4), 
156.8 (C-6), 124.6 (C-5), 110.1 (C-7), 47.3 (C-1ʹʹ), 25.4 (C-2ʹʹ); 19F NMR ( MHz CDCl3) 𝛿 
61.1 (3 × F); MS (ESI): [M + H]+ 252, found 252.1. 
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4.8.1.15 Synthesis of 2-chloro-4-pyrrolidin-1-yl-thieno[3,2-d]pyrimidine (4l) 
 
To 2,4-dichlorothieno[3,2-d]pyrimidine (87.5 mg, 0.427 mmol) in ethanol (4 mL) was 
added pyrrolidine (77 µL, 0.939 mmol). The solution was stirred at 22 °C for 18 h, at which 
point a crystalline precipitate could be observed. The precipitate was removed by filtration 
and washed with ethanol (3 × 5 mL). The crude residue was purified by column 
chromatography on silica gel (4:1 hexane/EtOAc) to give 4l (mg, 78%) as a colourless solid. 
Rf 0.53 (4:1 hexane/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 7.74 (d, 1H, H-5), 7.30 (d, 1H, H-
6), 4.00-3.74 (m, 4H, 4 × H-1ʹʹ), 2.15-1.97 (m, 4H, 4 × H-2ʹʹ); 13C NMR (100 MHz, CDCl3): 𝛿 
161.4 (C-2), 157.4 (C-4), 157.2 (C-8a), 133.0 (C-4a), 124.3 (C-8), 114.0 (C-5), 48.1 (C-1ʹʹ), 
25.7 (C-2ʹʹ); MS (ESI): [M + H]+ 240, found 240.3. 
4.8.2 Compound preparation 
Stock solutions of synthesised or purchased compounds were prepared in DMSO and 
diluted to achieve a final concentration of 50 µM with 10% DMSO for in vitro assays or 500 
µM with 1% DMSO for M. smegmatis assays. 
4.8.3 M. smegmatis growth and assay conditions 
The M. smegmatis mc2 155 wild type strain was used for growth assays. Cultures were 
grown aerobically at 37 °C in Middlebrook 7H9 liquid media or on 7H10 solid media 
supplemented with 0.5% (v/v) glycerol and 0.05% (v/v) tyloxapol and containing 10% (v/v) 
ADS enrichment (5%, w/v, bovine serum albumin fraction V (BSA); 2%, w/v, glucose; 
0.85%, w/v, sodium chloride). Freshly streaked 7H10 agar plates were used to generate 
starter cultures of M. smegmatis wildtype or mutant strains in 7H9 liquid media. Cultures 
were grown with or without the addition of 0.5 mM trehalose until they reached logarithmic 
phase, at which point they were diluted to the desired density for initiating experiments. 
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For assays, 150 µL M. smegmatis cultures with or without compounds of interest were 
incubated at 37 °C with continuous orbital shaking (Bioanalyzer, EON) in a transparent, flat-
bottom 96-well plate (Corning) over a period of up to 96 hours. External wells were not used 
for growth measurements and instead contained 250 µL of dH2O or medium to allow for 
evaporation. Initial cell densities of OD600 ~0.002 were used and growth was monitored by 
hourly OD600 measurements. Control wells contained medium only (sterility control), 
bacteria only (growth control) or rifampicin (bactericidal control). A final concentration of 1% 
DMSO in all wells was achieved by dilution of compounds stock solutions or the addition of 
DMSO to control wells. In each plate compounds were tested in triplicate at 500 µM with 
and without the addition of 0.5 mM trehalose. No difference in growth was observed resulted 
from trehalose addition in the absence of compounds. To determine MICs serial two-fold 
dilutions were prepared to give final concentrations of 500 – 4 µM. 
A 0.01% w/v solution of resazurin was prepared from the sodium salt (Sigma) in distilled 
water and filter sterilised. After growth of M. smegmatis cultures 30 µL resazurin solution 
was added and the plate was incubated at 37 °C for four hours before visualisation. A colour 
change from blue to pink was indicative of viable M. smegmatis cells. The MIC was defined 
as the lowest compound concentration with no bacterial growth. 
4.8.4 Antibiotic susceptibility testing in E. coli 
E. coli ATCC 25922 strain was provided by the A. Maxwell group (JIC). MICs were 
determined according to the standard protocol.22 Briefly, E. coli was grown for 16 h at 37 °C 
on an LB-agar plate, after which point LB liquid medium was inoculated with a single colony 
and grown to the desired OD600. A final inoculum of 105 cfu/mL was prepared based on the 
previously established conversion from OD600 to cfu/mL for this strain (Natassja Bush). A 
two-fold dilution series of each compound was prepared in a sterile U-bottom 96-well plate 
(Corning), to achieve final concentrations of 500 - 4 µM and 1% DMSO upon addition of 1:1 
v/v organism suspension. Plates were covered with a lid, incubated at 37 °C for 18 h and 
then inspected by eye and OD600 measurement. Each concentration was tested at least in 
triplicate and control wells of inoculated and uninoculated were included in each plate. 
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5. Investigation of 4-deoxy trehalose analogues as 
precursors for GlgE inhibitors 
5.1 Introduction 
M. tuberculosis GlgE is an essential maltosyltransferase that is an attractive drug target for 
TB therapeutics.1-2 GlgE inhibitors reported to date function as substrate or transition state 
mimics. These show moderate inhibition in vitro and binding at the GlgE M1P donor site 
has been confirmed by crystallographic studies.3-8 However, M1P-based compounds are 
not expected to exert an effect in vivo because M. tuberculosis lacks the capacity to import 
maltose and its derivatives. There are just five carbohydrate importers predicted from the 
genome sequence of M. tuberculosis.9 Three of these have been characterised and their 
specificities are limited to trehalose, glycerophosphocholine, and amino sugars, 
respectively.10-12 Therefore, unlike most other carbohydrates, trehalose is readily 
incorporated into mycobacteria. This is mediated by the LpqY-SugABC transporter, which 
can also tolerate modified substrates, whereby the uptake of trehalose analogues by both 
M. tuberculosis and M. smegmatis has been documented.13-15 
In the first step of the GlgE pathway, TreS isomerises trehalose to maltose, which is then 
phosphorylated by Pep2 to make M1P, with the two enzymes functioning as a hetero-
octameric complex.1, 16-17 A trehalose analogue that had been incorporated into the cytosol 
could therefore be converted into a M1P analogue, with the potential to inhibit GlgE. 
Blocking GlgE not only stops production of the α-glucan end product and therefore reduces 
M. tuberculosis virulence, but also causes the toxic accumulation of M1P via the TreS-Pep2 
or GlgM routes.18 How M1P elicits a pleiotropic stress response in the cell remains unknown, 
but it is possible that accumulation of the resultant M1P analogue could also be toxic. Thus, 
trehalose analogues could serve as precursors for TB antibiotics with up to three potential 
modes of action. 
My approach for the investigation of this hypothesis consisted of three parts: the synthesis 
of trehalose analogues, testing whether these were taken up into the mycobacterial cytosol, 
and determining whether these were processed into the GlgE pathway. If this could be 
established as a proof of concept, the next step would be modifying the trehalose analogue 
such that the resultant M1P analogue could inhibit GlgE. However, in the first instance, I 
focused on analogues that were likely to be processed by TreS. Previously, it was shown 
that TreS could tolerate a number of maltose analogues as substrates in the trehalose 
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synthesis direction, indicating some degree of substrate promiscuity.16, 19 Another study 
investigated the incorporation of asymmetrical azido trehalose analogues into M. 
smegmatis cells via labelling with a fluorescent probe. Unlike the other azido analogues, 
the incorporation of 4-azido trehalose by M. smegmatis was greatly reduced in a ΔtreS 
strain, suggesting that it could be processed by TreS in vivo.14 In principle, a 4-deoxy 
trehalose analogue would be converted into a 4-deoxy M1P analogue in the GlgE pathway. 
This could act as a donor for GlgE, but once incorporated into a malto-oligosaccharide, the 
non-reducing end is blocked and it cannot be further extended, impairing the production of 
α-glucan as a result. Therefore, 4-azido trehalose and other 4-deoxy trehaloses were good 
candidates for exploratory studies into this approach. 
In this chapter I address the following questions: ‘Can a synthetic route to 4-deoxy trehalose 
analogues be established?’ ‘Are 4-deoxy trehalose compounds taken up in mycobacterial 
cells?’ And, ‘Can 4-deoxy trehalose analogues be processed in the GlgE pathway?’. 
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5.2 4-Deoxy trehalose analogues 
5.2.1 Selection of 4-deoxy trehalose analogues 
The 4-azido trehalose analogue (5g) was of interest as it was found to be taken up by M. 
smegmatis in a TreS-dependent fashion. Additionally, the azido group offers a handle for 
the facile conjugation of other groups via click chemistry, which could be useful in 
subsequent localisation or imaging studies.14 Other 4-position modifications were 
considered that would be minimally sterically perturbing, but offer insight into the effect of 
different functionalities. Therefore, methoxy (4-OMe) and fluoro- (5i) substituents were 
targeted, with the latter also being of interest for 18F-PET imaging of M. tuberculosis 
infection.20 To investigate how stereochemistry at the 4-position affects uptake and TreS 
activity, the axial fluoro- analogue (5e) was also targeted, along with the galactose-type 
analogue (5c). Target compounds are shown in Figure 5.1. 
 
Figure 5.1 4-Deoxy trehalose target compounds. Modifications at the 4-position are 
highlighted in red. Compound numbering is in accord with Figure 5.2. 
5.2.2 Synthesis of 4-deoxy trehalose analogues 
Asymmetric trehalose analogues have typically been generated via the coupling of glucose 
derivatives, both chemically21 and enzymatically.22-23 The former inevitably involves lengthy 
protection/deprotection strategies, whilst the latter is particularly low-yielding for 4-position 
analogues. Therefore, I used an alternative chemical route for this work, with a trehalose 
starting material and by taking advantage of the differential reactivity of trehalose hydroxyls 
with respect to esterification, namely: 6,6' > 2,2' > 3,3' > 4,4'.24 As had been previously 
reported, it was possible to isolate hepta-benzoylated trehalose with a free 4-OH in 43% 
yield (lit. 58%),25 by optimisation of reaction conditions and careful separation of product 
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mixtures. The number and position of protecting groups were confirmed by MALDI mass 
spectrometry and full assignment of 1H NMR spectra, respectively. 
With compound 5a in hand, it was possible to generate most of the desired 4-deoxy 
trehalose analogues in two or three steps, as summarised in Figure 5.2. Reaction with 
diethylaminosulphur trifluoride (DAST) and dimethylaminopyridine (DMAP) achieved fluoro 
substitution with inversion of stereochemistry in 52% yield to give 5d, and subsequent 
deprotection gave the desired axial fluoro-trehalose analogue 5e. Inversion of the 4-
hydroxyl stereochemistry of 5a was achieved via a Lattrell-Dax epimerisation, aided by the 
equatorial orientation of the neighbouring 3-OBz.26 This involved conversion to a triflate 
leaving group and subsequent KNO2 substitution and hydrolysis to give 5b in 67% yield (lit. 
72%).25 This could be either deprotected directly to give target compound 5c, or reacted 
further to generate equatorial 4-deoxy trehalose analogues. 
An equatorial azide group was added via a further triflate leaving group and NaN3, in the 
presence of 15-crown-5, producing 5f in 79% yield (lit. 73%)25, which was deprotected to 
give target compound 5g. Reaction of 5b with DAST to generate the equatorial fluoro 
analogue was more challenging due to a competing elimination reaction. Multiple 
purification steps were required to eventually isolate purified 5h in 37% yield, which was 
deprotected to give target compound 5i. 
Synthesis of 4-OMe was attempted using the Purdie methylation with MeI and Ag2O, with 
an aim to avoid the highly basic conditions of more commonly used methylation procedures 
that would remove the alkali-labile benzoyl protecting groups. However, a complex mixture 
of differently benzoylated and methylated products was formed in a slow reaction, from 
which it was not possible to isolate the target compound. The addition of dimethyl sulphide 
significantly increased the rate of starting material consumption, but did not aid isolation of 
4-OMe, so the synthesis of 4-OMe was not pursued further. 
The identity and orientation of novel functional groups were confirmed by 1D and 2D 1H, 
13C and 19F NMR spectroscopic analyses. Interestingly, no coupling was observed between 
H-4 and H-5 in 5d or 5e and between F and H-5 in 5h or 5i, indicating that the 4-equatorial 
position in these compounds lies nearly orthogonal to the H5 proton, resulting in J coupling 
values of zero. 
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Figure 5.2 Scheme of 4-deoxy trehalose analogue synthesis. Modifications at the 4-
position are highlighted in red. Reagents and conditions: (a) BzCl, pyridine, 3 h, 0 °C – RT; 
(b) Tf2O, CH2Cl2, pyridine, 0 °C-RT, 0.5 h; (c) KNO2, DMF, RT, 3 h; (d) DAST, DMAP,, 
CH2Cl2, 0 °C – RT, 18 h; e) NaOMe/MeOH, 18 h; (f) NaN3, 15-crown-5, DMF 60 °C, 6 h; (g) 
Ag2O, MeI, Me2S, RT, 5 h. Yields: 5a 43%; 5b 67%; 5d 52%; 5f 79%; 5h 37%; 5c, 5e, 5g, 
5h quantitative. 
 
5.3  4-Deoxy trehalose analogues are incorporated into M. smegmatis 
cells by the trehalose recycling pathway 
5.3.1 Compound 5e inhibits the growth of M. smegmatis at high 
concentrations 
To test whether the synthesised 4-deoxy trehalose analogues had any negative effect on 
mycobacterial growth, I grew M. smegmatis for 25 h in the presence of the compounds at 
concentrations of up to 500 µM. At this concentration, 5g had no effect on M. smegmatis 
growth, consistent with what had previously been reported,14 along with compounds 5c and 
5i, for which growth inhibition studies had not been described. On the other hand, 5e had 
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previously been shown to be a substrate for the mycolate transferase Ag85 and showed 
mild inhibition against M. tuberculosis, with an MIC of 100 µg/mL (290 µM).13 Indeed, there 
was also a notable reduction of M. smegmatis growth with 5e at 500 µM, Figure 5.3. I then 
attempted to determine the MIC for this compound against M. smegmatis, which was > 1 
mM, indicating this compound is less potent against M. smegmatis. Therefore, as the 
compounds showed no or very low growth inhibition, I went on to determine whether they 
were incorporated into mycobacterial cells. 
 
Figure 5.3 Compound 5e at 500 µM partially inhibits M. smegmatis growth. The growth 
of M. smegmatis WT over 25 h was measured by optical density at 600 nm with or without 
500 µM trehalose or 4-deoxy trehalose analogues 5c, 5e, 5g or 5i. Only compound 5e 
negatively affected M. smegmatis growth. Data are representative of at least two 
independent experiments 
5.3.2 4-Deoxy trehalose analogues are incorporated into M. smegmatis cells 
To investigate the incorporation of the synthesised analogues into mycobacterial cells, I 
grew M. smegmatis WT in the presence of each compound. The previous study with 5g 
showed that 250 µM was required to detect cell labelling, ten-fold higher than for 2-azido 
trehalose or 6-azido trehalose.14 Therefore this concentration was used for uptake 
experiments and this was sufficient to allow reasonable M. smegmatis growth with 5e. I then 
lysed the cells and analysed the water-soluble extracts by high performance anion 
exchange chromatography (HPAEC) with pulsed amperometric detection (PAD) comparing 
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these to standards for each compound, Figure 5.4. As expected, all extracts, including 
those from untreated cells contained a peak corresponding to endogenous trehalose. 
Compound 5g was observed in cytosolic extracts as expected, and the uptake of 5c and 5e 
was also observed, with peaks that were clearly larger than that of trehalose. On the other 
hand, 5i was only detected at very low amounts, far less than that of trehalose. A study 
subsequent to this work has reported no uptake of 5i in M. smegmatis at 25 µM,20 
demonstrating that uptake is concentration dependent. Overall, all analogues were 
incorporated into M. smegmatis cells, with 5i at much lower levels. 
5.3.3 4-Deoxy trehalose analogues are incorporated via the trehalose 
recycling pathway 
Trehalose can be incorporated into the mycobacterial cell either by being anchored to the 
cell wall via the periplasmic Ag85 route or by being taken into the cytosol by the LpqY-
SugABC mediated recycling pathway.10 Previous work demonstrated that labelling with 5g 
was absent in a M. smegmatis ΔsugC strain, showing incorporation via the recycling 
pathway.14 To determine whether this held true for the other trehalose analogues, I repeated 
the growth and extractions with the M. smegmatis ΔsugC strain, as in section 5.3.2. For this 
strain, I saw an additional peak in the extracts from untreated cells, running at a longer 
retention time than trehalose. However, this was consistent across all samples and did not 
affect subsequent analyses. For all the analogues, uptake was negated in the ΔsugC strain, 
Figure 5.4, demonstrating that these are all incorporated via the trehalose recycling 
pathway. This conclusively demonstrates that all synthesised compounds were imported 
into the mycobacterial cytosol, where they can potentially be processed by the enzymes of 
the GlgE pathway, fulfilling the first criterion for targeting GlgE by the approach set out in 
this chapter. 
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Figure 5.4 4-Deoxy trehalose analogues are incorporated into M. smegmatis cells via 
the trehalose recycling pathway. HPAEC-PAD analyses of cytosolic extracts from M. 
smegmatis WT or M. smegmatis ΔsugC strains after incubation with 250 µM of 4-deoxy 
trehalose analogues. Chromatograms are scaled to the trehalose or analogue peak as 
appropriate. A) Extracts from untreated M. smegmatis WT and M. smegmatis ΔsugC show 
a peak corresponding to trehalose running at 18.0 min retention time, marked with a red 
arrow in the following panels. A large peak indicated with a blue arrow at a lower retention 
time likely corresponds to glucose and other reducing sugars that are poorly retained in the 
analytical column. Indicated with a green arrow is a peak of unknown identity running at a 
higher retention time, that was consistently observed in M. smegmatis ΔsugC extracts but 
this did not interfere with subsequent analyses. B) Incubation with 5c; C) Incubation with 
5e; D) Incubation with 5g; E) Incubation with 5i. B-D show clear LpqY-SugABC dependent 
uptake. E shows a very low level of LpqY-SugABC dependent uptake. For all 
chromatograms dashed red lines indicate the alignments with standards. Data are 
representative of at least two independent experiments. 
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5.3.4 Axial 4-deoxy trehalose analogues accumulate at higher levels 
relative to trehalose in the cell 
In the analysis of cytosolic extracts shown in Figure 5.4, the size of the chromatogram 
peaks for each analogue varies in comparison to that of trehalose. However, direct 
comparison is not valid as modifications to trehalose not only change ionisation and 
therefore, retention time in HPEAC, but also affect the capacity for oxidation, and hence the 
signal seen by PAD.27 To roughly quantify the level of accumulation relative to endogenous 
trehalose, 1:1 injections of each compound with trehalose were analysed and compared to 
cytosolic extractions, as shown in Table 5.1. The level of detection of 5c was similar to that 
of trehalose, as would be expected for these diastereoisomers. The signal seen for 5g was 
slightly less than that of trehalose, indicating the azide group moderately decreased the 
signal seen for this compound. The signals for the fluoro derivatives 5e and 5i were 3.0 and 
4.7 times less than that of trehalose, corresponding with the decrease in oxidation capacity 
resulting from a fluoro group substitution. 
Table 5.1 4-Deoxy trehalose analogues accumulate at different levels relative to 
trehalose. Each analogue was mixed in a 1:1 molar equivalence with trehalose. The 
resultant chromatogram signals were compared by determining the areas under each peak. 
The observed trehalose:analogue ratio varied depending on the identity of the compound, 
with the signal for trehalose appearing 1.3 – 4.7 fold increased relative to the analogue. This 
was used to adjust the ratio of trehalose:analogue observed in cytosolic extracts to give a 
more accurate estimate of the amount of each analogue relative to trehalose in the cell. 
Axial analogues 5c and 5e were both accumulated at approximately ten-fold higher levels 
than that of trehalose. Equatorial azido analogue 5g accumulated at approximately equal 
levels to that of trehalose. There was a three-fold excess of trehalose relative to the 
equatorial fluoro analogue 5i. Ratios are given to one decimal place. 
Compound Retention 
Time (min) 
Trehalose: Analogue Ratio 
1:1 Injection 
of Standards 
Cytosolic 
Extracts 
Adjusted 
5c 14.1 1.3 0.2 0.1 
5e 33.7 3.0 0.4 0.1 
5g 28.0 1.6 1.4 0.9 
5i 25.2 4.7 13.5 2.9 
 
Even when taking into account the lower signal observed for the fluoro analogues, 5i was 
present at a level three-fold less than that of trehalose. The level of 5g was approximately 
equal relative to trehalose. Interestingly, levels of both axial analogues were about ten-fold 
higher than that of endogenous trehalose. If the endogenous levels of trehalose remained 
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unchanged in these experiments, these differences could be attributed to changes in the 
efficiency of uptake or different levels of incorporation into trehalose metabolic pathways for 
each compound. However, as the presence of the compounds may have secondary effects 
on trehalose metabolism, for example in stress response pathways or inhibition of other 
trehalose-utilising pathways, it is not possible to make further conclusions from these 
experiments. The wider metabolic picture is clearly an important further consideration for 
the utilisation of trehalose analogues as precursors to GlgE inhibitors. Having established 
that the synthesised analogues are incorporated into the mycobacterial cytosol, the next 
step was to test whether they could be processed into the GlgE pathway. 
5.4  M. tuberculosis TreS does not isomerise 4-deoxy trehalose analogues 
To investigate the possibility of incorporation of the synthesised analogues into the GlgE 
pathway, I investigated whether they could be processed by recombinant M. tuberculosis 
TreS. The interconversion of trehalose and maltose by recombinant M. tuberculosis TreS 
had previously been studied in-depth with 1H NMR spectroscopy.16 When starting with a 
trehalose substrate, conversion to maltose can be monitored by the depletion of the 
trehalose H-1 peak at 5.10 ppm and the build-up of the α-maltose H-1ʹ and H-1 peaks at 
5.32 ppm and 5.14 ppm, respectively. The latter peak overlaps with the H-1 peak of α-
glucose that is released in a hydrolytic side reaction. The picture is further complicated by 
the mutarotation of α-maltose and α-glucose to give the corresponding β-anomers, as 
illustrated in Figure 5.5. Following the previously established protocol, 10 mM of 5c, 5e, 5g 
or 5i were incubated with 2 µM recombinant M. tuberculosis TreS and 1H NMR spectra 
recorded over time. 
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Figure 5.5 Monitoring the reaction of TreS by 1H NMR spectroscopy. A) The species 
present in a TreS-catalysed reaction. TreS catalyses the interconversion between trehalose 
and α-maltose, as well as a slower hydrolysis side reaction that releases α-glucose. The 
equilibrium position favours the formation of trehalose, however the flux in vivo is in the α-
maltose-direction. Relatively slow, non-enzymatic mutarotation of α-maltose and α-glucose 
gives the corresponding β-anomers. Potential 4-deoxy trehalose modifications are 
highlighted in red; R = OH for natural substrates. Anomeric protons are highlighted in blue. 
Adapted from Miah et. al. 2013.16 B) 1H NMR spectrum of TreS reaction products. The 1H 
NMR spectrum in the region 4.5 - 5.4 ppm after trehalose has been incubated with TreS. 
Peak labels correspond to the protons highlighted in A. 
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Figure 5.6 4-Deoxy trehalose analogues are not isomerised to maltose analogues by 
M. tuberculosis TreS. Representative 1H NMR spectra recorded (i) before addition of TreS, 
(ii) 40 h after addition of TreS and (iii) 52 h after TreS-addition, 6 h after addition 10 mM 
trehalose. For 5c, 5e and 5i spectra were identical after 40 h and up to one week (data not 
shown) after TreS-addition. For 5g, peaks corresponding to hydrolytic products were first 
observed after 24 h. The addition of 10 mM trehalose was followed by the immediate 
appearance of α-maltose and α-glucose peaks, along with the corresponding β anomers, 
Figure 5.5. This demonstrates the activity of TreS was not impaired and suggests it cannot 
use 4-deoxy trehalose analogues as substrates. 
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I expected that the corresponding maltose analogues would form more slowly from the 4-
deoxy trehalose analogues, as the formation of an α-1,4 bond would be impeded when the 
analogue orientation was such that the 4-position modification obstructed bond formation. 
However, conversion to the corresponding maltose analogue products was not observed 
even after incubation periods of greater than 1 week. After 46 h, addition of 10 mM trehalose 
showed rapid conversion to maltose, demonstrating that TreS activity was not obviously 
impeded and trehalose was the preferred substrate. For 5g a small amount of hydrolysis to 
glucose and 4-azido glucose was observed after 24 h. This suggests that M. tuberculosis 
TreS does not tolerate modifications at the 4-position of trehalose and therefore this type of 
trehalose analogue is not suitable to use as a precursor to a GlgE inhibitor. 
5.5  Discussion 
This chapter describes the exploration of trehalose-based precursors of GlgE inhibitors with 
4-deoxy trehalose analogues. I aimed to synthesise a selection of trehalose analogues, test 
whether these were imported into the mycobacterial cytosol, and determine whether these 
were processed in the GlgE pathway, with a view to then modifying the compounds to 
achieve GlgE inhibition. To this end, I synthesised four 4-deoxy trehalose analogues and 
demonstrated that these were incorporated to the M. smegmatis cytosol via the trehalose 
recycling pathway. However, the synthesised analogues were not processed by 
recombinant M. tuberculosis TreS, demonstrating that this type of analogue is not 
incorporated into the GlgE pathway and therefore, is not suitable for developing further as 
a GlgE inhibitor. 
The synthesis of the trehalose analogues was achieved by modifying a previously 
established synthetic route to 4-azido trehalose,25 which was readily adapted to make other 
4-deoxy trehalose analogues. These are not accessible by the chemoenzymatic method for 
making trehalose analogues established by the Swarts group22-23 and so this work provides 
a versatile route to this type of trehalose analogue that is likely to be valuable for other 
researchers. 4-Deoxy trehalose analogues could prove useful not only for mycobacterial 
research, but also in the investigation of the diverse roles of trehalose in other organisms, 
including as a stress protectant, energy store and carbon source.28 
These small modifications to the natural trehalose scaffold led to markedly different uptake 
and inhibition profiles in M. smegmatis. All four analogues were taken up via LpqY-SugABC, 
which is specific for α,α-trehalose over other disacchardies, but able to tolerate a range of 
asymmetric trehalose modifications.10, 14, 20 This work shows for the first time that LpqY-
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SugABC can accommodate trehalose analogues with different stereochemistry at the 4-
position than that of the natural substrate. However, modifications at the 4-position are 
generally not tolerated that well, because ten-fold higher concentrations are required for 
their uptake, compared to trehalose analogues altered at the 2 or 6 positions.14, 20 There is 
also some variation in LpqY-SugABC uptake across different mycobacterial species; for 
example 5g was not taken up M. bovis.14 The structure of LpqY-SugABC, which has not yet 
been determined, could shed more light on substrate constraints and how these might differ 
across species. It is also important to note that M. tuberculosis and M. smegmatis differ in 
their carbohydrate uptake capabilities. There are just five carbohydrate uptake permeases 
in M. tuberculosis versus 28 in M. smegmatis, most likely reflecting the limited nutritional 
environment of the phagosome versus the soil.9 
I showed that at 500 µM, 5e partially inhibited M. smegmatis growth, reflecting the inhibition 
seen in M. tuberculosis, but with a higher MIC of >1 mM in M. smegmatis, compared to 290 
µM in M. tuberculosis. Compound 5e is a substrate for recombinant Ag85 in vitro, 
suggesting that the growth inhibition of 5e could be due to interference in trehalose mycolate 
production.13 My work shows that whilst 5e is not processed by TreS, it accumulates in the 
cytosol at levels approximately ten-fold higher than trehalose, and therefore another 
mechanism of growth inhibition is possible. The increase in the relative amount of 4-deoxy 
trehalose analogues with axial substituents versus equatorial ones could mean these are 
more efficiently imported via LpqY-SugABC. Alternatively, they may serve as worse 
substrates for trehalose metabolising enzymes other than TreS, such as trehalases. It 
cannot be ruled out that the presence of the axial analogues decreases the cellular levels 
of trehalose, for example by inhibiting trehalose production. The metabolic profiles could be 
investigated in more detail with a chromatography method combined with mass 
spectrometry, such as GC-MS, and the use of internal standards and calibration curves for 
more accurate quantification. 
A more detailed analysis of the TreS mechanism gives insight into the lack of activity with 
4-deoxy trehalose analogues, Figure 5.7. The interconversion of trehalose and α-maltose 
by TreS follows a two-step double displacement mechanism with retention of configuration, 
as seen across the GH13 enzyme family.16, 19 In the trehalose to maltose direction, the 
binding of trehalose is followed by the formation of a covalent enzyme intermediate with the 
nucleophilic aspartate residue and the glucose unit in the -1 subsite. The glucose unit in the 
+1 subsite is mostly retained in the active site, with hydrolysis occurring in approximately 
10% of reactions. The +1 glucose moiety is repositioned to allow attack by the 4-OH, to 
form an α-1,4 bond and give maltose.19 Therefore, the conversion of 4-deoxytrehalose into 
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4-deoxymaltose could only be achieved when the trehalose analogue binds such that the 
modified 4 position is located in the -1 subsite. 
 
Figure 5.7 The catalytic mechanism of M. tuberculosis TreS. The M. tuberculosis TreS 
catalytic residues Asp (nucleophile) and Glu (acid/base) are labelled. The 4-position 
substitution in the disaccharide is indicated by R1 in red, with this being an equatorial 
hydroxyl in the natural substrate/product. The -1 donor and +1 acceptor subsites are 
labelled in blue. Trehalose binds at the active site, which allows attack by the nucleophile 
(top left panel) to form a covalent intermediate (top right panel). Attack by a water 
nucleophile leads to hydrolysis, which occurs in approximately 10% of reactions to release 
a glucose side product. Rotation of the glucose in the +1 subsite orientates the 4-OH for 
nucleophilic attack of the covalent intermediate (bottom right panel), forming an α-1,4 
glycosidic bond and releasing maltose (bottom left panel). The conversion of maltose to 
trehalose proceeds by the reverse pathway. 
 
The lack of substrate-bound TreS structures mean that the environments of the subsites 
are unknown. It could be argued that binding with the modified 4-position in the +1 subsite 
is more likely to be tolerated because this site would be inherently less restrictive and allow 
for rotation. Binding in this orientation could promote hydrolysis due to the lack of the 4-OH 
nucleophile for α-1,4 bond formation, but hydrolysis was only seen in small amounts for 5g. 
Coupled with the lack of significant TreS inhibition by the 4-deoxy trehalose analogues, this 
suggests that 5c, 5e and 5i are unable to bind well to TreS. For the galactose-type 
analogues 5c and 5e this can be attributed to the change in stereochemistry. Compound 5i 
might be expected to be more tolerated by TreS, at least in the +1 site, and the lack of 
activity could be due to the observed distortion of C-F bond, demonstrated by the altered J 
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values (Section 5.2.2). Crystal structures of TreS in an active state bound to trehalose or 
maltose substrates would reveal more details about the environment of the active site. The 
currently available TreS structures are of the enzyme in an inactive state with a leucine 
residue apparently blocking substrate binding,17, 29 precluding modelling of the substrates 
into the active site. 
It was previously reported that the labelling of mycobacterial cells with 5g was decreased 
in a M. smegmatis ΔtreS mutant strain.14 One explanation put forward for this was that 5g 
was incorporated into the cells via the GlgE pathway, hence when this is disrupted in a 
ΔtreS knockout strain less of 5g is incorporated into the mycobacterial cell. However, the 
findings presented in this chapter demonstrate that 5g is not processed along the GlgE 
pathway, but instead I showed that TreS has a low level of hydrolytic activity with 5g. An 
alternative explanation for the original observation is that 5g is outcompeted by trehalose in 
the ΔtreS mutant strain. Experiments in the original paper indeed demonstrated that 5g is 
most sensitive to trehalose competition. Additionally, there are elevated levels of trehalose 
in the ΔtreS strain. Thus, 5g is outcompeted by the natural substrate and hence the cell 
labelling with this compound is depleted.14 
The next steps for following up this work are the synthesis of trehalose analogues with 
modifications at different positions and testing whether these are converted to the 
corresponding maltose analogues by M. tuberculosis TreS. This is necessary to validate 
the approach of using trehalose analogues as precursors to GlgE inhibitors. The obvious 
candidates are trehalose analogues modified at the 2 and/or 6 positions, because trehalose 
analogues modified at the 3 position are tolerated less well by LpqY-SugABC.14, 20 The 1 
and 5 position analogues are synthetically accessible, but more likely to interfere with the 
mechanism of TreS. If any of these were successful, the analogues could then be tested 
with Pep2, either sequentially or with the TreS/Pep2 complex, to test for formation of the 
corresponding M1P analogue. The structures could be modified to achieve an end product 
capable of inhibiting GlgE and establish SAR, before testing compounds in vivo. 
5.6 Summary 
I explored the idea of trehalose analogues acting as precursors for GlgE inhibitors, using 
four synthesised 4-deoxy trehalose analogues. I showed that in M. smegmatis the 4-deoxy 
trehalose analogues were taken up via the LpqY-SugABC mediated trehalose recycling 
pathway, at different levels depending on the functional group and stereochemistry at the 
4-position. However, M. tuberculosis TreS was not tolerant of these 4-position 
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modifications, indicating that 4-deoxy trehalose analogues are not suitable for this overall 
approach. 
5.7 Materials and methods 
5.7.1 Synthesis of 4-deoxy trehalose analogues 
5.7.1.1 General methods 
All solvents used in organic reactions were anhydrous and purchased from Sigma Aldrich 
and used as supplied. Anhydrous D-trehalose was purchased from Tokyo Chemical 
Industry. All other solvents and reagents were purchased from Sigma Aldrich or Fisher 
Scientific and used without further purification. Analytical TLC was carried out using Merck 
aluminium backed sheets coated with 60-F254 silica gel. Spots were visualised by dipping 
the TLC plate in ethanolic 5% H2SO4 solution followed by heating with a heat gun. 
Compounds were purified by automated flash column chromatography using a Biotage 
Isolera™ Spektra One system with KP-Sil™, with Biotage SNAP and SNAP Ultra cartridges 
(Uppsala, Sweden). Optical rotations were measured at ambient temperature on a Perkin 
Elmer model 141 polarimeter using a sodium lamp. NMR spectra were recorded at 22 °C 
on a Bruker Avance III spectrometer at 400 MHz (1H), 100 MHz (13C) or 376 MHz (19F). 
Chemical shifts (𝛿) are reported in ppm using residual solvent signals from deuteriated 
solvents as references (CDCl3: 𝛿 1H 7.26 and 𝛿 13C 77.0). Assignments were made with the 
aid of COSY and HSQC experiments. Chemical shifts of 1H-coupled 19F NMR signals 
recorded in CDCl3 are reported with respect to external CFCl3 at 𝛿 19F 0 ppm. High-
resolution mass spectra (HRMS) were obtained using a Synapt G2 HDMS mass 
spectrometer (Waters Corp., Manchester UK) using positive electrospray ionisation. 
Nominal and exact m/z values are reported in Daltons. After work-up of the reaction 
mixtures, organic layers were dried over MgSO4, filtered and then concentrated under 
vacuum. 
5.7.1.2  2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1→1')-2',3',4',6'-tetra-O-
benzoyl-α-D-glucopyranoside (5a) 
 5a 
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Anhydrous trehalose (5.00 g, 14.6 mmol) was dissolved in pyridine (300 mL) and the 
solution was stirred and cooled on ice. Benzoyl chloride (13.6 mL, 117 mmol) was added 
drop-wise. The mixture was allowed to warm to room temperature and was stirred for a 
further 6 h. At this point, TLC (4:1 toluene/EtOAc) showed three products: Rf 0.71, Rf 0.43 
and Rf 0.16. The mixture was poured onto 1 M HCl (300 mL) and then extracted with CH2Cl2 
(3 × 300 mL). The extract was washed successively with NaHCO3 (1 L) and H2O (1 L) and 
then concentrated. The crude residue was purified by column chromatography on silica gel 
(4:1 toluene/EtOAc) to afford 5a (6.68 g, 43%) as a colourless solid: [α]D
20 + 231.4 (c 1.0, 
CH2Cl2), lit.25 + 225 (c 1.97, CH2Cl2); Rf 0.43 (4:1 toluene/EtOAc); 1H NMR (400 MHz 
CDCl3): 𝛿 8.08-7.98 (m, 8H, o-Bz), 7.93-7.88 (m, 4H, o-Bz), 7.86-7.82 (m, 2H, o-Bz), 7.60-
7.51 (m, 5H, m-Bz, p-Bz), 7.49-7.36 (m, 12H, m-Bz, p-Bz), 7.34-7.26 (m, 4H, m-Bz, p-Bz), 
6.25 (dd, 1H, 3J2',3' 10.1 Hz, 3J3',4' 10.0 Hz, H-3'), 5.93 (dd, 1H, 3J2,3 10.0 Hz, 3J3,4 9.6 Hz, H-
3), 5.69-5.61 (m, 3H, H-1, H-1', H-4'), 5.51-5.43 (two overlapping dd, 2H, 3J2',3' 10.1 Hz, 3J2,3 
10.0 Hz, 3J1,2 3.9 Hz, 3J1',2' 3.7 Hz, H-2, H-2'), 4.38 - 4.31 (m, 1H, H-5'), 4.21 (dd, 1H, 2J6a,6b 
12.4 Hz, 3J5,6b 4.0 Hz, H-6b), 4.06-4.01 (m, 1H, H-5), 3.97 (dd, 1H, 2J6a', 6b' 12.5 Hz, 3J5',6b' 
2.7 Hz, H-6b'), 3.89-3.75 (m, 3H, H-4, H-6a, H-6a'), 3.34 (d, 1 H, 3J4,OH 4.6 Hz, D2O-
exchangable, OH); 13C NMR (100 MHz, CDCl3): 𝛿 167.2, 166.9, 165.8, 165.6, 165.4, 165.0 
(7C, C=O), 134.1, 133.8, 133.6, 133.5, 133.4, 133.3, 133.1 (7C, p-Bz), 130.0, 129.9, 129.9, 
129.8, 129.8, 129.8, 129.5, 129.4, 129.2, 129.1, 128.9, 128.7, 128.7, 128.5, 128.5, 128.4, 
128.4 (35C, i-Bz, m-Bz, o-Bz), 93.0 (C-1), 92.8 (C-1'), 73.6 (C-3), 71.2 (C-2'), 71.1 (C-5), 
70.7 (C-2), 70.2 (C-3), 69.2 (C-4), 68.9 (C-4'), 68.6 (C-5'), 62.5 (C-6), 62.0 (C-6'); NMR 
spectra were in agreement with published values;25 HRMS, ESI-TOF/MS positive (m/z): 
calcd. for C61H50O18 [M+H]+: 1071.3070, found: 1071.3066. 
5.7.1.3  2,3,6-tri-O-benzoyl-α-D-galactopyranosyl-(1→1)-2,3,4,6-tetra-O-
benzoyl-α-D-glucopyranoside (5b) 
 
To a solution of 5a (4.00 g, 3.74 mmol) dissolved in dry CH2Cl2 (50 mL) was added dry 
pyridine (3.00 mL, 37.4 mmol). The solution was cooled on ice and triflic anhydride (1.27 
mL, 7.47 mmol) was added drop-wise. The reaction was allowed to reach room temperature 
and was stirred for a further 30 min, at which point TLC (4:1 toluene/EtOAc) showed 
5b 
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conversion to product. The mixture was diluted with CH2Cl2 (50 mL) and then successively 
washed with 1 M HCl (100 mL), 10% NaHCO3 (100 mL) and H2O (100 mL) and concentrated 
to give 4-deoxy-4-O-trifluoromethylsulphonyl-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-
(1→1')-2',3',4',6'-tetra-O-benzoyl-α-D-glucopyranoside (5a.1) (3.82 g) as a crude yellow 
solid: Rf 0.69 (4:1 toluene/EtOAc). This was used directly without further purification. 
To a solution of 5a.1 (3.82 g, 3.17 mmol) dissolved in DMF (50 mL) was added potassium 
nitrite (1.35 g, 15.9 mmol). The suspension was stirred at ambient temperature for 3 h at 
which point TLC (4:1 toluene/EtOAc) showed conversion to product. The mixture was then 
diluted with CH2Cl2 (50 mL), washed with brine (2 × 100 mL) and H2O (100 mL) and 
concentrated to give the crude residue, which was purified by silica column chromatography 
(4:1 toluene/EtOAc) to give 5b (2.68 g, 67% over 2 steps) as a colourless solid: [α]D
20 + 
194.6 (c 1.0, CH2Cl2), lit.25 + 151 (c 1.85, CH2Cl2); Rf 0.45 (4:1 toluene/EtOAc); 1H NMR 
(400 MHz CDCl3): 𝛿 8.09-8.03 (m, 4H, o-Bz), 7.99-7.91 (m, 4H, o-Bz), 7.90-7.86 (m, 2H, o-
Bz), 7.81-7.76 (m, 4H, o-Bz), 7.60-7.49 (m, 4H, m-Bz, p-Bz), 7.45-7.26 (m, 17H, m-Bz, p-
Bz), 6.25 (dd, 1H, 3J2',3' 10.1 Hz, 3J3',4' 9.9 Hz, H-3'), 5.92 (dd, 1H, 3J2,3 10.7 Hz, 3J1,2 3.1 Hz, 
H-2), 5.89 (dd, 1H, 3J2,3 10.7 Hz, 3J3,4 2.4 Hz, H-3), 5.75 (d, 1H, 3J1',2' 3.8 Hz, H-1'), 5.72 (d, 
1H, 3J1,2 3.0 Hz, H-1), 5.65 (dd, 1H, 3J3',4' 9.9 Hz, 3J4',5' 9.9 Hz, H-4'), 5.47 (dd, 1H, 3J2',3' 10.1 
Hz, 3J1',2' 3.8 Hz, H-2'), 4.37-4.20 (m, 4H, H-4, H-5',H-6a, H-6b), 4.07-4.00 (m, 2H, H-5, H-
6b'), 3.94 (dd, 1H, 2J6a',6b' 12.4 Hz, 
3J5',6a' 5.0 Hz, H-6a'), 2.66 (d, 1H, 3J4,OH 3.6 Hz, D2O-
exchangable, OH); 13C NMR (100 MHz, CDCl3): 𝛿 166.2, 165.9, 165.8, 165.7, 165.6, 165.4, 
165.0 (7C, C=O), 133.7, 133.6, 133.5, 133.3, 133.3, 133.2 (7C, p-Bz), 129.9, 129.9, 129.8, 
129.8, 129.7, 129.4, 129.3, 129.2, 129.1, 128.9, 128.7, 128.7, 128.7, 128.6, 128.4, 128.3, 
128.3, (35C, i-Bz, m-Bz, o-Bz), 92.9 (C-1'), 92.2 (C-1), 71.3 (C-2'), 70.9 (C-3), 70.3 (C-3'), 
69.0 (C-4'), 68.6 (C-5), 68.5 (C-5'), 68.1 (C-2), 67.4 (C-4), 62.5 (C-6), 62.2 (C-6'); NMR 
spectra were in agreement with published values25; HRMS, ESI-TOF/MS positive (m/z): 
calcd. for C61H50O18 [M+H]+: 1071.3070, found: 1071.3070. 
5.7.1.4  α-D-galactopyranosyl-(1→1)- α-D-glucopyranoside (5c) 
 5c 
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To a solution of 5b (235 mg, 0.219 mmol) in anhydrous methanol (2 mL) was added freshly 
prepared 1 M NaOMe in MeOH (1.54 mL, 1.54 mmol). The reaction mixture was stirred 
overnight at room temperature at which point the reaction was complete by TLC. The 
solution was neutralised, titurated with hexane (3 × 2 mL) and passed through quaternary 
ammonium resin (BioRad AG 1-X8), which was then washed with water (3 × 2 mL), to give 
pure 5c in quantitative yield: Rf 0.56 (1:1 MeOH/H2O); 1H NMR (400 MHz, D2O): 𝛿, 5.15 (d, 
1H, 3J1,2 3.9 Hz, H-1), 5.14 (d, 1H, 3J1ʹ,2ʹ 3.9 Hz, H-1ʹ), 4.00 (dd, 1H, 3J3,4 6.2 Hz, 3J4,5 6.2 Hz, 
H-4), 3.97-3.91 (m, 2H, H-3, H-5ʹ), 3.86-3.79 (m, 2H, H-2, H-6a), 3.78-3.63 (m, 5H, H-3ʹ, H-
5, H-6a, H-6ʹb, H-6b), 3.57 (dd, 1H, 3J2ʹ,3ʹ 10.0 Hz, 3J1ʹ,2ʹ 3.8 Hz, H-2ʹ), 3.37 (dd, 1H, 3J2ʹ,3ʹ 9.4 
Hz, 3J3ʹ,4ʹ 9.4 Hz, H-4ʹ); 13C NMR (100 MHz, D2O): 𝛿 93.3 (C-1'), 93.1 (C-1), 72.5 (C-3'), 72.1 
(C-5), 71.3 (C-4), 71.1 (C-2'), 69.7 (C-4ʹ), 69.3 (C-3), 68.9 (C-5ʹ), 67.9 (C-2), 61.2 (C-6ʹ), 
60.5 (C-6); NMR spectra were in agreement with published values;25 HRMS, ESI-TOF/MS 
positive (m/z): calcd. for C12H22O11 [M+Na]+: 365.1054, found: 365.10656. 
5.7.1.5  4-deoxy-4-fluoro-2,3,6-tri-O-benzoyl-α-D-galactopyranosyl-(1→1)-
2,3,4,6-tetra-O-benzoyl-α-D-glucopyranoside (5d) 
 
Compound 5a (805 mg, 0.752 mmol) and DMAP (193 mg, 1.58 mmol) were dissolved in 
dry CH2Cl2 (15 mL) and cooled on ice. DAST (199 µL, 1.50 mmol) was added drop-wise 
and the solution was stirred for 18 h at room temperature. After this period, TLC (10:1 
toluene/EtOAc) showed conversion to product. The reaction was quenched with H2O (20 
mL) and extracted twice with CH2Cl2 (2 × 20 mL). The combined organic phases were then 
washed with H2O (40 mL), and concentrated. The crude residue was purified by column 
chromatography on silica gel (10:1 toluene/EtOAc) to give 5d (423 mg, 52%) as a colourless 
solid: [α]D
20 + 206.9 (c 1.0, CH2Cl2); Rf 0.53 (10:1 toluene/EtOAc); 1H NMR (400 MHz CDCl3): 
𝛿 8.09-8.05 (m, 4H, o-Bz), 7.95-7.91 (m, 4 H, o-Bz), 7.90-7.86 (m, 2H, o-Bz), 7.84-7.78 (m, 
4H, o-Bz), 7.61-7.50 (m, 4H, m-Bz, p-Bz), 7.47-7.26 (m, 17H, m-Bz, p-Bz), 6.23 (dd, 1H, 
3J2',3' 10.1 Hz, 3J3',4' 9.8 Hz, H-3'), 5.94 (ddd, 1H, 3J3,F 26.5 Hz, 3J2,3 10.7 Hz, 3J3,4 2.4 Hz, H-
3), 5.89 (ddd, 1H, 3J2,3 10.7 Hz, 3J1,2 3.8 Hz, 4J2,F 1.1 Hz, H-2), 5.76-5.72 (two overlapping 
d, 2H, 3J1',2' 3.9 Hz, 3J1,2 3.8 Hz, H-1, H-1'), 5.65 (dd, 1H, 3J3',4' 10.0 Hz, 3J4',5’ 10.2 Hz, H-4'), 
5.46 (dd, 1H, 3J2',3' 10.1 Hz, 
3J1',2' 3.9 Hz, H-2'), 5.09 (dd, 1H, 
2J4,F 50.4 Hz, 3J3,4 2.4 Hz, 3J4,5 
5d 
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0 Hz, H-4), 4.35-4.18 (two overlapping ddd, 2H, 3J5,F 27.6 Hz, 3J4',5' 10.2 Hz, 3J5,6a 6.9 Hz, 
3J5,6b 6.7 Hz, 3J5',6a' 4.9 Hz, 3J5',6b' 2.5 Hz, 3J4,5 0 Hz, H-5,H-5'), 4.15-4.06 (m, 2H, H-6a, H-6b), 
4.03 (dd, 1H, 2J6a',6b' 12.4 Hz, 
3J5',6b' 2.5 Hz, H-6b’), 3.92 (dd, 1H, 2J6a',6b' 12.4 Hz, 
3J5',6a' 4.9 
Hz, H-6a'); 13C NMR (100 MHz, CDCl3): 𝛿 165.9, 165.7, 165.4, 165.4, 165.4, 165.0 (7C, 
C=O), 133.8, 133.8, 133.7, 133.6, 133.3, 133.3, 133.2 (7C, p-Bz), 130.0, 129.9, 129.9, 
129.8, 129.8, 129.7, 129.5, 129.3, 129.1, 129.1, 129.0, 128.8, 128.7, 128.6, 128.4, 128.3, 
128.3 (35C, i-Bz, m-Bz, o-Bz), 92.9 (C-1'), 92.5 (C-1), 86.7 (d, 1C, 1JC-4,F 187.2 Hz, C-4), 
71.3 (C-2'), 70.2 (C-3'), 68.9 (C-2), 68.8 (d, 1C, 2JC-3,F 18.3 Hz, C-3), 68.7 (C-4'), 67.9 (C-
5'), 67.8 (d, 1C, 2JC-5,F 18.3 Hz, C-5), 62.1 (C-6'), 61.5 (d, 1C, 3JC-6,F 5.7 Hz, C-6); 19F {1H} 
NMR (376 MHz, CDCl3): 𝛿 -218.8, 2J4,F 50.4 Hz, 3J5,F 27.6 Hz, 3J3,F 26.5 Hz; HRMS, ESI-
TOF/MS positive (m/z): calcd. for C61H50O18 [M+H]+: 1073.3026, found: 1073.3026. 
5.7.1.6  4-deoxy-4-fluoro-α-D-galactopyranosyl-(1→1)-α-D-glucopyranoside 
(5e) 
 
Compound 5d (255 mg, 0.238 mmol) was deprotected as above to give pure 5e in 
quantitative yield: Rf 0.75 (1:1 MeOH/H2O); 1H NMR (400 MHz, D2O): 𝛿 5.12 (d, 1H, 3J1,2 
3.8 Hz, H-1), 5.05 (d, 1H, 3J1ʹ,2ʹ 3.8 Hz, H-1ʹ), 4.77 (dd, 1H, 2J4,F 50.6 Hz, 3J3,4 2.6 Hz, 4J4,5 0 
Hz, H-4), 4.06-3.91 (m, 2H, H-3, H-5), 3.81 (dd, 1H, 3J2,3 9.8 Hz, 3J1,2 3.8 Hz, H-2), 3.73-
3.57 (m, 6H, H-3ʹ, H-5ʹ, H-6a, H-6b, H-6ʹa, H-6ʹb;), 3.49 (dd, 1H, 3J2ʹ,3ʹ 10.0 Hz, 3J1ʹ,2ʹ 3.8 Hz, 
H-2ʹ), 3.29 (dd, 1H, 3J3ʹ,4ʹ 9.5 Hz, 3J4ʹ,5ʹ 9.5 Hz, H-4ʹ); 13C NMR (100 MHz, D2O): 𝛿 93.5 (C-1, 
C-1ʹ), 90.4 (d, 1C, 1JC-4,F 177.7 Hz, C-4), 72.5 (C-3ʹ), 72.2 (C-5ʹ), 71.0 (C-2ʹ), 70.1 (d, 1C, 
2JC-5,F 17.7 Hz, C-5), 69.6 (C-4ʹ), 67.9 (C-2), 67.7 (d, 1C, 2JC-3,F 18.4 Hz, C-3), 60.5 (C-6'), 
60.1 (d, 1C, 3JC-6,F 5.9 Hz, C-6); 19F {1H} NMR (376 MHz, D2O): 𝛿 -219.6, ddd, 2J4,F 50.6 Hz, 
3J3,F 30.4 Hz, 3J5,F 30.4 Hz; NMR spectra were in agreement with published values;13 HRMS, 
ESI-TOF/MS positive (m/z): calcd. for C12H21FO10 [M+Na]+: 367.1011, found: 367.1013. 
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5.7.1.7  4-azido-4-deoxy-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1→1')-
2',3',4',6'-tetra-O-benzoyl-α-D-glucopyranoside (5f) 
 
A solution of 5b (866 mg, 0.809 mmol) and pyridine (0.651 mL, 8.09 mmol) dissolved in 
CH2Cl2 (12 mL) was cooled on ice and triflic anhydride (0.274 mL, 1.62 mmol) was added 
drop-wise. The reaction was allowed to reach room temperature and was stirred for a further 
30 min, at which point TLC (4:1 toluene/EtOAc) showed conversion to product. The mixture 
was diluted with CH2Cl2 (13 mL) and then successively washed with 1 M HCl (25 mL), 10% 
NaHCO3 (25 mL) and H2O (25 mL) and concentrated to give 4-deoxy-4-O-
trifluoromethylsulphonyl-2,3,6-tri-O-benzoyl-α-D-galatopyranosyl-(1→1)-2,3,4,6-tetra-O-
benzoyl-α-D-glucopyranoside (5b.1) (787 mg) as a dark yellow solid: Rf 0.75 (4:1 
Toluene/EtOAc). This was used directly without further purification. 
To a solution of 5b.1 (787 mg, 0.654 mmol) dissolved in DMF (5 mL) was added 
dicyclopentano 15-crown-5 (13 µL, 65.4 µmol) and sodium azide (213 mg, 3.27 mmol). The 
suspension was stirred at 60 °C overnight at which point TLC (10:1 toluene/EtOAc) revealed 
a single product. The mixture was cooled to room temperature, diluted with CH2Cl2 (5 mL), 
washed with H2O (3 × 10 mL), concentrated, and the crude residue was purified by silica 
column chromatography (10:1 toluene/EtOAc) to give 5f (702 mg, 79% over 2 steps) as a 
colourless solid: [α]D
20 + 224.8 (c 1.0, CH2Cl2), lit.25 + 259 (c 1.7, CH2Cl2); Rf 0.57 (10:1 
toluene/EtOAc); 1H NMR (400 MHz CDCl3): 𝛿 8.07-7.97 (m, 8H, o-Bz), 7.94-7.89 (m, 4H, o-
Bz), 7.86-7.83 (m, 2H, o-Bz), 7.69-7.52 (m, 5H, m-Bz, p-Bz), 7.51-7.37 (m, 12H, m-Bz, p-
Bz), 7.33-7.28 (m, 4H, m-Bz, p-Bz), 6.24 (dd, 1H, 3J2',3' 10.1 Hz, 3J3',4' 9.9 Hz, H-3'), 6.14 (dd, 
1H, 3J2,3 10.1 Hz, 3J3,4 10.0 Hz, H-3), 5.70-5.63 (m, 3H, H-1, H-1', H-4'), 5.47 (dd, 1H, 3J2',3' 
10.1 Hz, 3J1',2' 3.8 Hz, H-2'), 5.38 (dd, 1H, 3J2,3 10.1 Hz, 
3J1,2 3.8 Hz, H-2), 4.30 (ddd, 3J4',5' 
10.2 Hz, 3J5',6a' 4.4 Hz, 3J5',6b' 2.8 Hz, H-5'), 4.04-3.91 (m, 4H, H-5, H-6a, H-6b, H-6b'), 3.87-
3.78 (two overlapping dd, 2H, 2J6a',6b' 12.4 Hz, 3J4,5 10.2 Hz, 3J3,4 10.0 Hz, 3J5',6a' 4.4 Hz, H-4, 
H-6a').13C NMR (100 MHz, CDCl3): 𝛿 165.8, 165.8, 165.5, 165.4, 165.4, 164.9 (7C, C=O), 
134.1, 133.9, 133.6, 133.5, 133.4, 133.2, 133.1 (7C, p-Bz), 129.9, 129.9, 129.8, 129.5, 
129.1, 129.0, 128.9, 128.7, 128.6, 128.5, 128.4, 128.4, 128.2 (35C, i-Bz, m-Bz, o-Bz), 93.1 
(C-1'), 93.0 (C-1), 71.1 (2C, C-2, C-2'), 70.9 (C-3), 70.0 (C-3'), 68.9 (C-5), 68.7 (C-4'), 68.6 
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(C-5'), 62.3 (C-6), 61.8 (C-6'), 60.5 (C-4) NMR spectra were in agreement with published 
values;25 HRMS, ESI-TOF/MS positive (m/z): calcd. for C61H50O18 [M+H]+: 1096.3134, 
found: 1096.3134. 
5.7.1.8  4-azido-4-deoxy- α-D-glucopyranosyl-(1→1')-α-D-glucopyranoside 
(5g) 
 
Compound 5f (350 mg, 0.319 mmol) was deprotected as above to give pure 5g in 
quantitative yield: Rf 0.74 (1:1 MeOH/H2O); 1H NMR (400 MHz, D2O): 𝛿 5.14 (d, 1H, 3J1,2 
3.8 Hz, H-1), 5.08 (d, 1H, 3J1ʹ,2ʹ 3.8 Hz, H-1ʹ), 3.92 (dd, 1H, 3J2,3 9.7 Hz, 3J3,4 9.7 Hz, H-3), 
3.80-3.66 (m, 7H, H-3ʹ, H-5, H-5ʹ, H-6a, H-6ʹa, H-6b, H-6ʹb), 3.64 (dd, 1H, 3J2,3 9.9 Hz, 
3J1,2 
3.8 Hz, H-2), 3.55 (dd, 3J2',3' 10.0 Hz, 3J1ʹ,2ʹ 3.8 Hz, H-2ʹ), 3.41 (dd, 1H, 3J3,4 10.1 Hz, 3J4,5 
10.1 Hz H-4), 3.36 (dd, 1H, 2J3',4' 9.4 Hz, 3J4ʹ,5ʹ 9.4 Hz, H-4ʹ).13C NMR (100 MHz, D2O): 𝛿 93.4 
(C-1), 93.4 (C-1ʹ), 72.5 (C-5), 72.2 (C-5ʹ), 71.7 (C-3), 71.0 (C-2), 70.9 (C-2'), 70.7 (C-3ʹ), 
69.6 (C-4ʹ), 61.9 (C-4), 60.6 (C-6), 60.5 (C-6ʹ); NMR spectra were in agreement with 
published values;14 HRMS, ESI-TOF/MS positive (m/z): calcd. for C12H21N3O10 [M+Na]+: 
390.1119, found: 390.1117. 
5.7.1.9  4-deoxy-4-fluoro-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1→1')-
2',3',4',6'-tetra-O-benzoyl-α-D-glucopyranoside (5h) 
 
Compound 5b (769 mg, 0.718 mmol) and DMAP (184 mg, 1.51 mmol) were dissolved in 
dry CH2Cl2 (15 mL) and cooled on ice. DAST (190 µL, 1.44 mmol) was added drop-wise 
and the solution was stirred for 18 h at room temperature. After this period, TLC (10:1 
toluene/EtOAc) showed conversion to product. The reaction was quenched with H2O (20 
mL) and extracted twice with CH2Cl2 (2 × 20 mL). The combined organic phases were 
5g 
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washed with H2O (40 mL) and concentrated. The crude residue was purified by column 
chromatography on silica gel (10:1 toluene/EtOAc) to give 5h (285 mg, 37%) as a colourless 
solid: [α]D
20 + 246.0 (c 1.0, CH2Cl2); Rf 0.61 (10:1 Toluene/EtOAc); 1H NMR (400 MHz 
CDCl3): 𝛿 8.10-8.02 (m, 6H, o-Bz), 8.01-7.90 (m, 6 H, o-Bz), 7.86-7.82 (m, 2H, o-Bz), 7.58-
7.27 (m, 21H, m-Bz, p-Bz), 6.39-6.28 (m, 2H, H-3, H-3'), 5.76-5.69 (m, 3H, H-1, H-1', H-4'), 
5.56 (dd, 1H, 3J2,3 10.3 Hz, 
3J1,2 3.8 Hz, H-2), 5.46 (dd, 1H, 3J2',3' 10.3 Hz, 
3J1',2' 3.8 Hz, H-
2'), 4.77 (ddd, 1H, 2J4,F 50.6 Hz, 3J4,5 9.5 Hz, 3J3,4 9.5 Hz, H-4), 4.38-4.28 (m, 2H, H-5, H-5'), 
4.07-4.00 (m, 3H, H-6a, H-6b, H-6b'), 3.90 (dd, 1H, 2J6a',6b' 12.5 Hz, 
3J5',6a' 4.6 Hz, H-6a'); 13C 
NMR (100 MHz, CDCl3): 𝛿 165.9, 165.6, 165.5, 165.4, 165.4, 165.0 (7C, C=O), 134.1, 134.0, 
133.6, 133.6, 133.4, 133.3, 133.2 (7C, p-Bz), 129.9, 129.8, 129.8, 129.5, 129.2, 129.1, 
129.1, 128.9, 128.8, 128.8, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3 (35C, i-Bz, m-
Bz, o-Bz), 93.0 (C-1'), 92.6 (C-1), 87.0 (d, 1C, 1JC-4,F 188.4 Hz, C-4), 71.1 (C-2'), 70.8 (d, 
1C, 3JC-2,F 8.3 Hz, C-2), 70.5 (d, 1C, 2JC-3,F 20.3 Hz, C-3), 70.2 (C-3'), 68.8 (C-4'), 68.8 (C-
5'), 68.0 (d, 1C, 2JC-5,F 23.4 Hz, C-5), 61.9 (C-6'), 61.7 (C-6); 19F {1H} NMR (376 MHz, CDCl3): 
𝛿 -197.5, 2J4,F 50.6 Hz, 3J3,F 14.0 Hz, 3J5,F 0 Hz. HRMS, ESI-TOF/MS positive (m/z): calcd. 
for C61H50O18 [M+H]+: 1073.3026, found: 1073.3036. 
5.7.1.10 4-deoxy-4-fluoro-α-D-glucopyranosyl-(1→1')-α-D-glucopyranoside 
(5i) 
 
Compound 5h (180 mg, 0.168 mmol) was deprotected as above to give pure 5i in 
quantitative yield: Rf 0.77 (1:1 MeOH/H2O); 1H NMR (400 MHz, D2O): 𝛿 5.10-4.99 (m, 2H, 
H-1, H-1ʹ), 4.36-3.94 (m, 2H, H-3, H-4), 3.92-3.83 (m, 1H, H-5), 3.74-3.57 (m, 6H, H-3ʹ, H-
5ʹ, H-6a, H-6ʹa, H-6b, H-6ʹb), 3.54 (dd, 1H, 3J2,3 10.1 Hz, 3J1,2 3.6 Hz, H-2), 3.49 (dd, 1H, 
3J2ʹ,3ʹ 9.9 Hz, 3J1ʹ,2ʹ 3.8 Hz, H-2ʹ), 3.29 (dd, 1H, 3J3ʹ,4ʹ 9.5 Hz, 3J4ʹ,5ʹ 9.5 Hz, H-4ʹ); 13C NMR (100 
MHz, D2O): 𝛿 93.5 (C-1), 93.2 (C-1ʹ), 89.2 (d, 1C, 1JC-4,F 179.9 Hz, C-4), 72.5 (C-3ʹ), 72.2 
(C-5ʹ), 71.0 (C-2ʹ), 70.8 (d, 1C, 2JC-3,F 18.2 Hz, C-3), 70.5 (d, 1C, 3JC-2,F 8.2 Hz, C-2), 69.7 
(C-4ʹ), 69.6 (d, 1C, 3JC-5,F 24.4 Hz, C-5), 60.5 (C-6), 59.8 (C-6');19F {1H} NMR (376 MHz, 
D2O): 𝛿 -198.2, 2J4,F 50.9 Hz, 3J3,F 15.6 Hz, 3J5,F 0 Hz. NMR spectra were in agreement with 
published values;20 HRMS, ESI-TOF/MS positive (m/z): calcd. for C12H21FO10 [M+Na]+: 
367.1011, found: 367.1006. 
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5.7.2 Uptake of 4-deoxy trehalose analogues by M. smegmatis 
5.7.2.1  M. smegmatis strains and growth conditions 
M. smegmatis mc2 155 wild type strain was used as previously and M. smegmatis ΔsugC 
(Hygr) mutant strain was generously provided by R. Kalscheuer.22 Strains were grown 
aerobically at 37 °C in Middlebrook 7H9 liquid media or on 7H10 as described in Chapter 
4, with the addition of hygromycin (50 mg l-1) for appropriate antibiotic selection. Growth 
curves and MIC determination experiments were carried out in 96-well plates as described 
in Chapter 4. 
5.7.2.2  Extraction and analysis of small-molecule metabolites 
M. smegmatis wildtype or ΔsugC mutant were cultured in the presence or absence of 4-
deoxytrehalose analogues (250 µM) in 2.0 mL 7H9 liquid medium for 18 h, at which point 
culture densities measured by OD600 were all between 0.9 and 1.2. Cells were centrifuged 
(1500 g, 3 min) and washed (PBSB, 1.0 mL) three times, then resuspended in 2.0 mL 70% 
EtOH and lysed by mechanical disruption using 0.1 mm zirconia/silica beads on a FastPrep 
bead-beating instrument. Supernatants were cleared by centrifugation (16,000 g, 
Supernatants (16,000 g, 10 10 min, 4°C), dried in a speed-vac, and resuspended in 500 μL 
18 MΩ H2O. Small-molecule metabolites were collected via filtration through a spin 
concentrator with a 10 kDa molecular weight cut-off (Amicon). 
HPAEC-PAD was performed on a Dionex ICS3000 system with a CarboPac MA-1 analytical 
column (4 mm × 250 mm) and MA-1 guard column (4 mm × 50 mm) kept at 30 °C. Pulsed 
amperometry with standard quadrupole waveform was used for detection. The system was 
equipped with an autosampler kept at 10 °C that was set up to inject 10 μL sample volumes. 
Isocratic elution was performed using H2O (76%) and 2 M NaOH (24%) for a final eluent 
concentration of 480 mM NaOH at a flow rate of 0.4 mL/min. Standards of trehalose and 
each analogue were prepared at 10 μg/mL, Chromeleon 7 software (Dionex) was used for 
data processing. 
5.7.3 M. tuberculosis TreS-catalysed reactions 
Recombinant M. tuberculosis TreS was produced by F. Miah, as described previously.30 
Enzymatic reactions were prepared with 2 µM recombinant TreS, 10 mM trehalose/4-
deoxytrehalose analogue in 90 mM citrate buffer, pH 6.7, in a total volume of 600 µL with 
10% D2O. Reactions were monitored for up to 96 h by 1H-NMR spectra with suppression of 
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the water signal at 4.70 ppm. Signals at 5.32 ppm (d, α/β-maltose H-1), 5.24 ppm (d, α-
maltose + α-glucose H-1ʹ), 5.10 ppm (d, trehalose H-1, H-1ʹ), 4.47 ppm (d, β-maltose H-1ʹ) 
and 4.56 ppm (d, β-glucose H-1ʹ) were used to follow the consumption/formation of the 
natural substrates. 
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6. Discussion and Future Work 
The focus of this thesis was the development of potential anti-tubercular therapeutics by 
targeting M. tuberculosis α-glucan biosynthesis. The overall aims were to: 
1) Develop the fundamental understanding of mycobacterial α-glucan synthesis with 
structural studies of GlgB, and investigate α-glucan synthesis by GlgE and GlgB in 
vitro. 
2) Identify a small-molecule inhibitor of GlgB using high-throughput screening, and 
investigate SAR with a selection of modified compounds, along with in vivo activity. 
3) Investigate trehalose analogues as a route to GlgE inhibition in vivo. 
6.1 Mycobacterial α-glucan synthesis 
Compared to other biologically important carbohydrate molecules, α-glucans are relatively 
simple, consisting of just one type of monosaccharide subunit and two types of glycosidic 
linkage.1 Furthermore, α-glucans are generated from an activated sugar substrate by the 
action of just two enzymes in bacteria.2 However, the details of how they control the α-
glucan polysaccharide architecture were not fully understood. I showed that GlgE and GlgB 
were sufficient to synthesise actinomycete α-glucan in vitro, with similar branch lengths to 
α-glucan extracted from actinomycete cells. This implies that inherent properties of 
GlgE/GlgB are responsible for the distinct architecture, ruling out other factors, such as 
biophysical constraints in the cellular environment or the involvement of other enzymes that 
edit the structure. This contrasts with the synthesis of starch, which involves multiple 
isoforms of starch synthases, branching enzymes and isoamylases, each with distinct 
effects on glucan formation.3 
Not only were the average branch lengths shorter than those of mammalian and E. coli 
glycogen, but there was also a narrower distribution of DPs. Additionally, the A:BC chain 
ratio was lower, with a corresponding lower number of branches per B/C chain.4 This 
suggests that α-glucan derived from the GlgE pathway has an overall less diverse structure 
than that from classical glycogen synthesis. It is not yet known whether these differences 
have any biological consequence. It is possible to speculate that in M. tuberculosis the 
distinct architecture could play a role in α-glucan export, and recognition by human immune 
receptors. However, a previous study showed that the recognition of α-glucan by DC-SIGN 
was a general feature mediated by internal glucosyl residues, and similar binding responses 
for M. tuberculois α-glucan and bovine glycogen were observed.5 It remains to be seen 
whether the structural differences between α-glucans have a bearing on interactions with 
other immune receptors. Ongoing studies by J. Codee and co-workers aim to chemically 
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synthesise a library of α-glucan fragments,6 which could be used to assess the effect of 
branch length on the binding affinity to DC-SIGN and other immune receptors. 
It was predicted that the structural features of mycobacterial α-glucan are controlled by the 
activity of the branching enzyme GlgB. A low quality crystal structure of MtGlgB was 
previously published, however no ligand-bound structures existed for this enzyme.7 I solved 
the structure of MsGlgB and confirmed that the three-dimensional structures of the 
mycobacterial GlgB homologues were very similar, validating the latter as model for the 
former. I identified ten oligosaccharide binding sites in MsGlgB, including the donor site and 
a likely acceptor site. The residues that interacted with the oligosaccharide in the donor site 
were mainly conserved with those of the cyanobacterial branching enzyme, the only other 
branching enzyme structure with an oligosaccharide-bound at the active site.8 Considering 
the relatively distant evolutionary relationship of these two proteins, according to a 
maximum likelihood tree of GH13_9 branching enzymes previously published by Suzuki et 
al.,9 the donor site may be conserved across a number of other species. A more detailed 
comparison of branching enzyme sequences across actinobacteria, cyanobacteria and 
proteobacteria may indicate whether this is indeed the case. 
Considering the details of the branching mechanism, the contribution of the 
oligosaccharide-bound at the donor site to the final branch lengths depends on the action 
of the polymerase. Studies comparing the action of mycobacterial GlgE on different α-
glucan substrates showed that it prefers to extend A chains,4 which was consistent with the 
architecture of the enzyme’s acceptor site.10 Therefore, the length of newly created A chains 
will normally be transitory and bear little influence on the final branch lengths. This means 
that the length of the sugar accommodated in the branching enzyme donor site does not 
represent the final branch lengths. The low A:BC chain ratio of mycobacterial α-glucan 
demonstrates that most of the chains in the molecule are B chains. Furthermore, studies 
with labelled oligosaccharides demonstrated that mycobacterial GlgB transfer was strictly 
intrachain,4 indicating that B chains are mainly the residual portion of cleaved chains. 
Overall, this suggests that most branch lengths are controlled by the GlgB acceptor site, 
Figure 6.1. 
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Figure 6.1 Generation of mycobacterial α-glucan by GlgE and GlgB. GlgE prefers to 
extend A chains, which are then branched by GlgB via the cleavage and transfer of the non-
reducing end on to a 6-OH in the same chain. This creates a new A chain which can then 
be extended again by GlgE. The length of the chain in the GlgB donor site is therefore 
transitory, whereas the chain in the acceptor site is unlikely to change. Since most of the 
chains are B chains the distance between the cleavage point of the GlgB enzyme and an 
existing branch is likely to control the overall branch lengths. 
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I identified a distal acceptor site for GlgB, from which the complete acceptor site could be 
predicted. The relative orientation of oligosaccharides at this site was suggestive of a distal 
branchpoint, indicating that the enzyme can coordinate a branched structure, which is likely, 
given that the enzyme would typically act on a branched substrate. How the protein controls 
the relative locations of an existing branchpoint and a newly forming one is integral to the 
resultant branch lengths. However, without oligosaccharides bound in the proximal acceptor 
subsites it is not possible to draw further conclusions at this stage. 
Considering further the intrachain nature of transfer in the branching mechanism, this 
necessitates a significant shift in the position of the acceptor oligosaccharide of 2-3 
pyranose residues, given average branch lengths of DP 7-8 and average internal chain 
lengths of DP ~5. This could be facilitated by conformational changes in the protein, or the 
binding of the acceptor oligosaccharide in a conformation such that the 4-OH of the cleaved 
chain and the 6-OH that forms the new branch are close in space. Therefore, there may be 
alternative protein conformations that have not yet been detected by the crystallographic 
studies presented here. If the acceptor oligosaccharide adopts different conformations it 
may be challenging to determine these using crystallography, as the electron density for 
any one conformation may be weak. A branched oligosaccharide may help reveal acceptor 
subsites, but this work demonstrates that high concentrations of oligosaccharides of a 
defined structure are required to obtain strong electron density for bound ligands. The 
aforementioned synthetic fragments of α-glucans6 could therefore also be useful in this 
regard. 
Future studies could employ site-directed mutagenesis to determine which residues affect 
GlgB branch length specificity. Since I showed that α-glucan can readily be generated in 
vitro, this provides a system to quickly test the effect of mutagenesis on branch lengths in 
the context of the whole polymer. These results could be relevant to engineering the 
specificity of starch branching enzymes, which is a key objective in the field of starch 
research, as starches with specific branch lengths are desirable for different industrial 
applications.11 However, starch synthesis is a more complex process that involves the 
coordination of multiple starch synthases, branching enzymes and debranching enzymes12 
and hence, it may not be possible to directly translate the findings across kingdoms. 
6.2 Targeting M. tuberculosis GlgB and GlgE 
M. tuberculosis GlgB and GlgE are genetically validated drug targets, which can be targeted 
to both block the synthesis of an α-glucan virulence factor and to cause a lethal 
accumulation of M1P.13-14 This dual mechanism of action is distinct from all known classes 
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of TB drugs,15 making them attractive targets for the development of novel therapeutics that 
may be effective against multi-drug resistant strains of the bacterium. 
6.2.1 Targeting GlgB 
Here, I identify a potent MtGlgB inhibitor that represents the first validated, small-molecule 
inhibitor of an α-1,6 branching enzyme. Inhibitors of MtGlgB had previously been proposed 
from molecular docking experiments,16 however the results presented here suggest that 
these compounds do not actually bind to the protein. This illustrates the importance of 
counter-screens and biophysical methods to validate hit compounds.17 I synthesised a 
selection of analogues of 3a to investigate its SAR and, whilst these studies indicated that 
one edge of the compound was important for inhibition, the relationship between structure 
and potency was unclear. More chemical space must be explored before SAR can emerge. 
A more diverse library of structural modifications may also help identify a compound with 
improved potency. The addition of groups at other positions of the quinazoline rings is one 
option that can be investigated. 
Beyond this, generating selectivity for the in vivo target is the next priority for compound 
development. I showed that the original compound and some of the synthesised 
compounds inhibited the growth of M. smegmatis at concentrations of 125-500 µM, however 
this was not the result of GlgB inhibition. This suggests that the compound has another 
target in vivo. Similar sets of compounds have been shown to target folic acid 
biosynthesis,18-19 which could be the actual target here.20 This could be explored further by 
sequencing the genomes of spontaneously resistant strains and by transcriptomic analyses 
of cells that have been treated at sub-lethal concentrations. Medicinal chemistry efforts 
could then focus on modifications that would determine selectivity for the GlgB target over 
the other, for example because GlgB may be able to accommodate a bulky side group that 
other putative targets cannot. It is also important to test the compounds in M. tuberculosis 
cells, as there could be some differences in uptake and potency across the species. 
For future therapeutic application of MtGlgB inhibitors, one important consideration is 
selectivity, due to the existence of a human GlgB homologue.21 Whilst the M. tuberculosis 
and human GlgB enzymes only share 27% sequence identity, some catalytic residues are 
conserved so selectivity would have to be tuned to the mycobacterial enzyme. Historically, 
the existence of a human homologue was often a criterion used to rule out a potential 
bacterial drug target.22-24 However, there are now numerous examples of bacterial enzyme 
inhibitors that are highly selective for their target over a human homologue,25-27 even in 
cases of high sequence identity.28 On the other hand, a non-selective small-molecule 
branching enzyme inhibitor could also prove to be a useful tool for the investigation and 
manipulation of glycogen or starch synthesis. 
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Both goals of improving potency and selectivity would be greatly aided by the identification 
of the binding site of the compound. Here, I attempted this by crystallographic studies, but 
did not detect any additional electron density that suggested binding. Future work could 
explore advance modelling simulations or STD-NMR studies to try to identify this by other 
means. Only with the nature of the protein-inhibitor interactions known, can inhibitors with 
improved efficacy be developed using a rational approach. 
There are a number of options for identifying additional GlgB inhibitors, including screening 
more diverse libraries of compounds with the high-throughput assay developed in this work. 
However, the limited commercial availability of amylose-2800 could restrict the use of this 
assay in the future, necessitating the development of alternatives. One option is the use of 
synthetic substrates of a defined DP, which could be chemically modified to improve 
solubility. Hypothetically these could be installed with fluorophore groups that could give a 
differential read-out upon the creation of a branchpoint. Other studies have described the 
use of peptides to modify the activity of branching enzymes,29 which may be a further route 
for exploration here. 
6.2.2 Targeting GlgE 
By industrial standards, GlgE is a more attractive drug target because there is no close 
human homologue.22 However, efforts to identify small-molecule inhibitors from high-
throughput screening have been unsuccessful to date. Inhibitors based on substrate and 
transition state mimetics have been developed, however these are moderate binders, with 
the best reported thus far having a Ki value of 45 µM.30 Furthermore, they cannot exert an 
effect in vivo, as M. tuberculosis lacks the capacity to import maltose-based compounds.31 
Screening more diverse chemical libraries may yet yield inhibitors that are more drug-like 
and can therefore cross the mycobacterial membranes without the need for specific 
importers. Alternatively, it may be possible to rationally design an inhibitor that mimics 
features of M1P required for binding to GlgE, but avoids a carbohydrate scaffold. 
Here I investigated trehalose analogues as precursors of GlgE inhibitors, using 4-deoxy 
trehalose analogues. Whilst analogues were readily synthesised and incorporated into 
mycobacterial cells, they were not processed by M. tuberculosis TreS and so were not 
suitable for the development of GlgE inhibitors. Future work will explore whether trehalose 
analogues with modifications at the 2- and 6- positions are isomerised to the corresponding 
maltose analogues by M. tuberculosis TreS. Trehalose metabolism in mycobacteria has 
already attracted attention as a target for TB therapeutics due to the lack of trehalose in 
mammalian systems and its integral role as a component of the mycomembrane, in the 
form of trehalose mycolates.32 Previous studies have shown that trehalose analogues can 
be used for labelling cells via the attachment of fluorophores33-34 or the incorporation of 18F.35 
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Very recently, trehalose analogues with modifications at the 2,5 and 6 positions were shown 
to disrupt biofilm formation in M. smegmatis, which is linked to mycobacterial drug 
tolerance.36 However, whilst some analogues show promise as diagnostic tools, overall 
trehalose analogues were weak inhibitors of mycobacterial growth, with MIC values of ≥ 
100 µg/mL.33, 36 Furthermore, these studies support the hypothesis that extracellular 
trehalose is preferentially incorporated into trehalose mycolates, rather than other trehalose 
metabolic pathways. A trehalose analogue that will be converted to a GlgE inhibitor in vivo 
is therefore a challenging prospect, but given the paucity of GlgE inhibitors, it is an approach 
that merits further investigation. 
6.3 Future work on the GlgE pathway 
Inhibition of GlgE or GlgB in M. tuberculosis is lethal via the build-up of M1P, however the 
mechanism of M1P toxicity remains unknown. Similarly, the intracellular accumulation of 
galactose-1-phosphate is toxic in both yeast and humans, but the mechanism of toxicity has 
also not been determined.37-38 The pleiotropic stress responses observed upon M1P 
accumulation in M. tuberculosis include inhibition of respiration, induction of the stringent 
response and DNA damage, with the latter most likely to be the main cause of cell death.13 
These phenomena could be a direct result of the increased levels of M1P, because M1P is 
an activated sugar that can react with other nucleophiles in the cell and disrupt metabolic 
processes. Alternatively, the observed effects could be an indirect consequence of M1P 
accumulation, for example by causing an imbalance in phosphate metabolism. However, a 
recent study demonstrated that phosphate starvation in M. tuberculosis upregulates the 
production of α-glucan,39 suggesting that phosphate limitation is not the underlying 
mechanism. 
In M. smegmatis, the effect of removing either the glgE or glgB gene is less pronounced 
and is only detrimental to growth in the presence of exogenous trehalose and the resultant 
M1P accumulation is bacteriostatic, rather than bactericidal. In a S. venezualae ΔglgE 
strain, M1P accumulated only when it was grown on a maltose carbon source. This was 
also non-lethal, but was associated with a developmental delay phenotype, longer spores 
and reduced tolerance of these spores to stress.40 Ongoing studies with Pseudomonas 
aeruginosa and Pseudomonas syringae ΔglgE strains show that M1P accumulation occurs 
when they are grown on glucose media. In P. syringae, this is associated with a reduced 
tolerance to osmotic stress (S. Woodcock, personal communication with permission). 
Further work is required to determine how M1P accumulation results in these phenotypes 
and whether the underlying mechanisms are the same or vary between species. The 
microarray analyses used to characterise the stress responses of M. tuberculosis could be 
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applied to the other ΔglgE strains discussed above, to allow for comparison of upregulated 
and down regulated genes between species. If it could be established why M1P 
accumulation elicits such wide-ranging deleterious effects in M. tuberculosis but not in other 
species, it opens the possibility of targeting this mechanism by means other than GlgE or 
GlgB small-molecule inhibitors. 
Another question that remains unanswered is how an α-glucan molecule 100s of kDa in 
size is exported through the multiple layers of mycobacterial cell envelope to the capsule. 
Other mycobacterial virulence factors are secreted via membrane vesicles; however, this 
was shown not to be the case for α-glucan.41 In E. coli, capsular polysaccharides are 
exported by multiprotein complexes spanning the cell envelope,42 but equivalent 
homologues have not been found in mycobacteria. Improved annotation of the M. 
tuberculosis genome may aid the discovery of the α-glucan export system. 
6.4 Conclusions 
This thesis represents a significant step forward in both the fundamental understanding of 
mycobacterial α-glucan synthesis and the targeting of GlgE and GlgB to develop anti-
tubercular therapeutics. I provided direct evidence that GlgE and GlgB are necessary and 
sufficient to generate α-glucan and established that the distinct branch lengths seen in vivo 
are matched by those in vitro. I validated MsGlgB as a structural model of MtGlgB, which 
enabled the generation of high-resolution and substrate-bound structures. I identified ten 
oligosaccharide binding sites in MsGlgB, including the donor site and a likely acceptor site, 
giving unprecedented insight into substrate binding in α-1,6 branching enzymes. 
I then went on to investigate GlgB and GlgE as drug targets. Firstly, I developed a high-
throughput screening assay for GlgB and used this to identify an inhibitor, which binds in a 
1:1 molar ration with a Kd of 3.1 µM. I investigated SAR with a selection of modified 
compounds, which demonstrated that the aromatic face of the compound was most 
important for inhibition. I developed an assay to determine target selectivity in M. smegmatis 
and established that whilst some of the compounds inhibit M. smegmatis growth, this is not 
via GlgB inhibition, suggesting they have other targets in the cell. I went on to explore an 
alternative approach to generating GlgE inhibitors, via the in vivo conversion of trehalose 
analogues into GlgE substrate mimics. 4-Deoxy trehalose analogues were synthesised and 
taken up into the mycobacterial cytosol by the LpqY-SugABC transporter, but this trehalose 
modification was not tolerated in the GlgE pathway. 
Typically, it takes a minimum of 10 years to go from an initial hit to a marketable drug, with 
many potential pitfalls along the way.17 The work presented here therefore represents just 
a snapshot of the early stages of the drug discovery process. An in-depth understanding of 
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the pathways and enzymes targeted, along with tools such as X-ray crystallography, provide 
strong foundations for progress, and to deal with challenges down the line. With the 
alarming rise in MDR and XDR-TB,43 it is of vital importance that novel targets are explored 
now to create the new TB therapeutics of the future. 
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ABSTRACT: Actinomycetes, such as mycobacteria and
streptomycetes, synthesize α-glucan with α-1,4 linkages and
α-1,6 branching to help evade immune responses and to store
carbon. α-Glucan is thought to resemble glycogen except for
having shorter constituent linear chains. However, the fine
structure of α-glucan and how it can be defined by the maltosyl
transferase GlgE and branching enzyme GlgB were not known.
Using a combination of enzymolysis and mass spectrometry,
we compared the properties of α-glucan isolated from
actinomycetes with polymer synthesized in vitro by GlgE and
GlgB. We now propose the following assembly mechanism. Polymer synthesis starts with GlgE and its donor substrate, α-maltose
1-phosphate, yielding a linear oligomer with a degree of polymerization (∼16) sufficient for GlgB to introduce a branch.
Branching involves strictly intrachain transfer to generate a C chain (the only constituent chain to retain its reducing end), which
now bears an A chain (a nonreducing end terminal branch that does not itself bear a branch). GlgE preferentially extends A
chains allowing GlgB to act iteratively to generate new A chains emanating from B chains (nonterminal branches that themselves
bear a branch). Although extension and branching occur primarily with A chains, the other chain types are sometimes extended
and branched such that some B chains (and possibly C chains) bear more than one branch. This occurs less frequently in α-
glucans than in classical glycogens. The very similar properties of cytosolic and capsular α-glucans from Mycobacterium
tuberculosis imply GlgE and GlgB are sufficient to synthesize them both.
α-Glucans are widespread among bacteria, yeasts, plants,
insects, and mammals, and in most cases they are thought to
act as a store of carbon and energy. Arguably the best
documented α-glucan in bacteria is glycogen, which typically
accumulates under nitrogen-limiting growth conditions.1
Glycogen comprises linear α-1,4-linked malto-oligosaccharides
connected by α-1,6-linked branch points giving rise to an
arboreal (tree-like) dendrimer and particles tens of nanometers
in diameter. In the classical bacterial glycogen pathway, the α-
1,4-links are synthesized by glycogen synthase GlgA (E.C.
2.4.1.21), using ADP-glucose as the sugar donor (Figure 1),
and the α-1,6-linked branches are generated by GlgB branching
enzyme (E.C. 2.4.1.18). About 32% of sequenced bacterial
genomes contain the genes coding for the enzymes of the
classical pathway.2
The alternative GlgE α-glucan pathway has been discovered
recently,3,4 which is about half as widespread among bacteria as
the classical pathway.2 This involves trehalose synthase and
maltose kinase that convert trehalose into α-maltose 1-
phosphate (Figure 1), which is the donor for the maltosyl
transferase GlgE (E.C. 2.4.99.16) that creates α-1,4-linkages.5
Bioinformatic analysis suggests that even when organisms
possess both the classical and GlgE pathways, they possess only
one GlgB enzyme,2 implying the branching enzyme is shared
between both pathways. GlgB branching enzymes associated
with these pathways are members of the glycoside hydrolase
13_9 CAZy family.6,7 Interestingly, the gene for GlgB is often
clustered with the gene for GlgE rather than for GlgA in such
cases. Some organisms possess only the GlgE pathway, and we
have established using genetics that GlgE and GlgB are
necessary and sufficient for the biosynthesis of α-glucan in one
such organism, the actinomycete Streptomyces venezuelae.8
The GlgE pathway is widespread among other actinomycetes
such as mycobacteria.2 Indeed, both GlgE and GlgB have been
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genetically validated as potential drug targets for the treatment
of tuberculosis.3 Some species, including Mycobacterium
tuberculosis, possess not only the genes for the GlgE and
classical pathways, but also genes for a methyl glucose
lipopolysaccharide pathway (Figure 1). This pathway seems
to involve Rv3032 in the formation of α-1,4 linkages in the
highly modified malto-oligosaccharide product of this pathway.9
This specialized α-glucan is thought to chaperone fatty acid
biosynthesis. Carbohydrate metabolism in mycobacteria is
further complicated by the fact that the capsule coating the
cells is mainly composed of a glycogen-like α-glucan.10,11 This
polymer might contribute to virulence of M. tuberculosis by
binding to DC-SIGN to evade the host immune response.12−15
The capsular and cytosolic α-glucan polymers appear to be very
similar, with only subtle differences having been reported.15,16
Quite how each metabolic pathway contributes to each α-
glucan product is not yet clear.
Mycobacterial α-glucans appear to resemble classical
glycogen except for a higher degree of branching and
correspondingly shorter linear chains,10,16,17 This implies that
the branching enzyme in mycobacteria makes shorter branches
than the corresponding enzymes in organisms that synthesize
classical glycogen, such as in Escherichia coli.18 To address this
issue, we first characterized GlgE-derived α-glucan from S.
venezuelae, and α-glucans from mycobacteria. We then
determined the chain length specificity of actinomycete GlgB
branching enzymes and the chain specificity of M. tuberculosis
GlgE. This enabled us to establish how the GlgE pathway-
derived polymer is assembled, which has implications for how
the cytosolic and capsular α-glucans of M. tuberculosis are
synthesized.
■ MATERIALS AND METHODS
Materials. Dextrans (5, 12, 25, 50, 100, 150, 270, 410, and
1400 kDa), amylose from potatoes (average mass >150 kDa),
amylopectin from potato, individual malto-oligosaccharides
(degree of polymerization, DP2-7), rabbit liver glycogen and
pullulanases were purchased from Sigma-Aldrich (Gillingham,
United Kingdom). Malto-octaose (DP8) was purchased from
Carbosynth (Compton, United Kingdom). Amylose 2800
(mean DP 12.6 ± 5.3, median and mode DP11, DP6-16
contributing at least 5% of total malto-oligosaccharides
according to capillary electrophoresis) was purchased from
TCI Europe N.V. (Oxford, United Kingdom). α-Maltose 1-
phosphate was synthesized as previously described.19 [U-13C]α-
maltose 1-phosphate was a gift from John (Jack) Thompson.
Isolation of α-Glucans. Streptomyces venezuelae. ATCC
10712 was grown on sterile cellophane discs on MYM Tap agar
plates at 30 °C for 30 h. The cells were removed from the
cellophane, suspended in water (15 mL), and centrifuged at
4000g for 30 min. The cells were washed three more times,
suspended in water (10 mL), and disrupted by sonication. The
cell debris was pelleted by centrifugation at 30000g for 15 min,
and the resultant supernatant was washed twice with a 1:1 (v/
v) mixture of 0.2 M glycine, pH 10.5, and chloroform (10 mL).
The aqueous layer was concentrated to ∼8 mL using a rotary
evaporator and then centrifuged at 108000g at 4 °C for 2 h.
The gelatinous pellet was collected and dissolved in water (2
mL), and the α-glucan was precipitated with ethanol (3 vol) at
4 °C. The solid collected by centrifugation at 4000g for 10 min
was redissolved in water (8 mL) and centrifuged at 12000g for
10 min to remove insoluble material. The ultracentrifugation
and ethanol precipitation steps were repeated. Finally the pellet
was dissolved in 2 mL of water and freeze-dried to yield the α-
glucan as an amorphous white powder.
Mycobacterium smegmatis. Cells were grown on sterile
cellophane discs for 72 h at 37 °C on Difco Middlebrook 7H10
agar solid medium supplemented with 10% ADS (5% w/v
bovine serum albumin, 2% glucose, and 0.85% NaCl). Cells
were resuspended in 10 mL of water and disrupted by
sonication. α-Glucan was extracted as described above.
Escherichia coli. BL21(DE3) cells were transformed with a
pUC19 vector conferring resistance to carbenicillin. Cells were
grown at 37 °C for 22 h in nitrogen-limited M9 medium (1 L)
comprising Na2HPO4·7H2O (6 g), KH2PO4 (3 g), NaCl (0.5
g), pH 7.4, glucose (3 g), (NH4)2SO4 (0.22 g), MgSO4·7H2O
(0.25 g), CaCl2·2H2O (15 mg), and thiamine (10 mg),
supplemented with carbenicillin (100 mg). Cell were harvested
by centrifugation and resuspended in 10 mL of water. Glycogen
was isolated as described for α-glucan above.
M. tuberculosis. H37Rv cells were grown for 2 weeks in 100
mL cultures in a bovine serum albumin-free minimal medium
containing 20 mM glucose, 0.5% glycerol, and 0.05%
tyloxapol.20 Because of the loose attachment of the M.
tuberculosis capsule layer to the cell surface, treatment with
detergent and physical agitation were sufficient to quantitatively
strip off the capsule from cells and thus allow the satisfactory
separation of capsular and cytosolic α-glucan polymers.21 The
cells were harvested by centrifugation. The supernatant was
sterilized by passing twice through a 0.22 μm sterile filter, heat
inactivated at 65 °C for 12 h, and concentrated to 1.5 mL by
centrifugation (4000g) through a 30 kDa cutoff membrane
filtration device. The retentate was diluted with water (10 mL)
and concentrated to 1.5 mL. The concentrate was treated with
Figure 1. Metabolism of α-glucans thought to exist in Mycobacterium
tuberculosis. G6P, glucose 6-phosphate; G1P, glucose 1-phosphate;
M1P, α-maltose 1-phosphate; T6P, trehalose 6-phosphate; ADPG,
ADP-glucose; UDPG, UDP-glucose; MGLP, methylglucose lip-
opolysaccharide; PgmA, phosphoglucomutase; GlgC, ADP-glucose
pyrophosphorylase; GalU, UDP-glucose pyrophosphorylase; OtsA,
trehalose 6-phosphate synthase; OtsB, trehalose 6-phosphate
phosphatase; TreS, trehalose synthase; Pep2, maltose kinase; GlgE,
maltosyl transferase; GlgB, branching enzyme; TreX, debranching
enzyme; TreY, maltooligosyltrehalose synthase; TreZ, maltooligosyl-
trehalose trehalohydrolase; GlgA, glycogen synthase; Rv3032, putative
glycosyltransferase.
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absolute ethanol (5 vol), and the resulting precipitate was
collected by centrifugation. The solid was dissolved in water (1
mL) and centrifuged, and the resulting supernatant was freeze-
dried to yield capsular α-glucan as an amorphous solid. The cell
pellet was washed twice with 20 mM sodium phosphate buffer,
pH 7.4, containing 20 mM NaCl to remove all remaining
capsular material, resuspended in water, and heated for 4 h at
95 °C. The cell extract was centrifuged to remove debris, and
the supernatant was centrifuged at 108000g at 4 °C for 2 h. The
gelatinous pellet was dissolved in water (0.5 mL), and the α-
glucan was precipitated with ethanol (3 vol). The solid was
collected by centrifugation, redissolved in water (0.5 mL), and
freeze-dried to yield cytosolic α-glucan as an amorphous power.
NMR Spectroscopy. Solution-state NMR spectra were
recorded at 298 K on a Bruker Avance III 400 MHz
spectrometer and analyzed using Bruker TopSpin 2.1
(Rheinstetten, Germany). Chemical shifts in D2O are reported
with reference to residual water at δH 4.79 or to the methyl
resonance of internal acetone at δC 29.84 ppm. Assignments
were made with the aid of COSY and HSQC experiments. The
assignment of the peaks was based on our previous studies.3,22
Pulse field gradient DOSY experiments23 were carried out
with up to 5 mg of polymer in 0.6 mL of D2O at 313 K using
TopSpin 2.1. The gradient strength was incremented
longitudinally in 16 steps from 2% up to 95% of the maximum
gradient strength. Diffusion times and gradient pulse durations
were optimized for each experiment in order to achieve a 95%
decrease in the resonance intensity at the largest gradient
amplitude. Typically, diffusion time was set at 200 μs and the
diffusion gradient length at 3.5 ms. The 2D diffusion spectra
were analyzed with T1/T2 processing to derive the
corresponding diffusion coefficient. The relationship between
diffusion coefficient and molecular mass was determined using
a series of dextrans (Figure S2).
Molecular radii were calculated from the Stokes−Einstein
equation, which relates the diffusion coefficient D to the
macromolecular hydrodynamic radius r. The assumption that
the macromolecules are spherical is reasonable given the
morphology of particles according to electron microscopy
(Figure 2).
πη
=D k T
r6
B
where kB = 1.38 × 10
−23 J K−1, T = 313 K, and dynamic
viscosity of water η = 0.000653 N s m−2
(http://www.engineeringtoolbox.com/water-dynamic-
kinematic-viscosity-d_596.html)
Solid-state NMR measurements were performed at 293 K
using a Bruker 400 MHz Avance III spectrometer equipped
with a triple resonance probe at frequencies 400.23 (1H) and
100.64 MHz (13C). Amylose, amylopectin, and rabbit liver
glycogen were each packed in 4 mm zirconia rotors, and α-
glucan samples were packed into 12 μL CRAMPS rotors 4 mm
in diameter. Samples were rotated at a magic angle spinning
rate of 10 kHz. 1H−13C cross-polarization magic angle spinning
(CP/MAS) spectra were acquired using the following
parameters: 1H π/2 pulse length 3.5 μs, 13C π/2 pulse length
3.5 μs, and 1H−13C CP contact time 2 ms. SPINAL64
decoupling was used during signal acquisition with recycle
delay of 20 s. The Hartmann−Hahn conditions for 1H−13C
CP/MAS NMR experiment were set with hexamethylbenzene.
Typically, 256 scans were acquired for amylose, amylopectin,
and rabbit liver glycogen and 2048 scans for α-glucan. The 13C
chemical shifts were recorded with respect to trimethylsilane.
Transmission Electron Microscopy. Aqueous polymer
samples (typically 0.1 mg mL−1) were allowed to settle briefly
onto a 400 mesh copper grid with a carbon-coated pyroxylin
support film before being negatively stained. Glycogen and α-
glucan was stained with 2% aqueous uranyl acetate, pH 4.5, and
dextran was stained with 1% phosphotungstic acid. The grids
were viewed in a FEI Tecnai 20 transmission electron
microscope (Eindhoven, Netherlands) at 200 kV, and digital
TIFF images were taken using an AMT XR60B digital camera
(Deben, Bury St Edmunds, UK).
S. venezuelae was grown for 5 days on MYM-TAP solid
medium at 28 °C,24 and M. smegmatis was grown on Difco
Middlebrook 7H10 agar solid medium supplemented with 10%
ADS (5% w/v bovine serum albumin, 2% glucose, and 0.85%
NaCl) for 3 days at 37 °C. Single colonies of S. venezuelae and
M. smegmatis were positively stained for α-glucan using periodic
acid-thiocarbohydrazide-silver proteinate (PATAg) as previ-
ously described.8
Dynamic Light Scattering. Dynamic light scattering
analysis was performed on a DynaPro Titan (Wyatt
Technology Corporation, Santa Barbara CA, U.S.A.) equipped
with DYNAMICS software (v6) using a 12 μL sample cell at
Figure 2. Transmission electron microscopy of α-glucans, glycogen,
and dextran. Cells, isolated α-glucans, and dextran 100 were stained
using periodic acid-thiocarbohydrazide-silver proteinate (PATAg),
uranyl acetate, and phosphotungstic acid, respectively. Representative
images are shown. The scale bar represents 100 nm. The diameters
(Ø) of the particles (β particles in the case of α-glucans) are quoted as
mean ± SE (n). α-Glucan isolated from M. smegmatis had a diameter
of 35 ± 3 (21). Synthetic α-glucan was produced by treating
maltohexaose with M. tuberculosis GlgE and GlgB together with α-
maltose 1-phosphate. See main text and Table 1 for other measured
diameters.
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293 K. The sample concentration was typically 1 mg mL−1 in
water.
Iodine Complexes of α-Glucans. Lugol solution (1 mg
mL−1 I2 and 0.1 mg mL
−1 KI; typically 0.5 vol) was added to
samples of isolated polysaccharides, with further dilution in
water as appropriate, and absorbance was measured either using
a PerkinElmer Lambda 25 spectrophotometer (Coventry,
United Kingdom) or a BMG Labtech CLARIOstar microtiter
plate spectrophotometer (Ortenberg, Germany).
Reduction and Debranching of α-Glucans. Saccharides
were reduced by adding aqueous NaBH4 (typically 1 mg in 5
μL) to aqueous samples (in 25 μL). The mixtures were
incubated at 21 °C for 1 h, acidified with dilute acetic acid, and
treated with absolute ethanol (5 vol). The resulting precipitated
material was isolated by centrifugation and dried.
Polymer samples (typically in 25 μL) were debranched using
Pseudomonas sp. isoamylase (with typically 2 μL of a 1000 U
mL−1 stock solution) from Megazyme (Bray, Ireland) in 100
mM sodium acetate buffer, pH 4.0, at 37 °C for 3 h (as
illustrated in Figure 3A). NMR spectroscopy confirmed the loss
of α-1,6 linkages. Reactions were terminated by heating at 95
°C for 5 min, and the products were analyzed either directly or
after precipitation with ethanol (5 vol). Precipitated samples
were dissolved in water (50 μL) and freeze-dried to yield an
amorphous powder.
Mass Spectrometry. Matrix-assisted laser desorption/
ionization mass spectra were acquired as described previously3
on Bruker Ultraflex or Autoflex Speed MALDI-TOF/TOF
mass spectrometers (Coventry, United Kingdom), equipped
with a pulsed nitrogen laser emitting at 337 nm or Smartbeam-
II 2 kHz laser, respectively. Samples were typically mixed 1:2 v/
v with a 20 mg mL−1 solution of 2,5-dihydroxybenzoic acid in
50% aqueous acetonitrile and spotted on a target plate (Bruker
MTP 384 Polished Steel TF Target). Data were processed
using Bruker flexAnalysis software. The relative abundance of
malto-oligosaccharides of DP ≥ 4 was determined at least in
duplicate by measuring the area under the peaks of all isotopes
associated with each species of a given degree of polymerization
using the Sophisticated Numerical Annotation Procedure with
sugar-sodium adduct average composition. When experiments
involved quantifying both reduced and nonreduced malto-
oligosaccharides in a sample, the intensity of the main
isotopologue was used to quantify each species, taking into
account the contribution of any nonreduced isotopologues with
+2 Da when quantifying reduced species of the same mass. The
percentage contribution of such nonreduced isotopologues for
each DP of malto-oligosaccharide was determined from
experimental spectra of authentic compounds. Any difference
between the ionization efficiencies of reduced and nonreduced
malto-octoase was <15% in control spectra (data not shown),
showing that quantitative comparison between such species is
possible. Ion mobility mass spectrometry was carried out as
described previously.25 Samples were analyzed using a Synapt
G2 HDMS mass spectrometer (Waters Corp., Manchester,
UK) using electrospray ionization in traveling-wave mobility
mode with nitrogen and helium gas flows in negative mode.
Capillary Electrophoresis. Reducing saccharides were
labeled with 8-aminopyrene-1,3,6-trisulfonic acid to facilitate
their separation on the basis of charge and their detection by
fluorescence spectrophotometry. Samples (typically 5 μL) were
treated with 8-aminopyrene-1,3,6-trisulfonic acid (1 μL of 50
mM in 15% aqueous glacial acetic acid) and freshly prepared
NaCNBH3 in tetrahydrofuran (1 μL of 1 M). Reaction
mixtures were incubated at 37 °C for 4 h, diluted 10-fold with
water. Samples were subjected to capillary electrophoresis using
a Beckman Coulter PA800 ProteomeLab Protein Character-
ization System (High Wycombe, United Kingdom) using laser-
induced fluorescence detection with an excitation wavelength of
488 nm and an emission band-pass filter of 520 nm ±10 nm.
An SCIEX N-CHO capillary (50 μm internal diameter × 50.2
cm; 40 cm effective length to detector) was used with a
constant voltage of −30 kV, the anode at the detector, and a
temperature of 25 °C. The capillary was rinsed with SCIEX N-
CHO buffer, and the samples were introduced at a pressure of
0.5 psi for 5 s.
Figure 3. Cartoon showing the degradation of α-glucan by β-amylase
and isoamylase. (A) Isoamylase hydrolyzes the α-1,6-linked branch
points (indicated in purple). β-Amylase hydrolyses maltose units
iteratively from the nonreducing ends of linear chains (indicated in
green). A chains (shown in red) are left with a DP of either 3 or 2,
depending on whether the original DP was odd or even, respectively. B
chains (shown in blue) are left with an overhang of either DP 1 or 2
depending on whether the original overhang was odd or even,
respectively. C chains are degraded in the same way as for B chains
(not shown). (B) A chains are therefore extensively hydrolyzed by β-
amylase leaving a mean of 2.5 glucosyl residues (i.e., DP2.5). B and C
chains are hydrolyzed leaving a mean overhang of 1.5 glucosyl residues
(indicated by the broad green arrows). The contribution of the
hydrolysis of A and B/C chains to the extent to which β-amylase
degrades α-glucan (BAM) is indicated in the context of eq 1, which
can be rearranged to give eq 2 that defines A:BC. Thus, the right-hand
side of eq 1, in both the numerator and the denominator, relates to the
extent of hydrolysis of B plus C chains. The left-hand side relates to
the extent of hydrolysis of the A chains, where A:BC is the ratio of the
numbers of A to B plus C chains normalized to the number of B plus
C chains.
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Determination of the A:BC Chain Ratio. α-Glucan and
glycogen were each exhaustively treated for at least 1 h at 37 °C
with β-amylase from barley Megazyme (Bray, Ireland) in 10
mM MES pH 6.0. The only malto-oligosaccharide produced
was maltose according to mass spectrometry as expected. The
amount of maltose liberated by β-amylase was determined
using the 3,5-dinitrosalicylic acid method. A solution of 3,5-
dinitrosalicylic acid (43.8 mM 3,5-dinitrosalicylic acid contain-
ing 1.06 M potassium sodium L-(+)-tartrate and 0.4 M NaOH)
was added to a sample (1:1 v/v) with water and incubated at 95
°C for 5 min. The mixtures were cooled on ice for 10 min,
diluted 2-fold, and the absorbance of the mixtures was
measured at 540 nm and compared with a glucose calibration
curve. The amount of glucose residues liberated would have
been 2 times the amount of maltose detected. In separate
experiments, all glucosyl residues within a polymer were
liberated with Bacillus licheniformis α-amylase (EC 3.2.1.1 in 50
mM MOPS buffer, pH 7.0, at 99 °C for 6 min to generate
shorter dextrins) followed by Aspergillus niger amyloglucosidase
(EC 3.2.1.3 in 200 mM sodium acetate buffer, pH 4.5, at 50 °C
for 30 min to hydrolyze all remaining α-1,4 and α-1,6 linkages)
from the Megazyme Total Starch Assay kit K-TSTA 05/2008
(Bray, Ireland),26 allowing the total glucose content to be
determined using 3,5-dinitrosalicylic acid. All measurements
were carried out at least in duplicate. For example, three
independent replicate experiments were carried out with S.
venezuelae α-glucan giving 21.0 ± 4.7 (SD of replicate means).
The proportion of glucose residues liberated as maltose from
A and B/C chains by β-amylase (BAM) is defined by eq 1 as
illustrated in Figure 3.
= − + −
× +
BAM
((A:BC)(DP 2.5)) (DP DPBAM)
((A:BC) DP) DP (1)
where A:BC is the ratio of the numbers of A to B plus C chains
normalized to the number of B plus C chains (where, in this
context, the sole C chain per molecule is equivalent to a B chain
because it bears at least one branch also).
DP is the mean degree of polymerization of all chains (it is
assumed that all types of chain have a similar mean DP;
nevertheless, the lower the A:BC chain ratio, the less sensitive
eq 2 below becomes to differences in the mean DP of A
chains); e.g., five independent replicate experiments were
carried out with S. venezuelae α-glucan giving 7.3 ± 0.4 (SD of
replicate means).
DPBAM is the mean degree of polymerization of linear B
chains after digestion with β-amylase determined by mass
spectrometry (where maltose and malto-triose were ignored
because they were derived from A chains); e.g., four
independent replicate experiments were carried out with S.
venezuelae α-glucan giving 6.5 ± 0.2 (SD of replicate means).
Equation 1 can be rearranged to define the A:BC ratio to give
eq 2
= − − ×
× − +
A:BC
DP DPBAM (BAM DP)
(BAM DP) DP 2.5 (2)
Production of Recombinant Enzymes. The DNA
sequences of the glgB genes from M. tuberculosis H37Rv,
Mycobacterium smegmatis mc2 155, Streptomyces coelicolor A3(2)
isoform 1, and Streptomyces venezuelae ATCC 10712 were
synthesized with optimized codon usage for expression in
Escherichia coli (Genscript Corporation, Piscataway, NJ,
U.S.A.), allowing the production of each enzyme with an N-
terminal His6 tag and TEV cleavage site. Each gene was flanked
at the 5′ end by an NdeI restriction site and a sequence
encoding a His6 tag and a TEV protease cleavage site, and at
the 3′ end by a BamHI restriction site. Each gene, with
exceptions described below, was subcloned in to a pET-21a(+)
(Novagen, Watford, United Kingdom) vector using NdeI and
BamHI restriction sites and heterologously expressed in E. coli
BL21(DE3). The M. tuberculosis H37Rv glgB gene sequence
was mutated into that of M. tuberculosis CCDC5180 by
changing the codon for Ser470 into one for Pro using
QuikChange (Agilent Technologies, Santa Clara, CA, U.S.A.).
Cells containing the resulting expression plasmid were cultured
in Lysogeny Broth containing carbenicillin (100 μg mL−1) at 37
°C. When the cells reached an OD600 nm of 0.6, expression
was induced by the addition of 0.5 mM isopropyl β-D-
thiogalactopyranoside. After incubation at 30 °C for 2 h and
then 16 °C for 17 h, the cells were harvested by centrifugation
and resuspended in 50 mM Tris-HCl, pH 8.0, containing 15
mM imidazole, 300 mM NaCl, DNase 1, and a Complete
protease inhibitor cocktail tablet (Roche, Burgess Hill, United
Kingdom). A similar strategy was used for the production of the
other recombinant proteins. The cells were disrupted with a TS
Series Benchtop 1.1 kW cell disruptor (Constant Systems Ltd.)
at 25 kPSI. The resulting cell lysate was separated from the cell
debris by centrifugation at 20000g for 15 min at 4 °C. Enzyme
were purified from each cell lysate by application onto a 1 mL
FF HisTrap column (GE Healthcare, Amersham, United
Kingdom). Protein was eluted with 15−300 mM imidazole
gradient. Enzymes were further purified to remove any traces of
E. coli amylase activities using a HiLoad 26/60 Superdex 200
gel filtration column (GE healthcare) equilibrated with 20 mM
sodium phosphate buffer, pH 7.4, containing 20 mM NaCl. The
purified proteins were homogeneous according to SDS-PAGE
with Coomassie staining.
The production of S. venezuelae GlgB was not successful with
pET21a vector. The glgB gene was ligated into a lower copy-
number pBAD43 vector27 using NcoI and HindIII restriction
sites, placing the gene under the more stringent control of an
arabinose-inducible promoter. GlgB was produced in E. coli
TOP10 cells (Novogen) grown at 37 °C to an OD at 600 nm
of 0.6 in Lysogeny Broth before induction with 0.02% w/v L-
arabinose followed by a further 5 h of incubation. The enzyme
was purified using both Ni-affinity and size exclusion
chromatographies as described above.
Enzyme-Catalyzed Reactions. To generate synthetic α-
glucan and to determine the branch length specificity of GlgB
enzymes, 1 mM malto-hexaose and 10.1 mM α-maltose-1-
phosphate were incubated with 7 μg each of recombinant GlgE
and GlgB (giving <2 μM final concentrations) in 100 mM bis-
Tris propane, pH 7.0, containing 50 mM sodium chloride in a
total volume of 50 μL. After 18 h at 22 °C, a second aliquot of
α-maltose-1-phosphate was added. After a further 90 h, the
sample was heated at 95 °C for 5 min, cooled, and washed 5
times using a 10 000 Da cutoff membrane with 100 mM
sodium acetate buffer, pH 4.0, to remove small malto-
oligosaccharides. The sample was analyzed by electron
microscopy, mass spectrometry, or capillary electrophoresis
with or without debranching as appropriate.
In other experiments, malto-oligosaccharides (typically 5 mg)
were extended with GlgE (14 μg) and 6.6 mM α-maltose 1-
phosphate in a total volume of 122 μL at 37 °C for 3 h. The
enzyme was denatured by heating to 96 °C for 5 min. As
appropriate, GlgB (70 μg) was then added, for example, and the
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mixture was incubated at 30 °C for 2 h. The enzyme was then
denatured by heating and analyzed as described above.
The GlgE-dependent extension of acceptors with α-maltose
1-phosphate was monitored using malachite green to detect the
production of inorganic phosphate as described previ-
ously.3,19,28
■ RESULTS
Isolation of α-Glucan Particles from Actinomycetes
and Classical Glycogen Particles from E. coli. Before
characterizing GlgB branching enzymes from actinomycetes, we
characterized the α-glucans produced by these bacteria together
with classical glycogens to allow direct comparisons to be made.
To this end, α-glucans/glycogen were first isolated from the
cytosols of S. venezuelae, M. tuberculosis (the default strain in
this study is H37Rv), and E. coli, from the capsule of M.
tuberculosis, and from whole cells of M. smegmatis. We included
S. venezuelae because we have previously shown that this
organism generates α-glucan solely by the GlgE pathway.8 This
contrasts with E. coli, which generates its glycogen only via the
classical GlgA glycogen pathway.2,29 NMR spectra of the
isolated materials gave characteristic resonances of α-1,4- and
α-1,6-linked glucose polymers (examples of solution- and solid-
state NMR spectra of S. venezuelae α-glucan are shown in
Figure S1).17,30−32 Transmission electron microscopy showed
that each of the isolated polymers comprised β particles that
sometimes aggregated into larger α particles (Figure 2 and
Table 1).33 According to both transmission electron micros-
copy and dynamic light scattering, the β particles had diameters
ranging from ∼30 to ∼60 nm, consistent with previous
reports.15−17,30,34 Sectioned cells of S. venezuelae and M.
smegmatis that were stained for α-glucan showed the presence
of cytosolic β particles of a similar diameter (∼30−45 nm) to
that of isolated material (Figure 2). Only faint speckled staining
was observed on the exterior of M. smegmatis cells, suggesting
the presence of either little or diffuse capsular α-glucan in these
growth conditions. Pulse field gradient NMR spectroscopy
showed that isolated S. venezuelae α-glucan and rabbit liver
glycogen contained slowly diffusing α particles with diameters
of ∼240−280 nm, equating to ∼5 × 106 Da assemblies
comprising ∼30 000 glucosyl residues (Table 1 and Figure S2).
Similar values have been reported for material isolated from M.
smegmatis.35
Actinomycete α-Glucans Are Composed of Short
Linear Chains of Length ∼7−8. It has previously been
reported that the α-glucans of mycobacteria contain shorter
linear chains10,15−17,30,34,36 than those of classical glycogen.29 In
order to establish whether this was the case with S. venezuelae
α-glucan, the isolated material was treated with isoamylase to
hydrolyze the α-1,6 linkages (Figure 3A). Such a sample
remained in solution and did not give strongly colored
complexes with iodine according to absorbance spectroscopy
(Figure S3), as would be expected with liberated linear chains
having a degree of polymerization (DP) of <15.37 Indeed the
absorbance of the iodine complexes was only slightly greater
than with malto-heptaose. By contrast, debranched rabbit liver
glycogen yielded a little precipitate in the absence of iodine,
Table 1. Properties of α-Glucans and Glycogen
M. tuberculosis S. venezuelae rabbit liver E. coli
capsular cytosolic cytosolic glycogen glycogen
Size
TEM β particle (nm)a 63 ± 7 58 ± 2 42 ± 3 38 ± 2 34 ± 5
after β-amylasea,b ndc ndc 42 ± 3 29 ± 2 ndc
DLS β particle (nm)d 64 ± 8 64 ± 5 51 ± 11 59 ± 10 ndc
after β-amylaseb,d ndc ndc 54 ± 1 40 ± 1 ndc
NMR diffusion coefficient (m2 s−1)e ndc ndc 2.5 × 10−12 2.9 × 10−12 ndc
NMR α particle (nm)e ndc ndc ∼280 ∼240 ndc
NMR α particle (Da)e ndc ndc ∼5 × 106 ∼4 × 106 ndc
Linear Chain DPf
overall mean (DP) 7.0 ± 2.0 7.2 ± 1.9 7.3 ± 1.8 10.8 ± 4.6 11.0 ± 2.9
C meang ndc ndc 9.1 ± 2.5 ndc ndc
Extent of Branching from
overall mean DPh 0.14 0.14 0.14 0.09 0.09
NMR spectroscopyi ndc ndc 0.14 0.09 ndc
β-Amylase Treatment
mean DP (DPBAM)f 6.1 ± 1.4 6.2 ± 1.8 6.5 ± 1.6 8.6 ± 3.5 9.8 ± 3.3
residues liberated % (BAM) 31.1 33.0 21.0 ± 4.7 47.5 40.5
internal chain lengthj 4.6 ± 1.4 4.7 ± 1.8 5.0 ± 1.6 7.1 ± 3.5 8.3 ± 3.3
A:BC chain ratiok 0.6 0.6 0.2 ± 0.2 0.9 0.8
mean branches per B/C chainl ∼1.6 ∼1.6 ∼1.2 ± 0.2 ∼1.9 ∼1.8
aThe diameters of individual particles were determined by transmission electron microscopy (TEM) from at least 10 measurements (see Figure 2).
bThe size of glycogen particles after treatment with β-amylase. cNot determined. dThe hydrodynamic diameter of the dominant species of <100 nm
in each sample was determined using dynamic light scattering where at least five measurements were made. eThe diffusion coefficient, hydrodynamic
diameter, and molecular mass of the dominant large species assigned as α particles were determined using pulse field gradient NMR spectroscopy
(see Figure S2 for the calibration curve). fThe DP mean (mass average) was determined for products with a DP ≥ 4 using mass spectrometry (see
Figure 4 for representative spectra). Chain length distributions are expressed as SD. gThe DP of C chains was determined as described in Figure 5.
hExtent of branching (α-1,6 linkages divided by the sum of α-1,6 and α-1,4 linkages) equates to the reciprocal mean branch length. iExtent of
branching was also determined by integrating the appropriate anomeric resonances in 1H NMR spectra without solvent suppression of samples
subjected to repeated freeze-drying and resolubilization in D2O.
jCalculated from DPBAM minus 1.5. kThe ratio of the numbers of A to B plus C
chains normalized to the number of B plus C chains, from eq 2. lEssentially A:BC plus one.
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indicative of the liberation of linear malto-oligosaccharides that
were too long to remain in solution (>DP20). In the presence
of iodine, such a sample exhibited significant absorbance with a
λmax of ∼537 nm, revealing the liberation of linear malto-
oligosaccharides of DP up to ∼30.37
Matrix assisted laser desorption ionization mass spectrometry
showed that that debranched S. venezuelae α-glucan and rabbit
liver glycogen had mean DPs (mass average) of 7.3 and 10.8,
respectively (Figure 4 and Table 1), the latter consistent with
published values.29 The narrower distribution of DPs in α-
glucan compared with glycogen was also reflected in the
standard deviations of their means of 1.8 and 4.6, respectively.
The reliability of this analysis was independently verified using
capillary electrophoresis (Figure 4). For example, the S.
venezuelae material gave a value of 7.7 ± 2.2, which was similar
to the value of 7.3 ± 1.8 obtained with mass spectrometry.
Analysis of the materials from M. tuberculosis capsule and
cytosol showed that they comprised DPs of ∼7 that were
similar not only to that of S. venezuelae, but also each other
(Table 1). A similar value was obtained with material isolated
from whole M. smegmatis colonies (7.1 ± 2.0). By contrast, the
E. coli material had a longer mean DP of 11.0 ± 2.9 (Table 1),
as expected for a classical glycogen.29
Polymer samples treated with pullulanase from either Bacillus
acidopullulyticus or Klebsiella pneumonia also led to the cleavage
of α-1,6 linkages. However, the hydrolysis of α-1,4 linkages also
occurred such that glucose and maltose were the sole products
after 24 h. This side reaction and/or contamination of
pullulanase preparations might explain the very narrow
distribution of very short chain lengths reported in one study.16
The degree of branching (the ratio between the number of α-
1,6 linkages and the total number of linkages) can be calculated
from the reciprocal of the mean chain DP. This gave 0.14 and
0.09 for actinomycete α-glucans and glycogens, respectively
(Table 1). These values were independently verified by
integrating the anomeric resonances observed using 1H NMR
spectroscopy (Table 1). Furthermore, the values were
consistent with previous reports for materials isolated from
mycobacteria based on either methylation analysis, which gave
a degree of branching of 0.14,10,17,36 or enzymatic analyses.34
Figure 4. Branch length distribution of S. venezuelae α-glucan and rabbit liver glycogen. The α-1,6 linkages in the α-glucan were hydrolyzed using
isoamylase to <1% according to 1H NMR spectroscopy and subjected to either (A) MALDI MS or (B) capillary electrophoresis after treatment with
8-aminopyrene-1,3,6-trisulfonic acid and NaCNBH3, showing similar chain length distributions. Only after treatment with isoamylase were malto-
oligosaccharides observed (data not shown). (C) A sample treated with β-amylase before debranching was analyzed by MALDI-MS and showed a
loss of longer DPs and a relative gain of medium DPs of ∼6. Mass spectrometry of a sample that was treated solely with β-amylase showed the
presence of only maltose as expected (data not shown). Debranched rabbit liver glycogen was subjected to MALDI MS either (D) without or (E)
with pretreatment with β-amylase, leading to the substantial net reduction in DP. Only after treatment with isoamylase were malto-oligosaccharides
observed, and a sample that was treated solely with β-amylase showed the presence of only maltose as expected (data not shown). Additional
samples were analyzed as summarized in Table 1.
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The C Chain of S. venezuelae α-Glucan has a DP of ∼9.
Classical glycogen is an arboreal (tree-like) polymer. From the
sole C chain with its reducing end stem one or more α-1,6-
linked B chains that, in turn, bear further α-1,6 linked branches.
The extremities of the nonreducing ends of the polymer
comprise A chains that do not themselves bear branches. The C
chain is uniquely addressable through reduction with sodium
borohydride leading to an increase in mass by 2 Da. The
debranching of reduced S. venezuelae α-glucan allowed the
detection of small amounts of reduced linear malto-
oligosaccharides using mass spectrometry. For example, chains
with a DP of 8 in nonreduced control samples gave the natural
isotopic distribution of isotopologues (Figure 5). However, a
reduced sample showed a relative increase in the abundance of
the isotopologue with an additional two mass units. Such
reduced species must have been liberated C chains because
malto-oligosaccharides are detected by mass spectrometry in
samples of α-glucan only when they are debranched. The
reduced products had a mean DP ± SD of 9.1 ± 2.5 (Table 1).
Therefore, the C chains were slightly longer than the average of
∼7 of all chains within the polymer.
Internal Chain Length of Actinomycete α-Glucan B
Chains Is 4.6−5.0. To define the internal chain length of B
chains (i.e., between the branch point of B chains and the
furthest branch they bear as illustrated in Figure 3), α-glucan
samples were treated with β-amylase. This exoacting enzyme
hydrolyzes maltose units from the nonreducing ends of B
chains to within one or two glucosyl residues of the first branch
point it encounters, depending on whether the external chain
has an odd or even number of sugar residues.29,38 Given that
there is no detectable odd/even bias within the polymer chains,
the average overhang beyond the outermost branch after
digestion is 1.5 glucosyl residues in length. By contrast, A
chains are almost completely digested to give maltose and
maltotriose (Figure 3). After treatment, the mean DPs of
actinomycete α-glucans of DP ≥ 4 were 6.1−6.5 (Table 1 and
Figure 4), showing that a typical B chain of seven residues bears
a branch 4.6−5.0 residues from its own branch point (i.e.,
roughly half way along their length on their fourth or fifth
residue). This contrasts with classical glycogens from rabbit
liver and E. coli that have internal chain lengths of ∼7−8 (Table
1).
α-Glucan from S. venezuelae Has a Smaller A:BC Chain
Ratio than Classical Glycogen. The ratio of the number of A
vs B plus C chains (A:BC) of classical glycogen is typically close
to 1.29 The A:BC chain ratio can be determined from the mean
DP before and after treatment with β-amylase together with the
extent of hydrolysis by this enzyme (where eq 2 is derived from
eq 1, which is also illustrated in Figure 3). The mean number of
branches per B/C chain in a polymer of finite size is essentially
the A:BC chain ratio plus one. For example, consider a 17 kDa
polymer consisting of 105 glucosyl residues in 15 chains with a
mean DP of 7 (Figure S4). If each B and C chain bore only one
branch (Figure S4A), the polymer would comprise 1 A chain,
13 B chains one C chain, giving an A:BC chain ratio of close to
zero (0.07). If the polymer comprised B and C chains that bore
two chains each (Figure S4B), it would have eight A chains, six
B chains, and 1 C chain, giving an A:BC chain ratio of close to 1
(1.14).
α-Glucans were conspicuously less prone to hydrolysis by β-
amylase (21−33% glucose liberated) than E. coli classical
glycogen (∼40−47%) (Table 1). This was also evident from
electron microscopy and dynamic light scattering (Table 1)
that showed that only glycogen particles were significantly
diminished in size. The A:BC chain ratio with S. venezuelae α-
glucan was 0.2 ± 0.2, giving ∼1.2 ± 0.2 branches per B/C chain
(Table 1). The values for both types of M. tuberculosis α-glucan
were a little higher at 0.6 and ∼1.6, respectively. These values
contrast with those of 0.8−0.9 and 1.8−1.9, respectively, for
classical glycogens (Table 1).29
GlgB Enzymes from Actinomycetes Generate Rela-
tively Short Branches of DP ∼ 7−8. It might be expected
that the branch length specificity of GlgB branching enzyme
from actinomycetes reflects the shorter lengths present in the
α-glucans from these bacteria. The treatment of α-1,4-linked
amylose with a short or medium DP with M. tuberculosis GlgB
branching enzyme led to a loss of absorbance in the presence of
iodine (Figure S5), as previously described.39 The chain length
specificity of this enzyme was then determined by exposing α-
maltose 1-phosphate to GlgE and GlgB to generate a branched
α-glucan product that could be debranched and subjected to
mass spectrometry (Figure 6). The chains generated by M.
tuberculosis GlgB in the presence of M. tuberculosis GlgE had a
mean DP of 8.6 ± 2.5 (Table 2). This value was verified using
capillary electrophoresis, which gave 8.0 ± 3.1 (Table 2). No
branched products were observed when malto-octaose was
exposed to GlgB suggesting this malto-oligosaccharide was not
long enough to be branched. Mean values of between 7.2 and
8.5 were obtained when using S. coelicolor GlgE with GlgB from
either M. tuberculosis or a number of other Mycobacterium and
Streptomyces species (Table 2). This contrasts with chain DPs
of >10 observed with branching enzymes from organisms that
produce classical glycogen, such as that from E. coli.18,40 The
actinomycete GlgB branching enzymes therefore generate
relatively short branches, as predicted.
Figure 5. Detection of short C chains in S. venezuelae α-glucan. The
mass spectra show the isotopic distributions of the DP8 product of
debranched α-glucan with or without prior reduction. Without prior
reduction (black), the natural abundance isotopic distribution of
isotopologues was observable. With prior reduction with NaBH4 (red;
displaced slightly along the horizontal axis for clarity), a small but
significant relative enhancement of the isotopologue with two addition
mass units (1339.4 m/z for DP8) was observed (highlighted by the
bracket), indicative of the presence of small quantities of C chains of
DP8 that had been reduced at their reducing ends. Spectra of products
of DP4 to 14 were similarly recorded, and the absolute differences in
the signals with two additional mass units for each DP allowed the
chain length distribution of C chains to be calculated.
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M. tuberculosis GlgB Transfers a Nascent A Chain of
DP ∼ 8 to a Recipient Nascent C Chain of DP ∼ 9. The
mean chain DPs of the polymers generated in the presence of
GlgB and GlgE would include all A, B, and C chains, where the
B chains would dominate, and the C chains would be the least
represented. We therefore devised an experiment to define the
DP of nascent A chains that are transferred onto nascent C
chains (Figure 7A). Malto-octaose (DP8) was first treated with
GlgE and α-maltose 1-phosphate to extend it by maltose units
to give a series of products with an even number of glucosyl
residues. The sample was then boiled, to denature the GlgE,
followed by treatment with GlgB to introduce a single branch.
The sample was boiled again, to denature the GlgB, reduced
with NaBH4, and treated with isoamylase to cleave the α-1,6
linkages. This would liberate reduced C chains and nonreduced
A chains. All nonreduced species would be A chains. By
contrast, the reduced C chains would be significantly
contaminated with starting materials with an even number of
residues that would also be reduced. GlgB does not
discriminate between odd and even chain transfers. Therefore,
reduced species that had an odd DP would be liberated C
chains, with only a low level of contamination from hydrolytic
side-products, as described below.
Mass spectrometry was used to quantify the abundance of
reduced C chains that had an odd DP, giving a mean DP of 9.0
± 2.9 (Figure 7B and Table 2). For A chains, the distribution of
nonreduced species with an even DP (mean DP 8.1 ± 2.7; data
not shown) was similar to that of the odd species (mean DP 8.5
± 2.6 shown in Figure 7B) giving an overall mean DP of 8.3 ±
2.7 (Table 2). This value was consistent with the DP of 8.1−8.6
generated in the presence of GlgE as described above (Table
2). The overall higher abundance of reduced over nonreduced
chains was consistent with GlgB generating some hydrolytic
products. From this, the hydrolysis to branching ratio was
estimated to be ∼0.2:1 for such single branching events with
short-chain substrates.
Branching by M. tuberculosis GlgB Is Strictly Intra-
chain. Branching enzymes act by transferring a segment from
the nonreducing end of a malto-oligosaccharide to a hydroxyl
group at the six position of a glucosyl residue along a malto-
oligosaccharide, via cleavage of an α-1,4 linkage and a glycosyl-
enzyme intermediate.41 Both intra- and interchain branching
has been reported with GlgB enzymes.18,42,43 In order to
establish whether M. tuberculosis GlgB carries out intra- and/or
interchain transfers, we first generated 13C-labeled and
unlabeled populations of malto-oligosaccharides (Figure 8
and Figure 9). This was possible by exposing unlabeled
malto-tetraose (DP4) to GlgE in the presence of labeled or
unlabeled α-maltose 1-phosphate. These two populations of
molecules were then boiled to denature the GlgE, mixed, boiled
again, and then cooled, to allow any intermalto-oligosaccharide
associations that might potentially occur to be formed at
random. On exposure to GlgB, there would be three possible
outcomes (Figure 7). If the branching reaction were intrachain,
the masses of the products would be identical to those of the
substrates. If it were interchain, the label would be redistributed
Figure 6. Branch length specificity of GlgB branching enzymes. The
polymer, generated using M. tuberculosis GlgB, S. coelicolor GlgE, and
α-maltose 1-phosphate, was filtered to remove small malto-
oligosaccharides and then treated with isoamylase. The resulting
debranched sample was then analyzed using either (A) MALDI mass
spectrometry or (B) capillary electrophoresis. (C) A mass spectrum is
also shown of a sample generated with GlgB enzyme from S.
venezuelae. The mean branch lengths are shown in Table 1.
Table 2. Branch Length Distributions Generated by GlgB
Branching Enzymes in the Presence of GlgE
branch lengtha
source of GlgB source of GlgE MSb CEc
M. tuberculosis M. tuberculosis 8.6 ± 2.5 8.0 ± 3.1
S. coelicolor 8.1 ± 2.7 7.5 ± 3.5
A chains nad 8.3 ± 1.9e ndf
odd length C chains nad 9.0 ± 2.9e ndf
M. tuberculosis CCDC5180 S. coelicolor 8.4 ± 2.5 ndf
M. smegmatis mc2 155 S. coelicolor 8.5 ± 2.5 ndf
S. venezuelae S. coelicolor 7.9 ± 2.4 ndf
S. coelicolor isoform 1 S. coelicolor 7.2 ± 2.2 7.1 ± 3.1
aLength distributions shown are mean ± SD of products of DP ≥ 3 of
samples of malto-hexaose treated with GlgB, GlgE, and α-maltose 1-
phosphate followed by isoamylase. bDetermined using mass
spectrometry. cDetermined using capillary electrophoresis. dNot
applicable. eThe A and C chain length distributions were determined
from a single branching event as shown in Figure 7. fNot determined.
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in the products. If both types of reaction were to occur, there
would be a partial redistribution of the label in the products.
It was possible to generate labeled and unlabeled starting
materials with a DP of at least 20 (Figure 9). Closer inspection
of the unlabeled starting material showed that it contained the
expected natural abundance isotopic distribution (Figure 9B).
By contrast, the labeled material was dominated by a species
with the expected number of 13C labels, together with some
higher natural abundance isotopes associated largely with the
four unlabeled glucosyl residues (Figure 9D). In addition, there
was a low level of some species with one or two labels missing,
reflecting the fact that the α-maltose 1-phosphate was not quite
100% labeled.
Exposure of the mixed starting material to M. tuberculosis
GlgB led to little obvious change in the overall distribution of
chain lengths (Figure 10A). However, some hydrolysis had
occurred because of a slight increase in the presence of species
with an odd DP (Figure 10A) compared with the starting
materials, which contained relatively little (Figure 9). For
example, the unlabeled DP7 hydrolysis product had an
abundance 8% that of the unlabeled DP6 species, showing
that hydrolysis was a minor side reaction.
Most importantly, closer inspection of the main species with
an even DP showed that the products contained the same
distribution of label as the starting materials. For example, the
DP16 species, which would be expected to include a product
with a single branch point, had masses identical to those of the
starting materials (Figure 10B) by being either fully unlabeled
or with all but four glucosyl residues labeled. This is consistent
Figure 7. Branch length distributions of A and C chains generated by
M. tuberculosis GlgB are similar. (A) The scheme shows the
experimental design. Linear molecules and C chains are shown in
black, and A chains are shown in red, where Ø and Ored refer to
reducing end and reduced glucose residues, respectively. A population
of malto-oligosaccharides with even DPs was generated with GlgE,
malto-octaose, and α-maltose 1-phosphate. After heat-denaturation of
GlgE, the sample was treated with GlgB. After heat-denaturation of
GlgB, the sample was reduced and treated with isoamylase to cleave
the α-1,6 linkages. (B) The final products from the experiment were
subjected to mass spectrometry. The abundance of malto-oligosac-
charide ions are plotted as a function of their degree of polymerization
(DP). The quantification of reduced species took into account the
natural abundance of isotopes from experimental mass spectra of
debranched S. venezuelae α-glucan. This was necessary because the
larger the malto-oligosaccharide, the more naturally abundant species
with (m + 2)/z were in control samples. Nonreduced species with an
odd DP would have originated from A chains created by GlgB (plotted
in red), while reduced species would have originated from C chains
and hydrolytic products (plotted in black).
Figure 8. Experimental scheme to distinguish between intra- and
interchain mechanisms of GlgB. Linear molecules and C chains are
shown in black, and A chains are shown in red. Linear malto-
oligosaccharides were generated without or with labels by extending
malto-tetraose with M. tuberculosis GlgE using either [U-12C] or
[U-13C]α-maltose 1-phosphate, respectively (see Figure 9). A mixture
of these materials was then exposed to M. tuberculosis GlgB to establish
whether the distribution of the label was retained in the products or
not (see Figure 10). The filled circles, Ø, and Ored refer to labeled,
reducing end, and reduced glucosyl residues, respectively.
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with strictly intrachain branching because interchain branching
would have given additional species with intermediate amounts
of label.
In order to confirm that branching had indeed occurred, the
sample was reduced and then debranched (Figure 8). It was
immediately apparent that the overall distribution of species
was shifted to shorter DPs (Figure 10C) consistent with the
cleavage of branch points. Closer inspection of the products
confirmed that this was indeed the case. For example, the
reduced, labeled DP8 species had the identical isotopic
distribution (Figure 10D) as the starting material (Figure
9D), except for the addition of 2 Da to all ions. This is
consistent with starting material and liberated C chains (and
likely some hydrolytic products). Furthermore, this shows that
reduction was complete because no unreduced labeled species
were detected. By contrast, the unlabeled DP8 product
contained not only species with the same isotopic distribution
as starting material plus 2 Da, but also nonreduced species
amounting to over a quarter of the total unlabeled DP8 species
(Figure 10D). The unreduced species can only have been
derived from A chains formed by the branching reaction of
GlgB. Such nonreduced species, with and without labels, were
detected with a DP of between 5 and 10 giving a mean DP of
8.0 ± 1.4 for all liberated A chains, again consistent with the
branching specificity experiments described above. These
observations are therefore strongly supportive of a strictly
intrachain mechanism.
Re-Evaluation of the Ability To Detect Malto-
Oligosaccharides Containing an α-1,6 Branch Using
Ion Mobility Mass Spectrometry.We previously interpreted
the presence of two isomers of a malto-oligosaccharide with a
DP of 11 in samples of amylose treated with M. tuberculosis
GlgB as evidence for the ability to resolve linear and branched
materials using ion-mobility mass spectrometry.25 Careful re-
evaluation of reaction mixtures with and without enzyme
revealed that the relative abundance of the two observable
isomers was in fact somewhat variable and, more critically,
independent of GlgB (Figure S6). Reduction of a sample of
linear malto-oligosaccharide (amylose 2800) with NaBH4
clearly showed the collapse of the two isomers of DP11 into
one. This phenomenon resembles what we reported with
malto-hexaose (DP6), which was interpreted as the presence of
two conformers, where one is extended and the other forms the
first complete turn of a left-handed helix. Each turn of the helix
involves the formation of O(6)−O(2) hydrogen bonds
between glucosyl residues along the helical axis. Reduction of
the reducing end would open up the terminal glucopyranose
ring, disrupting the potential for such hydrogen bonding
involving this residue. We therefore now interpret the presence
of two isomers in the material with a DP of 11 in a similar way;
it could adopt either a conformation with two complete turns
of the helix or another more extended conformation. The
variability in the relative abundance of the two isomers likely
reflects very small differences in the stabilities of the two
Figure 9. Enzymatic synthesis of labeled and unlabeled malto-oligosaccharides. Malto-tetraose (DP4) was extended by M. tuberculosis GlgE with
either [U-12C] or [U-13C]α-maltose 1-phosphate as depicted in Figure 8. The filled circles and Ø in the structures refer to labeled and reducing end
glucosyl residues, respectively. To stop the reaction, the samples were boiled to denature the enzyme. (A) A mass spectrum of unlabeled compounds
showed the presence of a range of products. (B) The ions associated with each unlabeled product gave the expected natural abundance isotopic
distribution, as illustrated by the DP8 product shown. (C) A mass spectrum of the labeled compounds also showed the presence of a range of
products. (D) The ions associated with each labeled product showed the presence of the label, as illustrated by the DP8* product. The asterisk refers
to the presence of 13C-labeled glucosyl residues observed in all but the original DP4 acceptor.
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conformations in the gas phase, and reduction would disrupt
the formation of two complete helical turns.
GlgE Preferentially Extends A Chains over B and C
Chains. GlgE must extend chains to attain the requisite length
for GlgB to act. The B and C chains of an α-glucan cannot be
frequently extended by GlgE because the majority of B and C
chains bear only one branch, and their lengths clearly remain
unchanged after being formed by GlgB. To test this hypothesis,
the activity of M. tuberculosis GlgE was determined with rabbit
liver glycogen and S. venezuelae α-glucan, which have A:BC
chain ratios of 0.9 and 0.2, respectively (Table 1). This was
done by monitoring inorganic phosphate release from the
donor substrate of GlgE, α-maltose 1-phosphate. The kcat/Km of
the enzyme was 6.4-fold higher with rabbit liver glycogen
(Figure S7), consistent with GlgE exhibiting a preference for A
chains. We then treated an equal mass of either oligosacchar-
ides that contained a single branch, glycogen or α-glucan with
GlgE and 13C-labeled α-maltose 1-phosphate (for example, see
Figure S8). Mass spectrometry of debranched samples showed
the chains were extended by 94, 38, and 18%, respectively,
again showing a correlation between the number of available A
chains and the degree of extension.
Particles of α-Glucan Generated by GlgE and GlgB
Resemble Those Isolated from Cells. Polymers generated
by M. tuberculosis GlgE and GlgB from α-maltose 1-phosphate
and malto-hexaose (DP6) resembled those isolated from cells
according to electron microscopy (Figure 2). The mean
diameter ± SE of the synthetic material was about half (32 ±
2 nm) that of the biological polymer isolated from M.
tuberculosis, but their morphologies were similar. Similar sized
particles were generated when the reaction was carried out with
GlgE from S. coelicolor (30 ± 2 nm, n = 40). Comparable
diameters were also obtained when both S. coelicolor enzymes
were used either with malto-hexaose (29 ± 5 nm, n = 10) or
without (25 ± 4 nm, n = 10), showing that polymer initiation is
possible without a primer.
■ DISCUSSION
GlgB enzymes from actinomycetes generate polymers in the
presence of GlgE with DPs of typically 8.1 ± 2.5, which is
reasonably similar to the typical DP of 7.2 ± 1.9 observed in
polymer material isolated from cells. These are, to the best of
our knowledge, among the shortest branch lengths reported.
The shortest reported thus far for GH13 branching enzymes
appear to be 7.9 ± 3.4 from Vibrio vulnif icus44 and 8.0 ± 2.6
from Deinococcus geothermalis.45 We and others18 have
attempted to correlate the specificity of branching enzymes
with their amino acid sequence but have failed to identify any
obvious motif or domain responsible for any particular
property. Nevertheless, the two N-terminal domains of
Figure 10. M. tuberculosis GlgB catalyzes intrachain branching. Labeled and nonlabeled compounds (see Figure 9) were mixed in equal proportions,
boiled, cooled and treated with GlgB (see Figure 8 for experimental scheme). (A) A mass spectrum showed only minor changes in the profile of DP
compared with starting materials (see Figure 9). (B) None of the products with an even DP showed any redistribution of 13C labels, as illustrated
with the DP16 product. The filled circles, Ø, and Ored in the structures refer to labeled, reducing end, and reduced glucosyl residues, respectively.
Structures in black were derived from linear molecules and C chains, while those in the color red were derived from A chains. (C) The sample was
reduced with NaBH4 and treated with isoamylase to hydrolyze all of the α-1,6 linkages in order to confirm the presence of branches. The mass
spectrum showed the loss of compounds with the highest DP, consistent with the cleavage of branches. (D) The reduced products illustrate how the
reduced products (DP8red and DP8*red), derived from C chains and linear molecules, had the same isotopic distribution as the starting material,
while the presence of nonlabeled, nonreduced product (DP8) showed that sample must have contained A chains generated by GlgB (see Figure 8 for
the experimental scheme and the main text for further details).
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actinomycete GlgB enzymes, which include a family 48
carbohydrate binding module, do appear to be important
because chimeric enzymes have altered chain length specific-
ities.44,45
Interestingly, branching byM. tuberculosis GlgB was shown to
be strictly intrachain. This implies that the nascent recipient
chain, and by definition the remainder of the polymer, must
bind very tightly and noncovalently to the enzyme until the
nascent A chain is fully transferred to the recipient chain via a
glycosyl-enzyme intermediate. We and others41 have observed
that branching enzymes can generate some hydrolytic by-
products. This was more prevalent with short substrates,
implying fewer potential contacts with the protein lead to
weaker binding. With the M. tuberculosis enzyme at least, it
would appear that water, rather than another polymer chain,
acts as the acceptor after premature dissociation of the original
recipient chain.
We have shown that the internal chain length of α-glucan is
shorter than for classical glycogen. Many previous studies on
glycogens have estimated internal chain lengths based solely on
the degree of hydrolysis by β-amylase. This is inappropriate
given that glycogen contains almost as many A chains and B
chains, and A chains are almost completely digested.38 This
artificially decreases the calculated internal chain lengths to
such an extent that they would often not be long enough to
support the degree of branching that is known to occur. In
order to avoid this problem, we directly determined the length
of B chains with mass spectrometry after treatment with β-
amylase.
It is now possible to conceive of how α-glucans are generated
in organisms such as S. venezuelae (Figure 11), which possesses
the GlgE pathway and no other α-glucan pathway.8 It is known
that GlgE can initiate polymer synthesis without any primer,
such as glycogenin or a malto-oligosaccharide. It does this by
slowly hydrolyzing α-maltose 1-phosphate to give maltose,
which in turn is slowly extended to give malto-tetraose, one of
its preferred acceptor substrates.3,19 As soon as the malto-
oligosaccharide attains a length of ∼16 glucosyl residues, GlgB
will generate the first branch giving an A and a C chain of DP ∼
8−9. GlgE will then preferentially extend the A chain until it is
long enough to undergo branching to generate a new A chain
and the first B chain. The minimum length that seems to be
transferred can occasionally be three but is more typically four
or more in vivo and in vitro (Figure 4 and Figure 6). Each new A
chain forms a branch as close as three residues from the branch
point of the recipient chain, but more often on the fourth or
fifth. By contrast, the E. coli enzyme has been reported to prefer
the third residue for the first branch to be formed.18 GlgE and
GlgB will continue to extend and create new A chains,
respectively. Normally, a newly formed B chain will not be long
enough to allow a second branch to be introduced by GlgB.
However, GlgE appears to occasionally extend a B chain and,
when it attains sufficient length, GlgB introduces a second
branch into this chain. These additional events ultimately
generate the arboreal structure of the α-glucan. However, the
introduction of a second branch in a B chain is not a frequent
event because the mean number of branches per B chain is
1.2−1.6, considerably less than the value of 1.8−1.9 routinely
observed in classical glycogens. Indeed the A:BC chain ratios
for α-glucan are the smallest that have, to our knowledge, been
reported.29
Importantly, the majority of chains in an α-glucan are B
chains. Therefore, the overall mean linear chain DP of an α-
glucan must be principally defined by GlgB. This is because the
length of each B chain is initially defined by the recipient chain
length specificity of GlgB. We have established that M.
tuberculosis GlgB creates C chains of DP ∼ 9 Table 1 and
Figure 5), which matches that observed in the polymer isolated
from cells. It is reasonable to assume that it also generates B
chains of a length that matches those observed in the polymer
of ∼7−8. If GlgE readily extended B chains, one would expect
that the mean linear chain DP in the polymer would be much
greater, but this is clearly not the case. Rather, it would appear
that the occasional extension of individual B chains by GlgE
simply leads to GlgB acting again, significantly restricting any
potential to extend B chains within the polymer. Consistent
with this, the branch lengths generated by GlgB in vitro are not
obviously influenced by the presence or absence of GlgE in our
in vitro assays.
GlgE is capable of not only extending malto-oligosaccharides
with α-maltose 1-phosphate but also moving maltosyl units
between them in a disproportionation reaction.3,19 Perhaps this
second activity is important to prevent any chains from being
excessively extended because linear malto-oligosaccharides with
a DP of >20 have limited solubility in aqueous conditions.
Having previously used a genetic approach to show that the
GlgE pathway is both necessary and sufficient for the
biosynthesis of α-glucan in S. venezuelae,8 we have now
shown that GlgE and GlgB are sufficient to generate the
polymer from solely α-maltose 1-phosphate in vitro. Impor-
tantly, the α-glucans isolated from the cytosol and capsule of M.
tuberculosis were very similar not only to each other, but also to
that from S. venezuelae, which is derived exclusively from the
Figure 11. Scheme of α-glucan assembly by GlgE and GlgB. Linear
molecules and C chains are shown in black, A chains in red, and B
chains in blue. The Ø and Pi in the structures refer to the reducing end
glucose residue and phosphate, respectively.
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GlgE pathway. Although others have reported differences
between the two mycobacterial materials,15,16 such as in optical
rotation, particle size, and hydrolytic susceptibility, these
differences are subtle and could reflect differences in the way
in which the materials are isolated. The similarity in the
structures of the cytosolic and capsular materials implies that
they could be synthesized solely by the GlgE pathway. It
therefore remains to be established what role GlgA and Rv3032
have in the biosynthesis of α-glucan polymers in mycobacteria,
despite genetic evidence suggesting they could have a direct
role.15 Furthermore, how a kDa-MDa dendrimer with a
diameter of tens of nanometer is exported from a mycobacterial
cell remains unclear, since secretion via vesicles appears to have
been ruled out.46
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7.2     Appendix 2: Supplementary X-ray crystallography data  
MsGlgB structures presented in Chapter 2 
Dataset ID Apo-WT-MsGlgB DP4-WT-MsGlgB DP8-D416A-MsGlgB ACR-E469A-MsGlgB DP3-ACR-MsGlgB 
Data Collection      
Beamline I04-1 I03 I04-1 I03 I04 
Wavelength (Å) 0.9282 0.9763 0.9282 0.9762 0.9795 
Detector Pilatus 6M Pilatus3 6 M Pilatus 6M Pilatus3 6 M Pilatus 6M 
Resolution range (Å) 84.49-1.72 (1.75-1.72) 54.10-1.46 (1.48-1.46) 84.7-1.88 (1.92-1.88) 48.50-1.60 (1.63-1.60) 62.28-1.45 (1.47-1.45) 
Space group P21212 P21212 P21212 P21212 P21212 
a, b, c (Å)  98.49, 164.41, 54.52 97.36, 162.31, 53.75  98.79, 164.57, 54.42 97.00, 162.04, 53.64 97.67, 161.69, 53.79 
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Total observations 912,423 (46,131) 1,949,958 (86,737)  972,120 (60,979) 729,137 (37,025) 2,005,551 (97,080) 
Unique reflections 94,955 (4,676) 148,349 (7219) 73,128 (4,408) 111,249 (5,452) 151,467 (7,404) 
Multiplicity 9.6 (9.9) 13.1 (12.0) 13.3 (13.8) 6.6 (6.8) 13.2 (13.1) 
Mean I/σ(I) 9.6 (1.2) 16.3 (1.2) 11.3 (1.5) 9.7 (1.3) 16.8 (1.4) 
Completeness (%) 100.0 (100.00) 100.0 (99.9) 100.0 (100.0) 99.2 (98.8) 100.0 (99.9) 
Rmerge
a 0.152 (1.846) 0.073 (2.015) 0.184 (1.851) 0.095 (1.688) 0.082 (1.779) 
Rmeas
b 0.161 (1.949) 0.076 (2.105) 0.192 (1.922) 0.104 (1.828) 0.086 (1.874) 
CC1/2
c 0.998 (0.606) 1.000 (0.738) 0.998 (0.753) 0.998 (0.463) 1.000 (0.685) 
Wilson B value (Å2) 20.7 21.0 25.0 22.0 25.0 
Refinement      
Resolution range (Å) 84.49-1.72 (1.75-1.72) 54.10-1.46 (1.48-1.46) 84.7-1.88 (1.92-1.88) 48.50-1.60 (1.63-1.60) 62.28-1.45 (1.47-1.45) 
Reflections: working/freed 90,195/4,684 140,775/7,483 69,343/3,715 105,686/5501 143,858/7,518 
Final Rwork 0.164 0.125 0.173 0.176 0.124 
Final Rfree
e 0.186 0.160 0.206 0.192 0.161 
Estimated coordinate error (Å)f 0.089 0.052 0.125 0.078 0.054 
r.m.s bond distance deviation (Å) 0.0152 0.0103 0.0102 0.0102 0.0099 
r.m.s. bond angle deviation (°) 1.511 1.411 1.393 1.394 1.484 
No. of protein residues per chain (ranges) 723 (9-375; 380-736) 723 (9-375; 380-736) 722 (9-94; 99-736) 722 (9-94; 101-736) 722 (9-94; 100-736) 
No. of heterogen residues: sugar/water/otherg 0/759/9 4/737/9 35/636/6 13/411/15 17/901/18 
Mean B factors: protein/ligands/water/overall (Å2) 25/34/37/25 27/36/41/27 13/42/40/30 32/41/40/32 23/35/39/23 
Ramachandran: favoured/allowed/disallowedh (%) 97.6/2.3/0.1 98.2/1.7/0.1 98.5/1.4/0.1 97.8/2.1/0.1 98.0/1.9/0.1 
Protein Data Bank accession code N/A N/A N/A N/A N/A 
a Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl). 
b Rmeas = ∑hkl [N/(N  1)]
1/2 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, I(hkl) is the weighted average intensity for all observations i of reflection hkl and N 
is the number of observations of reflection hkl. 
c CC1/2 is the correlation coefficient between symmetry equivalent intensities from random halves of the data set. 
d The data set was split into “working” and “free” sets consisting of 95 and 5% of the data, respectively. The free set was not used for refinement. 
e The R factors Rwork and Rfree were calculated as follows: R = (| Fobs - Fcalc |)/| Fobs |where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively. 
f Based on Rfree as calculated by REFMAC5.
1 
g “Other” includes imidazole, glycerol, sodium ions, nickel and chloride ions. 
h As calculated using MolProbity.2 
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Apo-WT-MsGlgB 
 
 
DP4-WT-MsGlgB 
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PRIVATEER 
Name Chain Q1 Phi Theta Anomer D/L2 Conformation RSCC3 <Bfactor> Diagnostic 
GLC A 0.511 219.68 8.61735 alpha D 4C1 0.80 35.075 Ok 
GLC A 0.587 350.509 10.8085 alpha D 4C1 0.78 45.1464 Ok 
GLC A 0.604 27.5162 7.86233 alpha D 4C1 0.73 36.9482 Ok 
GLC A 0.570 154.594 3.29564 alpha D 4C1 0.77 33.7645 Ok 
 
DP8-D416A-MsGlgB 
 
PRIVATEER 
Name Chain Q1 Phi Theta Anomer D/L2 Conformation RSCC3 <Bfactor> Diagnostic 
BGC A 0.595 86.8336 9.67867 beta D 4C1 0.75 18.565 Ok 
GLC A 0.577 288.799 5.03079 alpha D 4C1 0.85 17.8491 Ok 
GLC A 0.565 172.664 3.55629 alpha D 4C1 0.86 18.9373 Ok 
GLC A 0.571 345.327 0.604983 alpha D 4C1 0.82 20.1836 Ok 
GLC A 0.559 37.067 5.87266 alpha D 4C1 0.87 20.3118 Ok 
GLC A 0.582 29.6918 8.86196 alpha D 4C1 0.90 18.7455 Ok 
GLC A 0.581 5.51538 11.7087 alpha D 4C1 0.73 19.2773 Ok 
GLC A 0.581 95.0614 11.6734 alpha D 4C1 0.72 20.1064 Ok 
GLC A 0.559 243.453 7.18061 alpha D 4C1 0.70 65.6225 Ok 
GLC A 0.573 42.9558 5.21885 alpha D 4C1 0.85 49.8527 Ok 
GLC A 0.556 158.581 2.90187 alpha D 4C1 0.88 41.69 Ok 
GLC A 0.574 87.9007 6.83329 alpha D 4C1 0.87 34.24 Ok 
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GLC A 0.548 43.0559 4.58215 alpha D 4C1 0.86 33.9445 Ok 
GLC A 0.546 280.702 2.91125 alpha D 4C1 0.83 33.8973 Ok 
GLC A 0.530 278.637 6.8716 alpha D 4C1 0.69 56.9383 Ok 
GLC A 0.569 193.402 3.0405 alpha D 4C1 0.82 49.7664 Ok 
GLC A 0.574 274.484 3.83747 alpha D 4C1 0.76 49.6091 Ok 
GLC A 0.545 76.6182 1.14197 alpha D 4C1 0.79 46.6155 Ok 
GLC A 0.555 91.4727 0.83588 alpha D 4C1 0.82 43.8091 Ok 
GLC A 0.568 104.849 1.68537 alpha D 4C1 0.85 39.6327 Ok 
GLC A 0.558 351.358 5.60606 alpha D 4C1 0.87 33.2055 Ok 
GLC A 0.548 260.225 6.13912 alpha D 4C1 0.82 46.14 Ok 
GLC A 0.543 79.6826 5.80724 alpha D 4C1 0.83 37.6573 Ok 
GLC A 0.533 43.4975 3.52916 alpha D 4C1 0.85 45.2236 Ok 
GLC A 0.519 287.537 8.01385 alpha D 4C1 0.69 59.5067 Ok 
GLC A 0.550 231.544 2.51996 alpha D 4C1 0.66 57.8264 Ok 
GLC A 0.547 200.239 3.03789 alpha D 4C1 0.73 78.6817 Ok 
GLC A 0.542 358.445 6.75598 alpha D 4C1 0.85 55.0145 Ok 
GLC A 0.547 34.2687 7.86902 alpha D 4C1 0.90 39.2318 Ok 
GLC A 0.541 46.4177 6.40408 alpha D 4C1 0.91 29.5955 Ok 
GLC A 0.549 90.9705 6.11333 alpha D 4C1 0.89 30.9273 Ok 
GLC A 0.532 20.7939 8.77359 alpha D 4C1 0.81 46.4873 Ok 
BGC A 0.532 36.4979 9.7292 beta D 4C1 0.59 69.5133 Ok 
BGC A 0.559 42.3375 4.5499 beta D 4C1 0.55 51.755 Ok 
GLC A 0.556 220.545 14.5887 alpha D 4C1 0.71 58.0975 Ok 
 
ACR-E469A-MsGlgB 
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DP3-ACR-MsGlgB 
 
PRIVATEER 
Name Chain Q1 Phi Theta Anomer D/L2 Conformation RSCC3 <Bfactor> Diagnostic 
GLC A 0.532 108.486 8.39016 alpha D 4C1 0.93 22.9991 Ok 
GLC A 0.567 87.365 5.27104 alpha D 4C1 0.89 35.0673 Ok 
GLC A 0.558 189.226 9.81099 alpha D 4C1 0.75 70.8918 Ok 
GLC A 0.533 333.195 4.05168 alpha D 4C1 0.69 50.8375 Ok 
GLC A 0.573 13.354 5.6516 alpha D 4C1 0.75 40.2191 Ok 
GLC A 0.558 39.973 10.6909 alpha D 4C1 0.90 40.9055 Ok 
GLC A 0.539 33.6354 5.43116 alpha D 4C1 0.91 29.4827 Ok 
GLC A 0.526 105.007 2.77795 alpha D 4C1 0.92 28.2291 Ok 
GLC A 0.497 89.4325 22.4068 alpha D 4C1 0.73 40.6618 Ok 
GLC A 0.573 304.065 5.91823 alpha D 4C1 0.49 50.9383 Ok 
GLC A 0.589 151.759 9.08439 alpha D 4C1 0.73 40.1382 Ok 
GLC A 0.550 137.474 7.77946 alpha D 4C1 0.82 25.9327 Ok 
GLC A 0.627 36.7132 6.8425 alpha D 4C1 0.88 20.67 Ok 
GLC A 0.561 80.0154 6.16169 alpha D 4C1 0.86 19.2382 Ok 
GLC A 0.591 321.059 7.66566 alpha D 4C1 0.85 22.2482 Ok 
GLC A 0.537 278.175 21.1158 alpha D 4C1 0.75 29.3183 Ok 
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MsGlgB structures that require further refinement 
 
Dataset ID Apo-D416A-MsGlgB Apo-E469A-MsGlgB Apo-D416A-E469A-MsGlgB DP8-D416A-E469A-MsGlgB 
Data Collection     
Beamline I04-1 I04-1 I04-1 I04-1 
Wavelength (Å) 0.9282 0.9282 0.9282 0.9282 
Detector Pilatus 6M Pilatus 6 M Pilatus 6 M Pilatus 6 M 
Resolution range (Å) 84.67-1.68 (1.71-1.68) 98.41-1.67 (1.70-1.67) 98.21-1.47 (1.50-1.47) 84.43-1.42 (1.44-1.42) 
Space group P21212 P21212 P21212 P21212 
a, b, c (Å)  98.72, 164.70, 54.55 98.41, 163.63, 54.26 98.23, 164.18, 54.46 98.48, 163.97, 54.23 
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Total observations 1,358,284 (69,014) 1,362,173 (67,063) 1,991,857 (91,830) 1846138 (90948) 
Unique reflections 102,252 (5,037) 102,557 (5,053) 150,312 (7,375) 166069 (8084) 
Multiplicity 13.3 (13.7) 13.3 (13.3) 13.3 (12.5) 11.1 (11.3) 
Mean I/σ(I) 11.0 (1.4) 15.1 (1.4) 15.6 (1.4) 13.6 (1.2) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 100.0 (99.9) 
Rmerge
a 0.160 (1.932) 0.111 (1.849) 0.089 (1.876) 0.091 (1.944) 
Rmeas
b 0.167 (2.007) 0.116 (1.923) 0.092 (1.956) 0.095 (2.038) 
CC1/2
c 0.998 (0.742) 0.999 (0.725) 0.999 (0.727) 0.999 (0.720) 
Wilson B value (Å2) 17.1 21.0 17.3 15.7 
Refinement     
Resolution range (Å) 84.67-1.68 (1.71-1.68) 98.41-1.67 (1.70-1.67) 98.21-1.47 (1.50-1.47) 84.43-1.42 (1.44-1.42) 
Reflections: working/freed 97,047/5,129 97,374 (5,106)  142,772 (7,451) 157,667 (8,310) 
Final Rwork 0.169 0.161 0.132 0.127 
Final Rfree
e 0.190 0.194 0.174 0.171 
Estimated coordinate error (Å)f 0.085 0.089 0.058 0.052 
r.m.s bond distance deviation (Å) 0.0147 0.0197 0.0274 0.0287 
r.m.s. bond angle deviation (°) 1.475 1.782 2.172 2.361 
No. of protein residues per chain (ranges) 722 (9-375; 381-736)    
No. of heterogen residues: sugar/water/otherg 0/748/8    
Mean B factors: protein/ligands/water/overall (Å2) 23/34/34/23    
Ramachandran: favoured/allowed/disallowedh (%) 98/1.9/0.1    
Protein Data Bank accession code N/A N/A N/A N/A 
a Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl). 
b Rmeas = ∑hkl [N/(N  1)]
1/2 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, I(hkl) is the weighted average intensity for all observations i of reflection hkl 
and N is the number of observations of reflection hkl. 
c CC1/2 is the correlation coefficient between symmetry equivalent intensities from random halves of the data set. 
d The data set was split into “working” and “free” sets consisting of 95 and 5% of the data, respectively. The free set was not used for refinement. 
e The R factors Rwork and Rfree were calculated as follows: R = (| Fobs - Fcalc |)/| Fobs |where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively. 
f Based on Rfree as calculated by REFMAC5.
1 
g “Other” includes glycerol and sodium ions 
h As calculated using MolProbity.2 
